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Several aspects of the activities of anti-lipopolysaccharide
(anti-LPS) immunoglobulins were assessed in relation to their
potential for therapeutic use in Gram-negative septicaemia.
i) The binding activities of immunoglobulins present naturally in
human blood donor sera to a wide range of LPS antigens were assessed
in an ELISA system. This assay incorporated LPS-polymyxin complexes
as antigens. There was wide variability in antibody reactivity to
different LPS both within and between individuals. ELISA was also
performed on IgG purified from donor sera. Immunoblotting with sera
or IgGs failed to produce results comparable to those in ELISA.
ii) Assessment was made of a putative relationship between anti-core
glycolipid (anti-CGL) antibodies and levels of endotoxin during
episodes of septic shock using ELISA and Limulus amoebocyte lysate
(LAL) assays. Results were complex but indicated an inverse
relationship between anti-CGL antibodies and endotoxin activities in
serum.
iii) Long-term immunisation of rabbits was carried out to determine
immunoglobulin responses to smooth LPS (S-LPS), rough LPS (R-LPS)
and lipid A. Six rabbits were each administered with a different
range of smooth or rough bacteria and antibody response was assessed
by ELISA. A complex series of responses was obtained, but antigenic
relationships between some LPS molecules was indicated.
iv) Antigenic expression of R-LPS was assessed by ELISA with 4
different antigen preparations of S_^ typhimurium R878 (LPS-polymyxin
complexes, uncomplexed LPS, outer membrane fragments, and
heat-killed bacteria). Absorption and inhibition studies indicated
that antigenic expression of LPS in all preparations was similar.
vi
v) Alteration of 1ipopolysaccharide was shown to occur in two
isogenic variants of E_^ coli (018: K1 and 018:K~). Variations were
observed in different media and at different points during growth.
Differences were also observed in the binding activities of core-
and O-antigen-reactive monoclonal antibodies under these conditions.
The anti-O-antigen antibody bound to bacteria grown under all
conditions, whereas the core-reactive monoclonal antibody bound to
both variants when grown in untreated sheep serum and at low levels
to only the non-capsulate variant when grown in heat-inactivated
serum.
vi) Endotoxin neutralising activity of 5 purified IgG was determined
in a LAL inhibition assay. Seven 1ipopolysaccharides were used as
activators and all IgG were shown to possess some inhibitory
activity against LPS. Extent of inhibition was not reflected by
ELISA profiles, and possible reasons are discussed.
vii) Several human immunoglobulin preparations were assessed for
their ability to prevent death in a range of animal models of
bacteraemia and endotoxaemia. A range of non-compromised and
immuno-compromised models were used to determine lethality of
purified LPS and viable bacteria in the presence and absence of
immunoglobulins. Some indications were obtained of protection
against lethal bacterial challenge, and thus of the potential
therapeutic value of selected human immunoglobulin products in
patients with septicaemia.
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1:1. Aetiology and Epidemiology of Gram-negative Septicaemia.
1:1:1. Causative Organisms of Gram-negative Septicaemia.
The advent of antimicrobial agents during the 1930s and 1940s and
their subsequent application, together with the improvement of care
and advancement of therapeutic drugs has enabled severely ill
patients, who would previously have died, to survive. This has
consequently introduced the possibility of infection by bacteria not
previously recognised as primary pathogens. That is, opportunistic
infection may occur as a result of the compromised state of these
individuals. It is in this recently developed niche that aerobic
(and to a lesser extent anaerobic) Gram-negative rod-shaped bacteria
have become predominant as causes of life-threatening infections,
especially in hospital patients, despite the application of
antimicrobial agents.
Prior to the advent of antimicrobial agents, Gram-negative bacteria
were known as primary pathogens causing, for example, brucellosis,
pneumonia, salmonellosis, and plague (Weinstein 1985; Young 1985b;
Young 1985c). These diseases were transmitted via animal or insect
vectors or in food and water, and possess an obviously different
mode of pathogenicity to the recently emerged group of Gram-negative
opportunist pathogens.
The incidence of nosocomial (hospital-acquired) infection caused by
both Gram-negative and Gram-positive organisms has been increasing
since the 1940s (Alford & Hall 1987; Cone & Woodward 1985; Haley e_t
al 1985; Mertens et al 1987; McGowan 1985; de la Torre et_ al 1985)
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in step with the increasing use of antimicrobial agents (Mayer &
Zinner 1985; Neu 1985; Young 1985c). Many of these infections are
caused by invasion of the blood-stream by bacteria, and the rate of
septicaemia found in hospitals has been shown to be up to 20 per
1000 patients admitted (summarised in Table 1:1).





7. 1 (U.K.) Ispahani et al 1987
2.8 (Denmark) Eliasen et al 1987
15.0 (Sweden) Julander 1987
13.2 (Spain) Bisbe et al 1988
2.3 (Spain) de la Torre et al 1985
19. 1 (Spain) Gatell et al 1988
13.5 (Israel) Seigman-Igra et al 1988
7.6 (E. coli only) (U.S.) Bodey et al 1985
4.5 (P. aeruginosa only) (U.S.) Bodey et al 1986
8. 1 (U.S.) DuPont & Spink 1969
2.85 (U.S.) Haley et al 1985
7.06-12.75 (U.S.) Kreger et al 1980b
3.4 (U.S.) Scheckler 1978
Of the cases of septicaemia, a large proportion are caused by
aerobic or facultative Gram-negative rod-shaped bacteria, and this
group of organisms represents from 12% to 37% of blood-borne
infections seen in hospitals. When the data for fatality resulting
from systemic infections is considered (as summarised in Table 1:2),
it can be seen that aerobic and facultative Gram-negative rods are
also responsible for a large proportion of deaths, thus reinforcing
the position of these organisms as major agents in hospital
infections.
The organisms responsible for the majority of cases of nosocomial
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septicaemia, as determined from many studies (Armstrong et al 1971;
Beytout e_t al 1987; Brown 1984; Eliasen et_ al 1986; Eng al 1987;
Finland & Barnes 1978; Forgacs et al 1986; Gatell et al 1988;
Ispahani jrt jal^ 1987; Julander 1987; Lacut et^ jal 1987; Miller &
Wenzel 1987; McGowan 1985; 1985; Peltola et £l 1987; Rosenthal 1986;
Siegman-Igra e_t al 1988; Whimby e_t jal 1987) are noted below along
with the relevent percentage of cases and percentage of total deaths
resulting from septicaemia (Table 1:2).










E. coli 8.2 - 36.6 8.2 - 19.0
Pseudomonas spp. 3.7 - 18.0 5.1 - 21.4
Klebsiella spp. 3.3 - 28.0 3.8 - 12.7
Enterobacter spp. 0.7 - 7.8 3.1 - 3.8
Serratia spp. 0 - 4.6 2.5 - 4.1













Other Streptococci 3.7 - 8.2 2.3 - 7.0
As can be seen in Table 1:2, Gram-negative bacteria, particularly
members of the family Enterobacteriaciae, are strongly represented.
Escherichia coli, Klebsiella aerogenes, Serratia marsescens, and
Enterobacter species, as well as the related non-enteric Pseudomonas
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species (especially Pj_ aeruginosa) predominate. Additionally these
organisms can be found in mixed infections, and also with anaerobic
bacteria and/or Gram-positive bacteria (see above references; Elting
jet al 1986; Finland & Barnes 1978; Kiani 1979; Miller & Wenzel 1987;
Vazquez e_t al 1987) .
In addition to Gram-negative aerobic or facultative organisms, other
bacteria are also isolated in cases of septicaemia (see above
references), including: Streptococcus species, pneumoniae being
predominant; Staphylococcus aureus and coagulase-negative
staphylococci; Bacteroides species - mainly B. fragilis, and fungi
(predominantly Candida species). Of these additional organisms it
has been found that Staphylococcus aureus is the most commonly
isolated, and although it causes up to 12.8% of bacteraemias, its
contribution to fatalities is lower than that of many of the
facultative Gram-negative organisms (see table 1:2).
From the data presented in the above table it can be seen that the
frequencies of infection and fatalities caused by an organism vary
between reports (perhaps reflecting the differing conditions and
therapeutic practices found in different hospitals, wards and
patient groups - see below) but it can undoubtedly be said that the
above mentioned Gram-negative organisms do represent a large
proportion of cases of nosocomial septicaemia, and contribute many
deaths in hospitals.
Further reports also indicate the increase in prevalence of
Gram-negative bacteria in septicaemia (Altemeier al 1967; DuPont
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& Spink 1969; Kreger _e_t a_l 1980a; McCabe & Jackson 1962a; McCabe &
Jackson 1962b; Scully & Henry 1985). It should also be noted that of
the Gram-negative rod-shaped bacteria associated with systemic
infections, Escherichia coli forms the largest proportion (30 to
70%), and results in a large number of deaths from septicaemia (20
to 60%) (see Table 1:2). Not all strains of coli, however, are
equally predominant in invasive infections and it is seen that only
eight O-serotypes (out of more than 160: see section 1:2) are
responsible for more than 50% of E. coli septicaemias (Cheasty et al
1979 ; Cross et_ a^ 1984; Kreger e_t al 1980a; McCabe jrt al 1978;
Orskov & Orskov 1975). A similar pattern of prevalence of certain
O-serotypes can also be seen for other Gram-negative species causing
septicaemia, including P. aeruginosa (Dick et al 1988; Moody et al
1972) and Serratia marsescens (Gaston et al 1988). Possible reasons
for the prevalence of specific O-serotypes as causes of septicaemia
are discussed later in section 1:2.
The presence of bacteria in the blood (bacteraemia) does not
necessarily result in the death of an infected individual, as
witnessed by the variability in the above mortality rates (see also:
Balk e_t _al 1984; van Deventer et al 1988a; Ledingham et al 1988b;
McCartney e_t al 1987). Bacteraemia without clinical indications is
observed mainly in individuals who are immunocompetent. Potentially
fatal septicaemia, however, occurs in defined groups of
immunocompromised individuals as described in section 1:1:2 below.
Bacteraemia can proceed to septicaemia, a condition in which
clinical signs of infection become apparent. This leads in many
cases to a condition called "septic shock" which is the final stage
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resulting from serious infection of the blood. Septic shock can also
result from a focus of infection in which case the infection is
referred to as "sepsis".
A proportion of septicaemias are caused by Gram-positive cocci (see
table 1:2), but it has been observed that all of the clinical
features and effects found in Gram-negative septicaemia (see section
1:3) are found in many cases of septicaemia caused by Gram-positive
organisms (Miller & Wenzel 1987; McCartney e^t _al 1987).
Additionally, clinical signs of septicaemia can be observed in
complete absence of a positive blood culture (Berger & Beger 1986;
Cahill et^ al 1987; Hass e_t al 1987; McCartney 1987; MacLean ert al
1967) .
Analysis of blood has revealed that in many instances endotoxin
(which is an integral component of the Gram-negative bacterial
envelope and is responsible for many of the effects of Gram-negative
septicaemia - see section 1:2 below) is present at high levels
during septicaemia in which Gram-negative, Gram-positive, or no
organisms have been isolated (Berger a_l 1988; Caridis j^t _al 1972;
van Deventer et al 1988a; van Deventner et al 1988b; Gaeta et^ al
1982; Harris jrt al 1984; Hass e_t al 1986; Jacob «rt jal^ 1977; Levin et^
al 1970; Lumsden et al 1988; McCartney et al 1987; Ohshio e_t al
1988; Rush e_t al 1988; Shenep e_t al 1988; Triger ^t _al 1978) . This
thus provides a strong indication that endotoxin is the major factor
in the pathogenesis of septicaemia. It has, in fact, been determined
that the clinical signs of bacterial invasion of the blood only
become apparent upon release of endotoxin (see above references).
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In cases of Gram-negative septicaemia it has been determined that
the levels of endotoxin far exceeds the amount contained on the
number of blood-borne organisms present (Caridis e_t jil^ 1972; van
Deventer e_t al_ 1988; McCartney ert jil 1987; Shenep et jal 1985a;
Shenep et_ al 1985b; Shenep e_t al 1988). The presence of endotoxin
could result from effective treatment of infection by antimicrobial
agents inducing release of endotoxin (Cohen & McConnell 1985; Goto &
Nakamura 1980; Shenep ^t al_ 1985a; Shenep et al 1985a), thereby
possibly accounting for some cases of "non-bacterial" septicaemia,
but since the levels are so high - in the range of 5 to lOOng/ml or
higher (an organism possesses femtogram amounts of endotoxin and a
gross bacteraemia has about 100 organisms per millilitre of blood) -
it is highly probable that blood-borne infection results in the
release of endotoxin from an endogenous source (see section 1:4).
This source may be a septic focus of infection (releasing organisms
and endotoxin into the blood), or alternatively the large pool of
Gram-negative rods present in the intestine (Caridas et_ al 1972;
Chedid ej: al_ 1968; van Deventner et _al 1988b; Freeman & Gould 1985a;
Jacob et^ jfL 1977; Kennedy e_t al_ 1965; Sori jrt _al 1988; Tancrede &
Andremont 1985). These possible sources would release endotoxin upon
an appropriate trigger as discussed in section 1:3. There is much
evidence which points to the latter source as being of great
significance in septicaemia.
The presence of bacteria in the blood is thus not essential for the
development of septic shock, but it is however, beyond doubt that
the organisms in the blood are indeed one requirement in the
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initiation of the complex processes associated with septicaemia
(refer to section 1:3).
Further support for the central role of endotoxin has been obtained
by the demonstration that all of the pathophysiological changes
associated with septicaemia can be obtained by challenging animals
with endotoxin purified from Gram-negative bacteria (see sections
1:3 and 1:4). It can therefore be said that it is the endotoxin of
the Gram-negative cell which is of central importance in the
development of the clinical syndrome associated with septicaemia.
The presence or absence of endotoxaemia thus has an important
bearing upon the severity of the syndrome and the survival of
patients.
It has, however, been postulated by Galanos and colleagues (Galanos
et al 1986) that systemic Gram-negative bacterial infection results
in heightened sensitivity of an individual to the activities of
endotoxin. It was suggested that any of a number of means may
contribute to this "hyper-reactivity", and this seems to support the
inter-linked roles for both bacteria and endotoxin in the
development of septicaemia.
Gram-negative septicaemia is therefore a result of the invasion of
the blood by any of a number of bacterial species, and/or their
endotoxins, from either a focus of infection or from an endogenous
source, as a result of some form of triggering mechanism, leading to
the serious clinical condition referred to as septic shock.
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1:1:2. Conditions Predisposing to Gram-negative Septicaemia.
The experience gained in intensive care medicine has revealed a
range of conditions which are now known to permit infection and
invasion of the blood by potentially pathogenic organisms such as
Gram-negative rod-shaped bacteria or their endotoxins. These
conditions are diverse and have been well documented (Alford & Hall
1987; Armstrong et al 1971; Baumgartner e_t j^l 1985; Brown 1984;
Bryan e_t al 1983; DuPont & Spink 1969; Freeman & McGowan 1978;
Gatell e_t al 1988; Harris e_t al 1984; Julander 1987; Klastersky
1985; Kreger et al 1980a; Kreger et al 1980b; Maki 1981; McCabe &
Jackson 1962a; McCabe & Jackson 1962b; McKellar 1985; Parker &
Parillo 1983; Sanford 1985; Siegman-Igra jrt al 1988; de la Torre e_t
al 1985; Young et al 1977). They include surgical manipulation of
the respiratory, intestinal and genito-urinary tracts, open-heart
surgery, malignancy and its treatment, immunosuppression,
immunodeficiency, burns and multiple trauma.
a) Surgical manipulation can permit septicaemia or endotoxaemia
(Freeman & Gould 1985a; Nagachinta e_t al 1987; Rocke _et_ al 1987).
This can result from contamination and infection of wounds and
surfaces exposed during surgery from an environmental source.
Alternatively, release of endogenous flora from the epidermis or
mucous membrane surfaces may occur, thus resulting in direct
invasion of the circulation. Manipulation of the intestine is a
particular risk for patients as it is a source of many potentially
pathogenic facultative Gram-negative organisms, and is also a major
source of endotoxin.
b) The lowered immune status present in certain immunodeficiency
states and during immunosuppressive treatment as well as that caused
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by the therapeutic agents required for treatment of malignancy can
also permit invasion of the circulatory system. At particular risk
are patients with neutropenia, who very easily become colonised with
environmental organisms (Minah et^ _al 1986), and who may possess
heightened sensitivity to LPS toxicity (Galanos et al 1986). In
addition, deficiencies in other cellular components, and in humoral
components of the immune system can lead to successful invasion of
the circulation.
c) Severe burns or multiple trauma result in a general lowering of
immune status thereby permitting colonisation of wounds. From these
wounds, entry into the blood can be gained, where organisms can
multiply, release endotoxin, and produce symptoms of septic shock
(Deitch et_ jd 1987; Mason e_t al_ 1986; Pruitt 1974; Winchurch e_t al_
1987) .
d) Instrumentation of patients may also permit the invasion of the
blood as a result of colonisation of catheters from an external
source, through infusion of contaminated parenteral fluids, or by
permitting entry of commensal organisms present on the skin or
organisms present in the environment.
e) Intestinal disruption by any of a number of means, permits the
release of bacteria or endotoxins into the circulation in larger
than normal quantities (see section 1:3). Alteration of the
integrity of the intestine could therefore lead to septicaemia or
endotoxaemia (van Deventer et al 1988b; Fink et al 1988; Gaffin et
al 1981).
f) Impairment of liver function is also a major risk factor for the
development of septicaemia or endotoxaemia (Cahill ed ad 1987;
Caridis et al 1972; Gaeta et al 1982; Jacob et al 1977; Lumsden et
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al 1988; Ohshio _et_ al 1988; Prytz et al 1976; Triger et_ al 1978;
Wardle & Wright 1970). This occurs because of the role of the liver
as a major organ of removal of bacteria and endotoxin in healthy
individuals (see section 1:3). Thus alteration of the efficacy of
this function would permit entry and persistence of bacteria and
bacterial products in the circulation.
Further groups at high risk include children up to one year old,
especially premature neonates (see for example Hill 1985) and aged
people (both groups having a lowered immune status) who often
succumb to septicaemia and meningitis caused by enterobacteria -
mainly E_^ coli and Klebsiella pneumoniae.
Finally, a recent addition to conditions resulting in septicaemia
has become noticeable - it has been observed that people with the
acquired immune deficiency syndrome (AIDS) are susceptible to
septicaemia and this has become a recognised cause of death among
AIDS patients (Celum et al 1987; De Wit et al 1988; Eng et al 1987;
Fischl et 1986; Nadelman et al 1985; Sperber & Schleupner 1987).
Septicaemia caused by species of Salmonella are to be found more
often than in the other groups of patients mentioned above. This
perhaps reflects the particular mode of immunosuppression found in
AIDS patients and also a requirement for a different mode of
pathogenesis for the organisms.
All of the above factors can therefore be of importance in the
progression of septicaemia and the definition of Gram-negative
septicaemia described above can now be expanded. Septicaemia can now
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be said to represent a nosocomial infection in patients who are
immunocompromised, resulting from invasion of the blood by
Gram-negative organisms - particularly enterobacteria - or endotoxin
from a site of infection, from an endogenous source, or from an
exogenous source.
Despite the prevalence of Gram-negative bacteria as causes of
nosocomial septicaemia, many cases of septicaemia can be seen to be
the result of infection outside the hospital environment (Bisbe et^
al 1988; Finland & Barnes 1978; Ispahani e_t al^ 1987; McCabe &
Jackson 1962a; Scheckler 1978; Siegman-Igra _et_ _al 1988; de la Torre
1985). These cases nevertheless result in hospitalisation of
individuals and a similar clinical outcome. Community-acquired
infections therefore add to the magnitude of the problem arising
from systemic infections caused by Gram-negative bacteria.
It has been observed that the species commonly causing
community-acquired septicaemia differ slightly in proportion from
those causing nosocomial septicaemia, with coli and Klebsiella
pneumoniae forming a greater proportion of cases (see above
references).
Another important factor to note is that the severity of the disease
underlying the septicaemia has a bearing on the outcome of infection
(Ispahani et al 1987; Kreger et_ al 1980b; Maki 1981; Miller & Wenzel
1987; McCabe & Jackson 1962a; McCabe & Jackson 1962b). It has been
demonstrated that more-severely compromised individuals (that is,
those with an underlying condition which is itself fatal) have a
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lower chance of survival from septicaemia than do less compromised
people. In addition, those people acquiring septicaemia within the
community possess similar modes of reduction in immune competence to
patients acquiring nosocomial infection, but their compromised
states are generally less severe, and patients acquiring septicaeia
within the community show higher rates of recovery.
It is obvious, therefore, that certain groups of individuals are
particularly susceptible to this type of infection. In these groups
there is a requirement for some form of immunodeficiency, the
severity of which has a bearing upon the outcome of infection. The
range of conditions which may enable opportunistic infection and
lead to septicaemia by any of a range of potentially pathogenic
Gram-negative bacteria is, however, large.
The host factors responsible for protection against septic shock
resulting from Gram-negative septicaemia, and treatment and
prevention strategies will be discussed in later sections (1:3 and
1:5 respectively).
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1:2. Structure and Function of Lipopolysaccharide in Gram-negative
Bacteria.
1:2:1. Structure of Gram-Negative Bacteria.
The Gram-negative cell has a more complex structure than that seen
in Gram-positive bacteria. The surface components of Gram-negative
bacteria comprise three layers as represented diagrammatically in
figure 1:1.
The outer membrane (OM) of Gram-negative bacteria is a unique
structure and is generally regarded as the outermost component of
the cell. In many cases, however, an additional polysaccharide
component is present on the surface. These "capsules" or "slimes"
are important virulence factors for many strains of Gram-negative
bacteria which cause septicaemia (see below), but are by no means
essential for the development of septic shock.
Beneath the outer membrane is the periplasmic space which contains
many proteins involved in bacterial metabolism, and additionally
lipoproteins which link outer membrane covalently to a thin layer of
peptidoglycan. Finally, below the peptidoglycan is the cell membrane
of the bacterium.
It is the lipopolysaccharide (LPS) of the OM that is responsible for
causing the symptoms associated with septicaemia, but before
discussing the toxic activities of LPS, the structure and
composition of this molecule and its role in virulence will be
summarised.
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Figure 1:1. Schematic diagram of the Surface Components of
Gram-negative Bacteria.
(from "Bacterial Cell Surface Techniques", Hancock and Poxton,
John Wiley & Sons, Chichster, 1988).
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1:2:2. Structure of the Outer Membrane (OM) of Gram-negative
Bacteria.
The OM of Gram-negative bacteria is a complex structure composed of
phospholipids, proteins and LPS. Of the constituents of the outer
membrane, LPS is the major component, representing more than 50% of
the weight of extracted OM (Costerton e_t jal 1974). Additionally,
lipopolysaccharide is the most antigenic structure of the outer
membrane and also the most structurally diverse.
The lipid component of the lipopolysaccharide molecule (lipid A)
interacts hydrophobically with phospholipids which form the inner
leaflet of the bilamellar outer-membrane, and the polysaccharide
component of LPS extends outwards from the cell surface. In addition
to LPS, the OM also possesses protein components, the majority of
which represent trans-membrane pores. As well as these structures,
the OM may be traversed by tubular protein polymers which can be
structures required for motility (flagella) or for attachment
(fimbriae).
The outer membrane of Gram-negative bacteria is therefore a highly
complex structure, of which the lipopolysaccharide component is
intimately involved in the processes of septicaemia.
1:2:3. Structure of Lipopolysaccharide.
Lipopolysaccharide is a complex amphipathic molecule which possesses
three distinct regions: i) a polysaccharide composed of repeating
oligosaccharide units - the O-antigen; ii) an oligosaccharide "core"
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region; and iii) an inner lipid component - Lipid A.
Q-polysaccharides.
The O-polysaccharide or, as it is more usually called, the
O-antigen, represents the outermost region of LPS (see figure 1:2),
and has been found to be composed of one to many repeating
oligosaccharide units commonly containing from 2 to 5 sugars. Larger
O-antigen units can, however, be found. The oligosaccharides of
these units form either a linear or branched structure (Hitchcock jrt
al 1986; Luderitz et al 1984; Orskov et al 1977; Rietschel & Brade
1987; Rietschel e_t al 1984b; Westphal e_t al 1983). These
oligosaccharide units form a repeating structure which extends
outwards from the cell surface in a helix. The repeating units are
hetero-oligosaccharides (composed of several different sugars) in
most cases, but a few examples of homo-oligosaccharides (repeating
units comprising one sugar) have been found in, for example,
Klebsiella and Enterobacter species.
O-antigens have been found to contain a wide range of sugar
molecules including hexoses, hexosamines, deoxyhexoses,
dideoxyhexoses, deoxyhexosamines, pentoses, and uronic acids (Knirel
et al 1988; Orskov jrt sfl 1977; Westphal e_t al 1983; Wilkinson ^t al
1973; Wilkinson e_t al_ 1975; Wilkinson 1977). In addition, non-sugar
constituents including phosphoryl, glyceryl, acetyl, pyruvyl, and
ethanolaminyl groups may be present.
As a result of the wide range of possible constituents, it can be
said that the O-antigen is a chemically and antigenically highly
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diverse component of LPS and therfore of the Gram-negative bacterial
cell surface. This is reflected in the ability to classify strains
of Gram-negative organisms by means of their O-antigen, which
results in a number of distinct "O-serogroups" that possess
strain-specific polysaccharide structures. For example, E. coli has
been shown to have over 160 O-serogroups. The antisera to some of
these O-antigens cross-react with other O-antigens to a greater or
lesser degree, but each O-antigen can be shown to possess a distinct
structure. Additionally, for other Gram-negative species an
0-antigen-dependent typing system has been obtained. These include
Pseudomonas aeruginosa (Lui et al 1983); Klebsiella aerogenes,
(Kauffmann 1969); Salmonella, (Edwards & Ewing 1972; Kaufmann 1969);
and Serratia marsescens (Guinee ert jil^ 1987; Pitt & Erdman 1984).
In addition to cross-reactivity observed within a species or genus,
some cross-reactivity can be seen between genera (Orskov j!t_ al 1977;
Perez-Perez e_t jLL 1986). It is known that certain E. coli O-antigens
show cross-reactivity with some strains of Vibrio cholerae,
Salmonella spp. and Shigella spp. reflecting the clinical syndromes
with which these serotypes are associated (see section 1:2:3). Other
such cross-reactivities are also known to occur. Thus despite the
diversity of components of O-antigen, some structural and antigenic
similarities can be observed between some serotypes of certain
organisms.
The structurally variable O-antigen component of lipopolysaccharide
is covalently linked to the "core" oligosaccharide.
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Core oligosaccharides.
Core oligosaccharide acts as a bridge between the O-antigen and the
lipid A. O-antigen is bound through its proximal saccharide to the
terminal or sub-terminal sugar in the core (usually a glucose
molecule), with lipid A binding at the opposite end of the core from
the O-antigen - figure 1:2.
The core region (which together with lipid A forms the core
glycolipid or CGL) of LPS is a short oligosaccharide composed of
usually 11 monosaccharides (Jansson et al 1981; Orskov et al 1978).
Within the core itself there are two distinct regions - the inner
and outer cores. Compositional, structural, and immunochemical
analyses of core oligosaccharides from several different genera and
species of Gram-negative bacteria have been carried out, showing
that many similarities exist, especially within the family
Enterobacteriaciae.
Analysis of core oligosaccharide structure has been facilitated
through the development of a series of "rough"-mutant strains from
various organisms (Brade et al 1988; Orskov _et al 1977; Westphal
al 1983). Mutants have been obtained which possess progressively
shorter oligosaccharides substituted onto lipid A. The mutants are
designated as the Ra, Rb, Rc, Rd, and Re chemotypes. The Ra
chemotype possesses a complete core oligosaccharide, Rb has one
sugar less, and so on until the Re chemotype which possess only one
type of sugar attached to lipid A - see figure 1:3. Re-CGL is the
smallest obtainable LPS produced "naturally" through mutation - no





FIGURE 1:3. Rough Lipopolysacchari.de Chemotypes of Salmonella.
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Rough mutants of minnesota, S. typhimurium, Escherichia coli, and
Pseudomonas aeruginosa have been produced, and additionally other
organisms have been studied (Holme et^ al 1968; Hudson e_t al 1978;
Luderitz £t al 1966). Those organisms of particular significance in
Gram-negative septicaemia whose core structures have been
well-studied are E_^ coli and P. aeruginosa, but little is known of
the structures of the cores of other Enterobacteriaciae causing
septicaemia.
It was originally believed that core oligosaccharides from many
different species of enterobacteria possessed an identical
structure, but it has subsequently been determined that E^ coli
itself possesses five different core structures and the genus
Salmonella possesses only one. Most of the variation which has been
observed occurs in the outer core region.
The sugars which are the common components of outer core are
glucose, galactose, and glucosamine. These can be found in all
enterobacterial cores so far examined, but they have been shown to
be present in different structural conformations - see figure 1:4
(Eskenazy _ejt a_l 1977; Jansson et al 1981; de Jongh-Leuvenink et al
1985; Luderitz e_t al 1982; Peters et_ al 1985; Perez-Perez e_t al
1986; Schimdt et_ al 1970; Tsang e_t al 1987). Additionally, outer
cores may possess non-sugar components of which phosphate and acetyl
groups are predominant.
In contrast to the outer core, the inner region shows a greater
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FIGURE 1:4. Structures of LipopoLysacchari.de Core regions of Sa Imonella, E ■ col i, and P. aeruginosa.
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degree of structural conservation between species. This region
comprises three molecules each of glycero-manno-heptose and
keto-deoxy-octulosonic acid (KDO), as well as phosphate,
diphosphate, and ethanolamine groups - figure 1:4 (above references;
Brade _et _al_ 1986; Brade jrt al^ 1988; Tacken al_ 1986). This region
therefore shows a greater degree of structural conservation between
species and indeed is identical among all Enterobacteriaciae.
Study of the core of Pseudomonas aeruginosa (Fensom & Meadow 1970;
Koval & Meadow 1975; Koval & Meadow 1977; Kropinski et^ a_l 1979; Rowe
& Meadow 1983; Sawada ert al 1985; Wells e_t al 1985) has revealed a
similar structure to that of enterobacterial cores. Differences are,
though, observed in the outer core where glucose and galactosamine
are present with the addition of a deoxyhexose (rhamnose) and an
amino acid (alanine) - figure 1:4. The inner core does, however,
seem to possess greater similarity to that of E. coli and
Salmonella, though only two KDO molecules and a single heptose
appear to be present. The gross structure and composition of this
core is, though similar to that of enterobacteria.
Conservation of core structure is reflected in the cross-reactivity
of antibodies (monoclonal and polyclonal) to this region across many
genera (Bogard ejt al 1984; Bogard ht al_ 1987; Brade & Galanos 1983;
de Jongh-Leuvenink e_t al_ 1986; Kirkland ej^ al 1986; McCallus &
Norcross 1987; Nelles & Niswander 1984; Pollack et al 1987; Siber et_
al 1985; Sidberry e_t al 1985; Young et. al 1975a).
The core region of LPS is therefore a chemically and structurally
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highly conserved region in comparison to the O-antigen, though minor
differences do exist.
As mentioned above, it is this core region which forms the link
between the O-antigen and the membrane-embedded lipid A component of
lipopolysaccharide.
Lipid A.
Lipid A is the innermost component of LPS and is embedded within the
outer leaflet of the OM through lipophilic interactions with
phospholipids. Lipid A is bound to the core region of LPS through
one of the KDO molecules of the inner core.
This hydrophobic lipid A moiety itself has a complex structure
(Batley _e£ jil_ 1984; Batley e_t al 1985a; Batley e_t al 1985b; Batley
et al 1985c; Brade e_t al 1988; Burton & Carter 1984; Luderitz et al
1973; Luderitz et al 1984; Mattsby-Baltzer & Alving 1984a;
Mattsby-Baltzer e_t al 1984a; Mattsby-Baltzer & Alving 1984b; Qureshi
££ al 1985; Raetz 1984; Rietschel et_ al_ 1984a; Westphal et al 1983).
It is composed of a di-glucosaminyl-glucosamine backbone to which
fatty acid chains, phosphates, and core are bonded - see figure 1:5.
The major structural differences found between lipid A from
different bacteria are in the composition of fatty acids and also in
the nature of the substituents present on the phosphate units.




Lipid A is therefore the least variable component of LPS, showing a
high degree of structural conservation between genera (Drewry et al
1973; Galanos e_t al 1984; Homma e_t al 1985; Matsuura £t_ al 1985;
Mattsby-Baltzer et^ al 1984b; Westphal 1983). In addition, lipid A
from different organisms show immunochemical similarities (Brade &
Brade 1985; Brade j2t al 1986; Elkins & Metcalf 1985; Galanos et al
1984a; Kasai ejt al 1985; Kirkland et_ al 1985; Mutharia e_t al 1984;
Pollack e_t al 1987; Ramachandra et al 1988; Rietschel jit al 1987).
It has been determined that the toxic activities (section 1:3) of
LPS reside in the lipid A component, and the continuing advances of
knowledge of the structure of lipid A is enabling determination of
structural components responsible for toxicity and immunogenicity
(Arata e_t al 1988; Chaby e_t al 1987; Elkins & Metcalf 1985;
Kanegasaki et al 1984; Kasai et al 1985; Kotani et al 1985; Kumazana
et al 1988; Proctor & Textor 1985; Rietschel et al 1984b; Shiba jrt
al 1984; Shimizu e_t al 1988; Takada e± a^L 1985; Takahashi et al_
1987 ; Takayama e£ al 1984a; Takayama et al 1984b; Tanamoto et aj^
1984) The toxic activities of lipid A and LPS (which are also
conserved between genera) are discussed in section 1:3.
The lipopolysaccharides of Gram-negative bacteria associated with
septicaemia thus show many structural, immunochemical, and toxic
similarities between species. Variation does, however exist, and can
be seen in each of the three components of the lipopolysaccharide
molecule. Greater variation is observed between enterobacterial LPS
and those of Bacteroides species, which is reflected in both
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immunogenic and toxic differences (Hofstad 1988; Johne et al 1987;
Luderitz e£ al 1984; Luderitz e_t jLL 1987; Rietschel et. al_ 1987).
Other organisms which are less closely associated with septicaemia
show even greater divergence of structure of LPS components,
although the basic gross structure remains (see for example
Hitchcock e_t al 1986; McCartney & Wardle 1985). Despite this,
lipopolysaccharide is a highly important component of an organism,
and plays an important role in the pathogenesis of septicaemia.
1:2:4. Biosynthesis of Lipopolysaccharide and Effect of Growth
Conditions.
The mechanisms involved in the synthesis of the O-antigen, core and
lipid A components of lipopolysaccharide have been determined at
both biochemical and genetic levels (Brahmbhatt et al 1988; Ishiguro
e£ al 1986; Orskov el al 1977; Osborn e_t al 1972; Wilkinson 1977).
Steps involved in the synthesis of lipid A continue to be uncovered
(Anderson ert al^ 1985; Coleman & Raetz 1988), as the structural
requirements for toxicity and immunogenicity become clearer.
The core-glycolipid component is formed in a stepwise process at the
cell membrane by addition of individual core sugar units onto lipid
A (Goldman ££ al 1988a; Goldman ej^ al 1988b; Orskov e_t al 1977 ;
Wilkinson 1977). O-antigen oligosaccharide units which have been
synthesised step-wise onto a carrier lipid, are then polymerised
onto core-glycolipid. The complete LPS molecule can then be
transferred to the outer surface of the outer membrane.
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Variation in the number of O-antigen units substituted onto
core-glycolipid can be seen between organisms (Chester & Meadow
1975; Gaston et al 1988; Goldman & Leive 1980; Hitchcock et al 1986;
Palva & Makela 1980; Peterson & McGroarty 1985; Rivera et d. 1988).
Even within a culture of a particular strain of an organism,
heterogeneity of LPS chain length is observed, although a
predominant length of chain is produced. In addition, substitution
with a single O-antigen unit (S-R LPS) and no O-antigen units
(R-LPS) are present in populations of bacteria.
It has been determined that alteration of the growth conditions of a
bacterium results in alteration of LPS chain length and, in some
cases, sugar composition (Chester & Meadow 1975; Collins 1964; Dodds
et al 1987a; Dodds e_t al 1987b; ; Hraback ejt al 1981; Kropinski et
al 1987; Ombaka e_t a1 1983). When growing rapidly in a rich medium
LPS is predominantly of shorter chain or S-R type. As a response to
progressively less conducive growth conditions, the chain length of
LPS is observed to increase, often in conjunction with a decrease in
growth rate. Similar alteration in O-antigen chain length has been
observed _in vivo for P. aeruginosa in infections in cystic fibrosis
(Cochrane _e£ al 1988). This has an important bearing _in vivo as the
presence of LPS with greater numbers of O-antigen units has been
shown to confer resistance to serum bactericidal activity (see
section 1:2:3).
The alteration of LPS has also been observed over the growth curve,
and has been shown to affect virulence and toxicity, as well as
resistance to antimicrobial agents and to host defence mechanisms
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(Benjamin jrt ajL 1986; Finch & Brown 1975; Finch & Brown 1978;
McCallus & Norcross 1987; Russell & Furr 1987; Russell et al 1987;
Shearer & Legakis 1985; Weiss jrt al 1986).
The growth conditions of a Gram-negative organism thus have an
important influence upon the structure of the LPS of the outer cell
membrane and therefore upon the virulence and toxic activities of
the molecule (see sections 1:2:3 and 1:3:1 respectively).
1:2:5. Role of Lipopolysaccharide in Virulence.
Since lipopolysaccharide is a major surface component it is expected
that it must perform some role in the virulence of an organism,
besides its role as the highly active endotoxin.
As mentioned above, lipopolysaccharide forms the major fraction of
the Gram-negative bacterial outer membrane, and as such acts as a
selectively permeable barrier between the cell and its environment.
This, in itself, is not a determinant of virulence, but it is an
invaluable role for LPS (and OM) in cell integrity and viability.
As a result of the many negatively-charged groups present throughout
the length of the LPS molecule (see section 1:2:2), positively
charged ions and molecules may be sequestered from the environment
onto the LPS at the cell surface. These ions could then be taken up
and used for essential processes in cellular metabolism. This
sequestration of positive ions may provide a distinct advantage when
these cations are in limited supply as may be observed when cells
are growing in vivo.
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Lipopolysaccharide plays a very important role in the process of
invasion from local sites into the bloodstream. coli, the
commonest organism causing septicaemia, has over 160 0-serotypes
(and hence over 160 different LPS structures), but only a small
fraction of these have been found to result in septicaemia (or other
invasive infections) (Orskov 1978; Orskov _et_ _al_ 1977). A similar
limitation of 0-antigen distribution has been determined for other
clinical conditions caused by E. coli (see table 1:3).
Table 1:3. Relationship of Q-serotype to Clinical





urinary tract infection 01;02;04;06;07;08;09;
01 1 ;022;025;062;075.
neonatal meningitis 01;06;07;016;0 18;083.
healthy faeces 01;02;04;06;07;08;
018;025;045;075;08 1.
As can be seen in the above table, there are only 12 0-serotypes of
E. coli commonly found in cases of septicaemia. The 0-serotypes
responsible for particular types of infection have been shown to
possess very similar structures thereby confirming the role of LPS
as an important determinant in the pathogenic processes of many
infections.
A similar situation to that seen for E. coli may be observed with
other Gram-negative organisms, but less is known of the 0-antigenic
structure of many of these, therefore little can be concluded,
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although it is observed that a limited range of O-antigen serotypes
of Serratia marsescens causes the majority of systemic infections
(Gaston e_t aJL 1988). One exception to this is Pseudomonas
aeruginosa, in which all O-serotypes can be found causing
septicaemia (and other infections), but those isolated belong
predominantly to only a small number of the O-serotypes (Dick e_t al
1988; Moody j^t al 1972; Zweerink et al 1988b). It is possible,
therefore, that the situation where all serotypes can cause
infection but some are more predominant, may be observed more
commonly for non-commensal organisms which cause septicaemia, while
commensal organisms show a limited range of O-serotypes which can
produce invasive infections.
It has been determined that LPS may effect invasion of the
circulation by aiding adherence of bacteria to tissues and transfer
across the tissue barrier. It appears that the O-serotypes of E.
coli which enable invasion may have a role in augmenting adherence
to host cell surfaces. This is best exemplified for intestinal
infections caused by Shigella, Salmonella, and some strains of E.
coli (Nevola e_t al 1985; Nevola e_t jal 1987; Smith 1977; Smith &
Parsell 1974). These strains possess acidic O-polysaccharides which
in some way permit local invasion of tissues. It is most likely,
therefore, that bacteraemia arising from endogenous flora where
perforation of colonised surfaces has not occurred may therefore
result through LPS of particular structure and composition enabling
adherence of bacteria to mucous membranes followed by entry into
blood.
3 1
Once entry into the circulation is achieved, a bacterium then faces
the immunological defences of the host, and here again LPS plays an
important role in the prevention of an effective immunological
response to the bacterial cells. There are several means by which
this may be acheived:
i) One possibility by which an organism can prevent an immune
response being mounted is by mimicking a host antigen. Because of
the wide range of sugar components of lipopolysaccharides it is
possible that some O-antigens may resemble certain host
polysaccharides, but this does not appear to be a common occurrence
for LPS, as the vast majority of O-antigens are highly immunogenic
and efficiently elicit production of specific antibodies (see
section 1:4). One example of known cross-reactivity exists between
the O-antigen of E. coli 086 and blood group B antigen (Springer
1971) .
ii) It has been shown that some lipopolysaccharide O-antigens
possess anti-phagocytic and/or anti-complement activity (Brown &
Williams 1985; Williams et al 1983; Williams et al 1986; Young 1972;
Young 1975b), thereby preventing removal of bacteria from the
circulation and/or bacteriolysis by serum. This has been
demonstrated by the use of rough mutants (lacking O-antigen) of
virulent strains of bacteria which are phagocytosed or lysed by
complement far more rapidly than their O-antigen containing parent
strains (Betz e_t 1981; Makela et_ al^ 1973; Orskov 1978; Porat e_t
al 1987; Sansano et al 1985; Schiller 1988; Shaio & Rowland 1985) in
the absence of specific antibodies. Similar results have also been
obtained by comparison of serum sensitive and serum resistant
O-antigen containing strains of organisms (Ciurana & Tomas 1987;
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Cryz _et_ al 1984; DeMatteo e_t al 1981; Goldman & Lieve 1984; Goldman
et al 1984; Grossman et al 1987; Jessop & Lambert 1986; Loos & Clas
1987; Michael & Landy 1961; Sansano jrt al 1985; Tomas _et_ al 1986;
Tomas ^rt al 1988; Taylor 1983). These serum resistant strains often
possess LPS with greater substitution of O-antigen units onto core
glycolipid, but the sugar composition and structure of the molecule
may also have a bearing (Jiminez-Lucho e_t jLL 1987; Rozenberg-Arska
et al 1986) .
It appears that lipopolysaccharide activates complement at a site
distant from the cell surface and thus lysis is prevented. Further
evidence for the role of LPS as an anti-complement component has
been demonstrated through the ability of free LPS to prevent killing
and phagocytosis (Tanamoto j2t al 1984; Vukajlovich 1986; Young
1975), probably by activation of complement therefore resulting in
its depletion.
Lipopolysaccharide therefore has a very important role in prevention
of complement dependent processes, through any of a number of means,
but the precise requirements for these antiphagocytic and
anti-complementary activities are uncertain.
iii) It has been postulated in several reports that the O-antigen
prevents access of antibodies to antigens on the surface of the OM
(Bentley & Klebba 1988; Jessop & Lambert 1985; Kelly jrt al 1987;
Saxen e_t al 1986; Shenep jrt al 1987; Vuopio-Varkila e_t al 1988a).
This would therefore prevent access to conserved structures of the
OM such as proteins and the core region of LPS, which may otherwise
be protective. This factor could represent another means of
preventing an effective immune response.
iv) LPS is a polyclonal B-cell mitogen (see section 1:3) and
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stimulates the production of many antibodies which do not recognise
antigens on the Gram-negative bacterial cell surface. This could
serve to divert a specific immune response away from the bacterium
or endotoxin, thereby lowering the efficiency of the anti-bacterial
and anti-LPS response.
v) The major means of protection from bacterial pathogens is by the
production of specific antibodies (see section 1:4). The endotoxin
molecule , particularly the O-antigen, is highly immunogenic and
elicits the production of many antibodies to each of the three
regions. These antibodies may possess opsonic, bacteriolytic, or
anti-endotoxic activity. Despite the advantage of possession of
antibodies, this does not ensure their effective activity. In some
cases antibody has been shown to bind to O-antigen at its distal
position, thereby permitting activation of complement at a site
distant from the bacterial outer membrane thus preventing
bacteriolysis (Engels e_t jil 1985; Rozenberg-Arska e_t al 1986).
Antibodies to conserved regions of LPS and also proteins could
possibly permit bacteriolysis by complement, but the O-antigen
prevents access of antibodies to these sites by steric hindrance
(see iii). The inhibition of binding to conserved sites on the
outer-membrane may present less of a problem _in vivo as endotoxin
produces its toxic actions only upon liberation from the cell
(section 1:3), which results in exposure of conserved regions and
would permit binding of antibodies.
vi) Lipopolysaccharide also has a major role in the alteration of
many host functions of the immune and other systems. This function
of LPS in pathogenesis is discussed in detail in section 1:3.
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There are thus many possible means by which lipopolysaccharide can
influence the virulence of Gram-negative bacteria with regard to
systemic infection, but its most clearly defined role is that as
endotoxin, which results in many of the pathophysiological
alterations seen in septicaemia as described in section 1:3.
1:2:6. Other Bacterial Components Affecting Virulence in
Septicaemia.
There are many components of the bacterial cell in addition to
lipopolysaccharide, which may have an important bearing on the
pathogenic processes involved in septicaemia. These factors may be
either components of the outer membrane or extracellular molecules.
Surface Components.
All components of the surface of Gram-negative bacteria appear to
play a role in the pathogenesis of septicaemia, among those are
outer membrane proteins, fimbriae and capsule (see for example
Brubaker 1985).
Outer-membrane proteins (omp) play a vital role in the ability of a
cell to assimilate nutrients from the environment, and it has been
shown that alteration of growth conditions results in changes in
expression of omp. As with LPS, variation observed under different
conditions may also have an influence on pathogenicity, but the
precise role of alteration in omp is not clearly defined in
septicaemia.
Flagella are major components of the envelope of many Gram-negative
bacteria, and represent an antigenic structure which is used for
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serotyping purposes. These flagella are responsible for motility of
Gram-negative bacteria, but they appear to possess little role in
the pathogenesis of septicaemia although they may be important in
other infections.
Fimbriae present on the cell surface also appear to be an important
factor during septicaemia. There are several types of these
protein-polymers, which all serve to aid in attachment to, and
invasion of host surfaces. Recent work by Saukkonen jrt a_l (1988) has
determined a putative role for fimbriae during invasive infections,
and particularly in septicaemia, by aiding adherence of cells to
vascular endothelium therefore preventing the removal of bacteria by
phagocytosis. This could also permit local tissue damage (Steadman
et al 1988) and contribute to the septic syndrome by causing release
of mediators from the endothelial tissue and the cellular immune
system at the sites of bacterial adherence.
Of greatest importance to invasive infections, secondary to that of
LPS, is the capsule of an organism. This is a polysaccharide
component which is present in many strains of Gram-negative bacteria
as the outer-most structure external to the outer-membrane.
The capsular polysaccharide can vary from a thin layer on the
bacterial surface, to a massive gelatinous excretion which is
visible under the light microscope with appropriate staining. The
components of capsules are as diverse as those found in
lipopolysaccharide, with many saccharide and non-saccharide units
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present (Jann & Jann 1977; Jann & Jann 1983; Jann & Jann 1987;
Orskov e_t al 1977; Sutherland 1985). It has indeed been determined
that some capsules represent extracellular O-antigen and are
therefore structurally and antigenically identical to the
polysaccharide of LPS.
Certain capsules enable invasion of tissues and blood, and also
perform anti-phagocytic and anti-complementary functions (Allen e_t
al 1987a; Allen jrt jLL 1987b; Bortolussi _et_ al 1979; Cross e_t al
1984; Cross et al 1986; Stevens et al 1980; Tomas et al 1986; Welch
et al 1979; Williams et_ al 1983; Williams e_t al 1986). These
activities are performed as a result of the high negative charge and
high hydrophilicity of the capsule. If, however, anti-capsular
antibodies are present then activation of complement and
antibody-dependent phagocytosis can occur, resulting in cell lysis
and/or removal (Bortolussi & Ferrieri 1980; Cross ^et_ al^ 1983; Raff
et al 1988; Williams jrt al 1988). This is overcome in some strains
through production of a non-immunogenic capsule, such as the Kl or
K5 capsule of coli, or by production of a mass of capsular
material. Strains carrying the Kl or K5 capsules are, in fact,
observed to cause a large proportion of invasive infections (Cheasty
et al 1978; Cross et al 1984).
Despite the advantages for a pathogen to possess a capsule, many
non-capsulate organisms can also effect invasion and resist
phagocytosis or complement lysis as a result of the presence of
certain lipopolysaccharide structures. Capsules are particularly
important for strains which would otherwise be serum sensitive, as
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observed for some invasive strains of E. coli which possess LPS
which does not confer resistance to serum killing or phagocytosis.
Additionally, capsule is also important to pathogenic organisms
which naturally possess only rough LPS on their surfaces as
witnessed by the presence of rough strains of coli in invasive
infections (Cheasty et_ al 1978; Cross et^ al 1984) and P. aeruginosa
in some localised infections (Cochrane e_t al 1988; Fomsgaard al_
1988; Kelly e_t al 1987). In addition, organisms which possess only
rough type LPS, or lipo-oligosaccharide, such as Neisseria
meningitidis and Haemophilus influenzae, capsule assumes great
significance in pathogenesis.
It has been observed that, as with LPS, growth conditions markedly
alter expression of capsular polysaccharides. At high growth rates
very little capsule is produced, but during nutrient limitation
there is a massive increase in production of capsule and
concomitantly surface hydrophilicity, and therefore increased
virulence.
Extracellular Components.
Many Gram-negative organisms produce extracellular proteins (see for
example Brubaker 1985). The production of these toxins or enzymes
could therefore contribute to the pathogenic and pathophysiological
processes of septicaemia, as well as in other disease processes. In
septicaemia, no clearly defined role has been determined for toxins
from most organisms, except P^ aeruginosa for which exotoxin A is
believed to be an important determinant (Cryz et^ al 1984; Miller &
Wenzel 1987; Pollack 1984; Pollack & Young 1979; Pollack et. al
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1983). The putative role of these molecules must therefore not be
ignored.
Many components of the Gram-negative organism, therefore, may have a
part to play in the pathogenesis of septicaemia, but those most
closely linked to the development of invasive infections are LPS and
capsule. Of these, LPS is undoubtedly by far the more important
factor, as discussed in this and the following sections.
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1:3. Endotoxic Activities and Host Response to Lipopolysaccharide.
1:3:1. Physiochemical Aspects of Endotoxicity.
It has become clear that lipopolysaccharide (endotoxin) is the
bacterial component responsible for the syndrome associated with
septicaemia and septic shock. This has been demonstrated with animal
models which have been challenged with purified LPS from any of a
range of organisms, resulting in production of all of the
pathophysiological changes observed in septicaemia. Recent evidence
has also uncovered the presence of endotoxin at high levels in the
circulation during episodes of septicaemia. Together, these two
factors strongly indicate that LPS is the component of greatest
significance in the processes involved in septicaemia.
The toxicity of LPS is expressed only upon its release from the
bacterial cell surface, and not while it remains an integral
component of the outer membrane of viable organisms. This accounts
for the finding that bacteraemia itself does not necessarily lead to
septic shock, but the presence of endotoxin in the blood
(endotoxaemia) with or without bacteraemia does. The source of this
endotoxin could either be bacteria which have been effectively
treated with antibacterial agents resulting in cell lysis, or
alternatively the large pool of endotoxin present in the intestine
(see section 1:1:1).
The mode of presentation of lipopolysaccharide in vivo in an
infected individual has an important bearing upon its potential
toxicity as there are several forms in which LPS may be present in
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the blood:
-Firstly, LPS can be found as an integral component of the bacterial
cell, but, as mentioned above, cell-bound endotoxin cannot express
toxic activities because exposure of the lipid A region is required
for this purpose. It does appear that core-glycolipid epitopes may,
however, be exposed to a great enough extent to exert immunogenicity
im many individuals (Mackie et al 1982).
-Secondly, LPS may be found in fragments of outer membrane - or
blebs - which have been sloughed off the cell during the process of
normal growth in vivo as has been observed in some Klebsiella
(Straus et^ al_ 1985; Straus 1987) and Pseudomonas cepacia (Straus eT.
al 1988) infections as a response to metabolic conditions, although
it has been observed that LPS is released from the cell surface as a
by-product during proliferation of bacteria. Additionally,
release of LPS in complexes has been observed for other organisms,
including E. coli (Gankema et al 1980; Goris et al 1988; Hoekstra et
al 1976; Mackowiak 1984; Morrison & Rudbach 1981; Rothfield &
Pearlman-Kothencz 1969; Russell 1976; Tesh e_t al 1986; Tesh &
Morrison 1988), Pseudomonas aeruginosa (Cadieux e_t al 1983), and S.
typhimurium (Lindsay et al 1973; Mackowiak 1984; Rothfield &
Pearlman-Kothencz 1969) when organisms are grown _in vitro, and may
therefore also occur during the infectious process. These complexes
may thus also occur during growth _in vivo, and further support for
this exists as increases in endotoxin are observed during
proliferation of bacteria in an experimental animal system (Shenep
_et al 1985a). It has also been determined that these complexes of OM
may possess significant toxic activities, as observed for K.
aerogenes (Straus 1987) and P. cepacia (Straus £t. al 1988), and may
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thus contribute significantly to the development of septic shock.
-A third possibility is that LPS released from a cell upon lysis may
form micelles through hydrophobic interactions between lipid A
units. The relevance of micelles to the toxic activities is unsure,
and it is more likely that LPS is released in complexes with other
om structures.
-Serum lipoproteins appear to be of importance in the interactions
of LPS with host modulatory systems. Of particular importance are
high density lipoproteins (HDLP) which have been shown to bind
rapidly to circulating free endotoxin (Abdelnoor et al 1982; Munford
& Dietschy 1985; Munford et^ al 1982; Novitsky e_t al 1985; Tobias &
Ulevitch 1983; Tobias jt_ jal 1985; Ulevitch & Johnston 1978; Ulevitch
et al 1979; Ulevitch et^ al 1981; Warren e_t al 1987b), and many such
complexes may be found. These LPS-HDLP complexes may, however,
effectively neutralize toxicity (Warren e_t al^ 1986; Warren et _al
1988), although a report of preservation of toxicity has been
documented (Freudenberg e_t al_ 1980). HDLP-LPS complexes might only
be found during the early stages of endotoxaemia when a host remains
relatively healthy, with the levels of endotoxin rising once HDLP
has been saturated. Two recent reports (Berger & Beger 1988; Konig
et al 1988) have indicated that HDLP may play no significant role in
the neutralisation of LPS toxicity. The role for HDLP thus remains
doubtful, although other serum factors have been implicated (see
above references) .
Low density lipoprotein (LDLP) may also be of importance in the
presentation of LPS in vivo, but reports of its relevance are few
(Morel _et jal 1986; Navab e_t a^ 1988). It does appear, however, that
LDLP allows LPS to retain full toxicity.
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-Finally, LPS may be present as free molecules in the circulation,
not complexed or bound in any way. It would be expected that LPS in
this form would produce its greatest toxicity, but it would be
difficult to demonstrate the presence of free LPS Jan. vivo.
Another factor which has been shown to influence the toxicity of LPS
is the nature of the cations which bind to the negatively charged
groups present throughout the length of the molecule, and also the
solubility of the molecule (Baggerman et al 1987; Brade et_ al 1987a;
Csako et al 1986; Galanos & Luderitz 1975; Galanos & Luderitz 1976;
Goodman ejt al 1984; Komuro e_t al 1987; Ogawa & Kanoh 1984). The
nature of the cations and solubility appear to be linked to the
amphipathic nature of LPS, as alteration in toxicity by
positively-charged ions appears to be the result of alterations in
solubility of the LPS or LPS-complexes. For example, it has been
determined that weakly positive ions, such as triethylamine, produce
a highly soluble form of LPS which expresses high toxicity, probably
as a result of exposure of lipid A. In contrast to this, when
predominantly divalent cations are bound to the LPS molecule (Mg^+
or Ca^+) the solubility of LPS is reduced, resulting in a lowered
toxicity (which may be caused by LPS molecules forming complexes via
ionic bridges and thus reducing exposure of lipid A). The ions which
are present _in vivo would thus influence the relative toxicity of
endotoxin.
LPS prepared from both smooth and rough strains of bacteria possess
the toxic activities. The toxic moiety of LPS is the lipid A and the
structural and conformational requirements for toxicity continue to
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be uncovered (Galanos e_t al 1984b; Galanos e_t al 1985; Homma al
1985; Matsuura e_t al_ 1985; Shimizu e_t al 1988; see also section
1:2). Lipid A itself is highly insoluble, and therefore its toxic
activities are not fully expressed unless it is solubilised in some
way. There is a requirement for at least the presence of a KDO unit
(representative of Re LPS) to enable solubilisation and expression
of toxicity. Solubilisation of lipid A can also be achieved by the
use of various agents, including conjugation to bovine serum albumin
(Galanos et _al 1972; Ogawa et al 1986), incorporation into liposomes
(Banerji et eL_ 1979; Dijkstra et al^ 1987; Kataoka et al 1971), or
alteration of ionic form (Galanos & Luderitz 1975; Galanos &
Luderitz 1976), although all of these alter the toxicity in some
way.
The toxicity of lipid A (and hence LPS) from different species has
been shown to differ. LPS from Enterobacteriaceae has been shown to
be far more toxic than LPS from Pseudomonas species, which is in
turn more toxic than LPS from Bacteroides species (Johne et al 1987;
Luderitz et al 1978). This effect seems to reflect differences in
the structure of the lipid A from these organisms.
The size of the core oligosaccharide in LPS from rough mutant
bacteria also affects the toxicity of LPS, most likely as a result
of differences in the solubility of the molecule as a result of the
presence of different sugar molecules. When only KDO units are
substituted onto lipid A, lower toxic activity is obtained than when
progressively more sugars are present (Morrison & Rudbach 1981). The
size of O-antigen has also been shown to affect solubility and
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toxicity of free lipopolysaccaride (Cryz jjt a1_ 1984b). The number of
sugars substituted onto lipid A and the size of the O-antigen thus
affect the solubility of LPS and, as a result of this, its toxicity.
The expression of toxicity of LPS is a complex process under the
influence of many factors, but despite this, LPS has been shown to
possess a wide range of activities both jin vivo and Jar vitro.
1:3:2. Toxic Activities of Endotoxin and Pathophysiology of Septic
Shock.
LPS binds non-specifically to most cells and tissues - probably
through hydrophobic interactions and by binding to receptor sites -
as well as to humoral factors (Bradley 1979; Braude 1980; Cybulsky
et al 1988; Dinarello 1983; Freudenberg jjt al_ 1982; Kalter ert al_
1985; Luderitz et al 1984; Mathison & Ulevitch 1979; Morrison 1983;
Morrison 1987; Morrison & Rudbach 1981; Morrison & Ryan 1979;
Morrison & Ulevitch 1978; McCartney & Wardlaw 1985; Nowotny 1987;
Rietschel & Brade 1987; Rietschel _et^ aT 1984b; Rubenstein ejt aJ
1962; Wolff 1973; Zimmerman & Dietrich 1987). Because it interacts
with so many host systems, LPS is a potent effector molecule,
resulting in the release and/or activation of many endogenous
mediators. The host factors involved include complement (via
classical and alternate pathways) (Goldstein 1985; McPhaden & Whaley
1985), prostaglandins, interferons, platelet activating factor
(Hsueh et al 1987; Wallace 1987), interleukins (Keppler et al 1987;
Northoff jet. a_l 1987; Urbaschek & Urbaschek 1987), Hageman factor,
and cachectin (tumour necrosis factor) (Bauss jet_ jQ 1987; Beutler &
Cerami 1987; Cerami & Beutler 1988; Mannel et al 1987; Michie jitj al
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1988; Old 1987). LPS can also directly affect the action and
function of phagocytic cells, leukocytes and platelets (Baker et al
1988; Groenveld et_ _a]L 1988; Haeffner-Cavillon al 1985; Luscher
1987; McCuskey et al 1987; Parker & Parillo 1983; Regel e_t jQ 1987;
West et al 1985).
As a result of massive activation and alteration of the humoral and
cellular immune systems, the complement system, as well as the other
systems involved, a febrile condition is induced, which leads to
reduced blood pressure, leukocytosis and leukopenia,
thrombocytopenia, alteration of metabolism, and release of further
mediators. This condition may then proceed further to produce
hypovolaemic shock, respiratory oedema, respiratory collapse, and
disseminated intravascular coagulation (Ali et al 1987; Al-Sarraf e_t
al 1988; Cybulsky et al 1988; Fowler et al 1983; Gathiram ert al
1987a; Gelin 1980; Harris et al 1987; Luce 1987; McCartney & Wardlaw
1985; Rogers-Jacob & Bone 1986). These later stages of septicaemia
result intfsyndrome which is called septic shock and which, in the
majority of cases, results in death.
The activation of the complement system by endotoxin has been
studied in great detail and appears to be of central significance in
the initiation of the febrile state which accompanies septicaemia
(Goldstein 1985; McPhaden & Whaley 1985; Vukajlovich 1986;
Vukajlovich et al 1987). Upon release of endotoxin from bacteria,
complement is activated by both the classical and alternative
pathways, causing release of febrile mediators and immune
activators.
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The means by which LPS activates the other cellular and humoral
mediators of toxicity is unclear, but it is believed that some toxic
effects may result from disruption of cellular membranes by lipid-A
(Kilpatrick-Smith e_t al 1985; Shands 1973), or by causing release of
cellular contents. There is also evidence that LPS localises
intracellularly in the nucleolus of cells and may thus alter protein
synthesis (Lucas jrt al 1985) causing cell lysis or possibly release
of immune system mediators or possibly even through the formation of
immune complexes contributing to tissue damage (Ohshio ejt al 1988).
LPS may also affect intracellular enzymes, resulting in the
alteration of normal cellular metabolism and production of immune
mediators. The normal immune response may thus be amplified by the
high levels of LPS present in the circulation.
Lower doses of endotoxin do not produce the above detrimental
effects, but do, on the contrary, result in beneficial effects
(Morrison 1983; Ribi 1984; Urbaschek & Urbaschek 1987). LPS is a
non-specific B-cell mitogen and can produce a general increase of
antibody levels to many antigens (Ribi ej: al 1987), and in relation
to this, LPS is a potent adjuvant, causing amplification of immune
response to various antigens. A clearer example can be observed
after either Gram-negative infection or challenge with non-lethal
doses of endotoxin or endotoxin precursors. These can produce a
non-specific resistance to subsequent infection (Chase e_t ajL 1983;
Chong & Huston 1987; Vuopio-Varkila _et_ al 1988b) and could be used
to modify the immune response of individuals at high risk of
infection. Low doses of LPS have also been shown to possess
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anti-tumour activity through induction of cachectin (tumour necrosis
factor - TNF) (Carswell et al 1975; Freudenberg et al^ 1984; Ribi ej;
al 1982; Ribi et al_ 1984). LPS therefore possesses potentially
therapeutic activities and much work is being carried out at present
in assessing its role and the role of structural analogues as a
therapeutics agent in septicaemia and certain other clinical
situations.
The role of lipopolysaccharide as a mediator of toxicity in diseases
does not stop with septicaemia. Its role in several diseases has
been confirmed, including Toxic Shock Syndrome (de Azavedo _et_ al
1985), Adult Respiratory Distress Syndrome (Fain et £l 1983; Fowler
et al 1983; Kaplan ej. al 1979), renal failure (Bailey 1976; Wardle
1982; Wardle & Wright 1981), liver disease (Young et al 1986), heat
stress (Gaffin ejt al_ 1981), radiation sickness (Gaffin e_t al 1987),
and a putative role has also been suggested in production of tissue
damage in periodontal disease (Lucas et_ al 1985). It may well turn
out that LPS is a far more important mediator of disease in many
more situations than is known at present.
Irrespective of its mechanism of activation and modification of host
immune response, LPS is undoubtedly a highly active toxin of great
importance in septicaemia, and as a result of its diverse actions it
is central to the development of septic shock.
1:3:3. Host Response to Endotoxin.
Not every person is susceptible to systemic infection by
Gram-negative opportunistic pathogens (see section 1:1:2 for
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pre-conditions) and most people are capable of mounting an immune
response to the causative organisms and/or endotoxins. The
effectiveness of this response has an important influence upon the
outcome of septicaemia.
All factors of the immune system have been found to be important
determinants of the outcome, and ineffectiveness of any of these
could result in an overwhelming bacteraemia leading to septicaemia
and septic shock (as discussed in section 1:1:2). Many of the
symptoms of septicaemia and septic shock do, however, result from
massive activation of the immune system by LPS as mentioned
previously. The balance between appropriate protective response and
overactivation of the immune system is thus finely divided.
In a "normal" individual, invasion of the blood is usually prevented
by the non-specific host defences present on the mucous membranes
and skin. When organisms do penetrate these surfaces, there are many
factors which can prevent overwhelming infection of the blood. These
include removal of bacteria from the circulation by the
reticuloendothelial system (RES) and other phagocytic cells,
destruction of bacteria inside phagocytes, opsonisation of bacteria
and neutralisation of bacterial products by antibodies, and
activation of the complement cascade by either classical or
alternative pathways, resulting in bacteriolysis.
It appears that the presence of bacteria up to certain levels can be
tolerated, but if numbers exceed a threshold value, septicaemia may
result. The development of septicaemia most probably occurs as a
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result of a blockade of the RES by the sheer number of bacteria
present, massive activation of complement, and removal of protective
antibodies. This would prevent further removal of bacteria or their
products and permit an increase in levels of bacteria and endotoxin
in the blood, leading to expression of endotoxicity.
Alternatively, if bacteria are efficiently lysed by the host immune
mechanisms (complement and antibody) or by effective treatment with
antimicrobial agents, endotoxin is released and could then proceed
to activate mediators of toxicity (as described above) if not
removed from the circulation.
One further possibility resulting in release of endotoxin would be
through application of therapeutic agents which (either directly or
as a side-effect) alter the permeability of the intestinal lumen
thereby allowing entry of endotoxin into the circulation. Once again
this would result in expression of toxic activities of LPS if not
rapidly removed. This could additionally be achieved during
ischaemic damage to the bowel or tissue perfusion, thereby releasing
vast amounts of endotoxin (Freeman & Gould 1985a).
It can be seen that in a non-compromised individual large numbers of
bacteria or large amounts of endotoxin would thus be required to
induce septicaemia, as removal of all but very high concentrations
of bacteria and LPS could be obtained. As a result of an
immunocompromised state (whether by depletion of complement,
antibody, phagocytosis, or cell-mediated immunity), this condition
could be achieved more rapidly. Compromised patients are therefore
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observed to enter into septicaemia at a higher rate.
Even in a healthy person, endotoxin is constantly seeping from the
intestine into the blood, but is removed by phagocytic cells in the
liver before it can mediate its toxicity. Despite the removal of
endotoxin, an antibody response can be generated.
Much evidence points to the role of the liver (and to a lesser
extent, the spleen) in clearance of bacteria and endotoxin and their
release into the circulation. It has been shown that a high rate of
clearance by phagocytic cells in the liver (hepatocytes) correlates
well with survival from septicaemia, while a lowered efficacy of
clearance is linked with a poorer rate of survival (Billiar j2t al
1988; Cheslyncurtis e_t a_l 1988; Freudenberg jrt al 1982; Jacob et al
1977; Katz et al 1984; Lumsden et al 1988; McCuskey et al 1987;
Prytz jrt al 1976; Shirai e^ j^l 1988; Thompson j^t al 1988) . Any means
by which this important function of the liver is depleted would thus
allow entry of LPS into the circulation from the intestine.
Therefore liver dysfunction resulting from underlying disease,
therapy, or the action of certain toxins may reduce the liver's
ability to remove LPS and bacteria and detoxify endotoxin, thereby
permitting development of septicaemia and septic shock.
Other phagocytic cells and organ systems also have important roles
to play in the removal of bacteria and/or endotoxin. Phagocytic
cells provide a non-specific defence system which can provide
protection against systemic bacterial or endotoxin challenge (Hammer
et al 1981; Regel jrt al 1987; Vuopio-Varkila 1988; Vuopio-Varkila &
Makela 1988). Polymorphonuclear leukocytes (PMNL) and macrophages
have both been demonstrated to sequester endotoxin, and have been
shown to possess activities which alter the LPS molecule, and which
may also reduce its toxicity (Duncan & Morrison 1984; Farley et al
1988; Freudenberg & Galanos 1986; Freudenberg & Galanos 1988;
Freudenberg et al 1985; Munford & Hall 1985; Munford & Hall 1986;
Weinstein & Young 1976; Young & Armstrong 1972). In addition, PMNL
have been shown to possess a protein which causes lysis of
Gram-negative bacteria (Hovde & Gray 1986a; Hovde & Gray 1986b;
Tedesco e_t 1986; Veld jet al 1988). Thus phagocytic cells provide
further means of protection from systemic infection, and have an
important role in Gram-negative septicaemia.
Exposure of Gram-negative bacteria to normal human serum in the
absence of specific antibodies, results in the release of
lipopolysaccharide from cells and reduction in the number of viable
organisms (Tesh & Morrison 1988; Tesh e_t al 1986). This appears to
occur through the action of complement (C') upon cells, and this
system is central in the prevention of systemic bacterial invasion.
Complement possesses both lytic and opsonic activities for intact
Gram-negative bacteria via both the classical and alternative
pathways (lhara et^ al 1982; Loos & Clas 1987; Loos e_t al_ 1978;
McPhaden & Whaley 1985; Rowley 1973; Rozenberg-Arska et al 1986;
Schiller 1988; Sculier & Klastersky 1984; Taylor 1983; Wright &
Levine 1981; Vukajlovich 1986). The C' system is effective against
many strains of organisms, though there are some which can prevent
effective action of complement (see section 1:2). Complement
therefore has an important role both by itself and in conjunction
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with other components of the immune system, for the lysis and
removal of organisms from the circulation.
Within the population a wide range of antibodies of IgG, IgM, and
IgA classes have been detected which recognise Gram-negative
bacteria and their lipopolysaccharides. A wide range of levels of
these antibodies to a variety of O-antigen, core oligosaccharide,
and lipid A components of lipopolysaccharides have been shown to
exist (G.R. Barclay - unpublished data; Appelmelk ej: a_l 1985;
Appelmelk et_ al 1986b; Appelmelk e_t al 1987a; Barclay & Scott 1987;
Brade & Galanos 1983; Braude 1980; Brauner e_t al 1987; Cohen &
Norins 1966; Fomsgaard _et al 1987a; Gleeson jit al 1987; Jacobson _et_
al 1987; Kataoka et. al 1971; Law & Marks 1985; Marget 1987;
Mattsby-Baltzer & Alving 1984b; Mattsby-Baltzer & Kaijser 1979; Nys
et al 1987; Nys ejt al 1988; Schedel et_ al 1987; Scott & Barclay
1987; Stoll et al 1985; Stoll et al 1987; Vanesian et al 1987; Young
1972; Young e_t al 1975b). Antibody titres have been shown to rise
from birth - as a result of production of antibodies against
organisms which form the commensal flora (Chedid _et al 1968) - up to
the age of three. After this age, titres remain fairly stable (Law
and Marks 1985). It has also been observed that, within individuals
in a blood donor population, levels of antibodies to a particular
lipopolysaccharide remain fairly stable over a period of up to
twelve months (G.R. Barclay unpublished results).
Because O-antigen is the outermost component of LPS, and also the
major antigenic structure, antibodies to many O-antigens from
organisms which cause septicaemia (and others that do not) can often
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be found at high levels in healthy people. Despite the prevalence of
antibodies to O-antigen, antibodies to core glycolipid (CGL -
comprising lipid A and core oligosaccharide) have also been detected
in all individuals studied.
Anti-O-antigen antibodies are specific to a particular O-antigen,
although some limited cross-reactivity can be observed within and
between some organisms (section 1:2). Anti-core glycolipid
(anti-CGL) antibodies show far greater cross-reactivity between
different species and genera, but these antibodies are present at
lower levels than the O-antigen-specific antibodies. In spite of the
lower concentrations of anti-CGL antibodies, they may perform an
equally important role in protection against the effects of systemic
release of Gram-negative bacteria or endotoxin.
Core glycolipid is the LPS component against which naturally
cross-reactive antibodies can be detected. Antibodies to outer core
possess the ability to cross-react with other Gram-negative bacteria
because of the similarities observed in outer core structures (see
section 1:2) although this ability is restricted because of
structural heterogeneity. Inner core structure is more highly
conserved between genera, and consequently antibodies directed
against inner core are highly cross-reactive. Additionally,
antibodies to lipid A can also be detected at low levels, and these
also would be expected to possess cross-reactivity.
Antibodies to lipopolysaccharides have been shown to possess
antibacterial properties of relevance in septicaemia by three main
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means: firstly, antibodies can perform opsonic activities, either
directly or via complement, enabling uptake of cells or endotoxin
into phagocytes; secondly, antibodies can result in bacteriolysis by
activation of complement, thereby releasing endotoxin; and finally,
antibodies may act in an anti-endotoxic capacity, neutralising or
modulating the activities of LPS. The first two functions are
performed mainly by antibodies directed against the O-antigen of LPS
(Dunn 1988; Frank et al 1987; Gaffin & Wells 1987; Just et al 1987;
Kim ert al 1988; Lam et^ jLL 1987a; Lam et^ al 1987b; Mclntyre j^t al
1986b; Pudifin et al^ 1985; Sawada e_t al 1987; Young 1984), and
appears to be a lesser role for anti-core antibodies. In contrast,
reports indicate that antibodies to core glycolipid can bind to free
lipid A and CGL, but variation is seen in the ability to bind to
whole organisms (Appelmelk e_t al 1988; Elkins & Metcalf 1985;
Gigliotti & Shenep 1985; Miner e_t al 1986; Teng e_t jl 1986).
Anti-CGL possess only limited opsonic and bactericidal ability, if
any at all (Betz et al 1982; Crowley et al 1982; van Dijk e_t al
1981; Kirkland & Zeigler 1984; Mehta et al 1988; Michael & Mallah
1981; Miner et al 1986; Rietschel & Galanos 1977; Vreede et al 1986;
Welch et al 1979; Young 1984; Young & Stevens 1977; Young ej^ al
1975a), and perform mainly antitoxic activities through binding to
epitopes within lipid A and/or core, and inhibiting binding of
endotoxin to humoral and cellular targets, thereby preventing
activation of the immune system. Anti-O-antigen antibodies may also
perform anti-toxic activity by enabling removal of LPS in some of
its possible forms (see section 1:3:1) from the circulation.
Antibodies directed against 1ipopolysaccharide therefore have a
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central position in the prevention of development of septicaemia,
and depletion of anti-LPS antibodies could permit progress of this
condition.
Further support for the central role of antibodies in septicaemia
has been obtained in a series of clinical studies. Antibodies to
O-antigen and core glycolipid endotoxin have been shown to fall
during the acute phase of septicaemia, but rise in patients that
survive (Nys et al 1988; Peter et al 1979; Pudifin e_t a_l 1985;
Schedel 1988). Decreasing levels of antibodies are associated with
patients who ultimately die, while patients maintaining elevated
levels of antibodies, or with increasing antibody levels show a far
higher rate of survival (Brauner et al 1986; Brauner e_t al_ 1987;
Cohen j2t jLl 1987; Freeman & Gould 1985b; Freeman & Gould 1986;
Matthews e_t al 1986; McCabe _et al 1973; Nys et_ jil^ 1987; Pollack e_t
al 1983a&b; Young 1972). In relation to this, patients who possess
high levels of antibodies prior to septicaemia have been shown to
show a lower infection rate and a higher survival rate than those
with negligible levels of antibody (Pollack & Young 1979; Stoll _et
al 1985).
The above observations therefore re-inforce the highly important
role of anti-LPS antibodies in septicaemia and endotoxaemia, and
elevation of antibodies to LPS may be of great significance in the
prevention and reduction of symptoms of septicaemia, although
antibodies may in some cases lead to production of circulating
immune complexes which may lead to tissue damage (Ohshio _et_ al
1988) .
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Other serum factors also have a role to play in the prevention of
septicaemia. Several factors have so far been discovered in various
species of vertebrates, including humans. These include factors
which bind endotoxin resulting in neutralization of activity, and
also proteins which effect bacteriolysis. It should be noted that
these factors cannot be ignored as they appear to be important in
resistance and immunity to endotoxin. Among these components are
high-density lipoprotein (Munford e£ al 1982; Novitsky £t_ ad 1985;
Ulevitch & Johnston 1978; Warren & Chedid 1987), although the role
of this has recently been queried (Berger & Beger 1988; Konig et al
1988). Low molecular weight proteins (Brade and Brade 1985; Tobias &
Ulevitch 1983; Tobias et^ al 1985; Tobias e_t al 1986) which bind and
alter toxicity of LPS have also been implicated, as have a
bactericidal protein (Farley et_ al^ 1988), and a macroglobulin
(Michael & Rosen 1963). In addition, several other factors have been
demonstrated to possess LPS-binding properties, and may also play
important roles in neutralisation and/or removal of endotoxin from
the circulation (Bailey 1976; Berger & Beger 1988; Cahill 1983;
Jirillo et al 1986; Johnson £t al 1977; Warren et al 1985; Yamaguchi
et al 1986; Yamaguchi et al 1987). These factors appear to possess
endotoxic modulating activity, but their relevance to the human
situation is not clearly defined at present, as most have so far
been discovered in other species.
Many factors are obviously involved in protection of individuals
from the deleterious effects of septicaemia or endotoxaemia, but it
is obvious that despite these factors, many cases are still
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observed. The difference between appropriate response and
over-reactivity, resulting in septic shock, is finely balanced and
dependent upon both host and pathogen factors. As the host
components responsible for the prevention of sepsis become clearer,
and in view of the severity of this syndrome, it is necessary that
appropriate preventative and therapeutic measures are available to
reduce or remove the threat of fatalities caused by Gram-negative
septicaemia. Those measures which are currently available, as well
as emerging regimens, are discussed in section 1:5.
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1:4. Small Animal Models of Gram-negative Septicaemia and
Endotoxaemia.
Because of the severity of the syndrome associated with septicaemia,
it has become necessary to develop animal models to evaluate the
effects of systemic infection by Gram-negative bacteria and their
endotoxins, and to assess potential therapeutic regimens. A wide
range of animal models has been developed, each possessing different
physiological and immunological responses to bacterial or endotoxin
challenge.
The species of animal which is most reactive to endotoxin is man
(Greisman & Hornick 1969; Michie et_ 1988; Westphal 1975; Wolff
1973). It has been shown that man is sensitive to nanogram ( 10-^
gram) or even picogram (10~'2 gram) amounts of LPS per millilitre of
blood. Reactivity to these levels of lipopolysaccharide is observed
even in healthy individuals. Animal models can therefore only be
used to give an indication of effects of bacteria or LPS or
protective activity of agents in humans.
Many animal species have been used to determine various factors
involved in septicaemia, but in most cases very high doses of
bacteria and/or endotoxin, in comparison to those needed in humans,
have been required to produce the symptoms of septicaemia or death
resulting from septic shock. The animal of closest sensitivity to
that of humans is the rabbit and it has found use in several models.
As a result of the lower sensitivity of other animal species to
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endotoxin and bacteraemia, it has been necessary to induce a state
of compromise in these animals. Compromise of animals by a variety
of means has led to a reduction in challenge doses required to
produce septic shock. In addition, in some instances the mode of
compromise has produced a condition in the animals similar to
conditions which permit septicaemia in hospital patients. Induction
of a state of compromise in animals can therefore result in
production of models of greater relevance to the evaluation of
septicaemia and therapeutic strategies.
The animals which have found most usage as models of septicaemia or
endotoxaemia include mice, rats and rabbits, and to a lesser extent,
cats, dogs, sheep, pigs, and primates. Two general models have come
into use:
i) endotoxaemia, in which animals are challenged with endotoxin
purified from bacterial cells,
and ii) infection, in which live bacteria are used to challenge the
model. Additionally, several modes of compromise of animals are also
in use as described below.
1:4:1. Models of Endotoxaemia.
Endotoxin can be found at high levels in the blood and tissues of
patients with septicaemia. Thus it seems appropriate that challenge
of model species with lipopolysaccharide would be a relevant means
of mimicking the systemic effects of endotoxin. It has indeed been
shown that challenge of animals with endotoxin results in production
of the symptoms associated with septic shock, therefore challenge
with endotoxin does appear to be relevant for the assessment of
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septic shock.
Mice and rats have received greatest attention as models for
endotoxaemia. A wide range of sensitivities to LPS has been obtained
in different strains of these animals, with doses of up to 2mg being
required to produce symptoms in some strains.
Actinomycin D Model.
Treatment of mice or rats with actinomycin D prior to challenge has
produced an increase in sensitivity to the toxic effects of
lipopolysaccharide of greater than 100000 fold (Brown & Morrison
1982; Dunn et_ al 1986; Pieroni et_ al 1970). After treatment with
actinomycin D it has bee shown that it is possible to reduce the
dose required to produce 50% lethality (LD50) from approximately
200ug to 10~3ug. Other strains of animals show reduction of doses
required for LD50 to 30ug or 150ug, although the factor of reduction
remains approximately 10^. Actinomycin D acts by potentiating the
reactivity of host systems to LPS activation by a mechanism which is
not clear. This has allowed reduction of the challenge dose required
to produce pathophysiological changes in the animal models.
Galactosamine Model.
One other means of compromise which has found usage in mice or
rabbits is the reduction of efficient removal of LPS in the liver
through treatment with D-galactosamine (Freudenberg e_t a_l 1986;
Freudenberg & Galanos 1988; Galanos et al 1979; Lehmann et al 1987).
This aminosugar affects hepatocyte function and depletes their
capacity to efficiently perform their phagocytic function. This
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therefore permits levels of endotoxin in the circulation to remain
high, resulting in prolonged expression of LPS toxicity, and
increased pathophysiological alterations in the animals. As a result
of the persistence of high levels of LPS, the LD50 is reduced from
200-300ug to l~5ng (a factor of 10^) dependent upon the strain of
animal.
Schwartzman Reactions.
The local Schwartzman reaction in rabbits has been used as a means
of determining toxicity of LPS for many years (Ito e_t j^l 1985;
Ziegler e_t jal 1973b). In this model, non-compromised rabbits are
challenged intradermally with non-lethal doses of
lipopolysaccharide. After 24 hours, animals are then challenged
intravenously with a second non-lethal dose of LPS which produces
dermal necrosis at the original sites of challenge - a reaction
which is referred to as the local Schwartzman reaction. This
reaction is representative of the disseminated intravascular
coagulation (DIC) reaction observed during the latter stages of
septicaemia (see section 1:3:2). In this model intravascular
coagulation occurs locally at the site of initial challenge and
produces necrosis of the tissues. This model can also be used to
assess the protective capacities of anti-LPS antibodies.
The general Schwartzman reaction is a similar model to the above. In
this case the initial challenge is given intravenously, which
produces systemic DIC upon challenge with the second dose of LPS.
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Other Models of Endotoxaemia.
Additionally, models using sheep, pigs, cats, or dogs, or even chick
embryoes have also been used, but to a lesser extent. There are also
several other means of sensitisation of animals to the actions of
endotoxin, as discussed by Galanos ejt al (1986), Pieroni jst al
(1970) and Wichterman e_t al (1980), but those mentioned above
represent the most widely used.
Each of the models of endotoxaemia has been shown to mimic only
certain aspects of septic shock in humans, but nevertheless they do
provide useful insights into the many activities of endotoxin and
anti-endotoxic molecules.
1:4:2. Models of Infection.
Models of infection have found wider application than models of
endotoxaemia. Once again rodents have been used most commonly and a
variety of modes of immunocompromise has been applied.
Some strains of rodents have been used without any means of
compromise. This does, however, require very high challenge doses of
bacteria (often over 10^ organisms) in order to produce a febrile
state and septic shock. This causes difficulty in assessment of
physiological responses and potential therapeutic agents because of
the very high bacterial concentrations in relation to those found in
cases of septicaemia.
Neonatal rats have found use in assessment of virulence of
Gram-negative bacteria in systemic infections and in determination
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of effectiveness of antibody therapy (Hill & Bathras 1986; Kim &
Anthony 1983; Raff et al 1988; Saukkonen, Nowicki & Leinonen 1988).
This again has required very high doses of bacteria to mimic the
effects observed in humans. A similar rat model has also found use
in assessment of physiological changes during septicaemia.
As a result of the high resistance to the effects of endotoxin or
Gram-negative bacterial challenge, it has become necessary to induce
a state of compromise in animals used as models of septicaemia as in
models of endotoxaemia. Several means of compromise of these animals
have been developed, either to reduce the immune competence of
animals or to increase the virulence of challenge organisms.
Models of Neutropenia.
A state of sub-lethal neutropenia induced in an animal results in a
greatly increased susceptibility to bacterial challenge (Raff e_t al_
1988). Treatment of mice with cyclophosphamide results in profound
neutropenia within 5 days. This results in a marked lowering of
challenge dose required to produce fatal septicaemia (from lO^-lO^
organisms to below 100) and thus easier assessment of therapeutic
agents.
Prior development of a similar neutropenic model by Collins e_t _al
(1986) where bacteria are inoculated into a local wound, followed by
the application of antimicrobial agents in addition to
immunoglobulins has also produced an effective means of assessing
the therapeutic activity of antibodies. This model results in a
local infection which proceeds into septicaemia over a period of
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time, and may thus be a good representations of septicaemia as
observed in some clinical situations.
Another neutropenic model which may mimic the natural course of
septicaemia is that of Ziegler e_t al (1973a) in which rabbits are
rendered neutropenic by treatment with nitrogen mustard. This
permits invasion of the circulatory system by bacteria which were
previously administered to the animals and were permitted to
colonise the intestine. Induction of neutropenia permits invasion of
bacteria from the intestine followed by their proliferation,
resulting in a febrile condition which proceeds in many cases to
death.
A similar model to the above has been described (Teng e_t a_l 1988) in
which neutropenic rabbits are inoculated intra-ocularly with
challenge organism (in this model aeruginosa), producing a
serious local infection which proceeds to septicaemia.
A further model in which neutropenia is induced has been developed
recently by Zweerink and others (1988). In this model mice with a
congenital immunodeficiency state (resulting in an inability to
produce antibodies to carbohydrates and other antigens), were
rendered neutropenic. These mice were then challenged with
Pseudomonas aeruginosa and treated with monoclonal antibodies. This
produced a model which reduced challenge doses of bacteria required
to produce septic shock, and seems to represent another model which
parallels certain clinical conditions which may lead to septicaemia.
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Models with Mucin and/or Haemoglobin.
Increase of the virulence of bacteria by the use of mucin and
haemoglobin (Appelmelk jrt al 1986; Marks et_ ^1 1982) or mucin alone
(Coughlin & Bogard 1987) has permitted the reduction of lethal dose
to very few organisms (less than 100 organisms in most cases) and a
concomitant improvement in assessment of protective activity of
anti-LPS monoclonal antibodies in these models. Haemoglobin permits
growth of bacteria, probably by acting as a source of iron for the
organisms (Dunn et al 1983a; Dunn £t al 1983b; Dunn et al 1984).
Other Models of Infection.
Wichterman e_t al_ ( 1980) have described a model of septicaemia with
normal intestinal flora. This is produced by puncturing the caecum
of neonatal rats which develops into peritonitis and septicaemia.
Many parameters of infection can be studied including potential
therapeutic strategies. This model is said to possess many of the
features of septicaemia in man and is thus of particular relevance
to the study of septicaemia. Further means of bacterial challenge
are also discussed by Wichterman.
There are many animal models of septicaemia and endotoxaemia
currently in use, a small proportion of those commonly used being
discussed above. No model can be said to adequately mimic the
situation observed in septicaemic patients, but the models do
provide valuable insights into the processes involved in in the
actions of endotoxin and bacteria upon living organisms. A highly
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valuable use of animal models (and the reason for which many of the
above mentioned models were developed) is for the assessment of
potential therapeutic agents, and many of the therapeutic agents
mentioned in section 1:5 have been assessed by using some of these
models.
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1:5. Therapy and Prophylaxis for Septicaemia caused by Gram-negative
Bacteria.
As a result of the high fatality rate of Gram-negative septicaemia
it has been necessary to develop preventive and therapeutic
strategies to cope with this problem. Many such measures have been
taken, with a resultant variation in prevention of fatalities. Means
which have found use are antimicrobial agents, immune system
modulators, and preparations of antibodies, as well as means of
physiological resuscitation. Many of the problems encountered in
septicaemia occur as a result of inappropriate or inadequate
therapeutic or preventive measures. It is thus essential that the
most relevant strategies are employed to prevent loss of life.
1:5:1. Antimicrobial Therapy of Gram-negative Septicaemia.
There are many antimicrobial agents with proven efficacy against
Gram-negative bacteria, and which have therefore found application
in the treatment of septicaemia and other infections (Allen &
Moellering 1985; DeMaria et al 1985; Esquembre _et al_ 1987; Kreger e^
al 1980b; Pizzo & Young 1984; Stutman et al 1986; Verhagen ej: ad
1986; Young 1985a; Young 1985b). Wide variation in the success of
these agents has been described by many authors, with only limited
protection observed in many reports. Therefore the usefullness of
most antimicrobial agents is restricted. In fact, many of the
fatality rates noted in table 1:2, section 1:1:1, were obtained
during administration of antimicrobial agents.
There are some reports of higher efficacy with certain agents, but
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again the "cure" rate remain fairly low with occassional reports of
high efficacy (Baruchel et al 1986; Daenen & de Vries-Hospers 1988;
Gathiram e_t al_ 1987b; de Jongh e_t a_l 1985; McKellar 1985; Pierard
1986; Rolin & Bouanchaud 1986; Warren et^ al 1985a; Weinstein 1986).
Even lipopolysaccharide-binding antimicrobial agents - cationic
polypeptides such as polymyxin - are of limited use because of their
toxicity to animals (Peterson et al 1985b; Peterson et al^ 1987;
Rocque et al 1988; Warren et al 1985a), although there have been
instances where polymyxin has been shown to reduce certain metabolic
alterations seen in experimental septic shock (Flynn et al 1987).
Newer agents which directly affect synthesis of lipopolysaccharide
have been shown to possess strongly anti-Gram-negative activity
(Goldman e_t al 1987; Hammond e_t al_ 1987). Many aspects of these
compounds have yet to be assessed, but these antimicrobial agents
are potentially of use in the therapy of septicaemia.
Although an antimicrobial agent may be effective both _in vitro and
in vivo, this does not ensure survival of patients. A probable
reason for this is that it is the endotoxin of the cell wall which
is causing the alterations in patients and not intact bacteria
themselves, and antimicrobial agents are not directed towards LPS.
Evidence has recently been produced by several groups of researchers
which has shown that the antibacterial agents may actually be
directly involved in the pathogenesis of septic shock. Shenep and
co-workers (Shenep & Mogan 1984; Shenep et al 1985b) have determined
in a rabbit model of infection that bactericidal antibiotics are
effective in lowering the numbers of organisms present in the blood
69
by lysis of the bacteria, but this causes a resultant increase in
the level of endotoxin. Bacteriostatic antibiotics, on the other
hand, have little effect on bacterial concentration whilst endotoxin
levels remain stable. This means that, when applied to humans,
either approach could therefore lead to worsening of the patients
condition rather than improvement. Further groups have also shown
that LPS is released in large quantities by antimicrobial agents,
both Jni vivo and Jji vitro (Cohen & McConnel 1985; van Deventner et^
al 1988; Editorial 1985; Freeman 1980; Goto & Nakamura 1980; Hopkins
1977; Hopkins 1978; McConnell & Cohen 1986; Tauber et^ al 1987).
Antibacterial agents must thus be chosen carefully to minimise the
possibility of detrimental effects caused by release of endotoxin.
A further adverse role for antimicrobial agents in the pathogenesis
of septicaemia exists. A large proportion of bacteria isolated in
cases of septicaemia (whether from endogenous or environmental
sources) have been determined to have acquired increased resistance
to the most frequently applied anti-bacterial agents (Acar 1985;
Finland 1977; Lacey 1984). This means that infection by bacteria
with pre-existing resistance occurs, therefore reducing the range of
agents which can be used.
The actions of antimicrobial agents are not all deleterious, and
many have been shown to aid the immune system in removal and/or
lysis of bacteria. Many studies have shown that the expression of
LPS on the bacterial surface is altered when organisms are grown in
the presence of sub-lethal doses of antimicrobial agents, which
permits easier access of antibodies and therefore enhanced
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complement activation. This results in increased bacteriolysis,
phagocytosis and intracellular killing (Dalhoff et al 1986; Overbeek
_et al 1987; Trautman et al 1985; Wiemer et al 1985; Williams 1987).
It has also been shown that a combination of antimicrobial agents
and anti-LPS antibodies act synergistically in experimental models
of septicaemia (Collins e_t al 1986; Greisman jrt _al 1979; Neeley &
Holder 1987) .
Antimicrobial agents therefore possess actions which are both
beneficial and deleterious, and use of these agents must be
carefully assessed. Despite the potential for releasing endotoxin,
antimicrobial agents may, however, provide a useful adjunct to
immunological therapeutic strategies.
1:5:2. Other Therapeutic and Preventive Strategies.
In addition to application of antimicrobial agents, there are
non-anti-bacterial strategies which are employed under various
situations. When septic shock occurs it is necessary for many
patients to receive supportive care throughout the acute stages. The
management of many septic shock patients requires fluid and oxygen
resuscitation, application of immunomodulatory drugs and vasoactive
agents, and replacement of reticulo-endothelial factors, as well as
other physiological modifiers in addition to antimicrobial agents
(Karakusis 1986; Ledingham & McArdle 1978; Ledingham et_ al 1984;
Ledingham _al 1988b; Luce 1987; Wolff 1982; Young 1985c; Zimmerman
& Dietrich 1987). These modes of support have produced at best only
minimal benefits. They may, however, be useful adjuncts to other
therapies as they provide support to a patient with lowered immune
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competence, but do not aid in the removal or neutralisation of the
mediators of septicaemia. As these measures rely upon an already
weakened host immune system to effect recovery, they cannot be
regarded as a reliable therapeutic regimen, although as knowledge of
the processes of septic shock advances, the requirements for
effective resuscitation are becoming clearer.
The success of resuscitative and supportive measures in preventing
fatalities has been shown to be dependent upon the timing of their
initiation. If applied early after onset of a febrile state, a
higher rate of success is observed than if initiation of supportive
care is delayed (G. Ramsay - unpublished results). This phenomenon
may have an important influence on the outcome for any mode of
therapy.
One means which has been shown to reduce the frequency of
septicaemia is selective bowel decontamination (SBD) in which a
range of oral antibacterial agents is given to patients at known
risk of septicaemia prior to surgery (Alcock & Ledingham 1988; Karp
et al 1988; Ledingham e_t al 1988b; Schmeiser e^t a_l 1988; van der
Waaij 1988; Wells et^ al^ 1987; Wiesner e_t al_ 1988). This results in
removal of most potentially pathogenic aerobic and facultatively
anaerobic commensal organisms, which results in a fall in the number
of cases of septicaemia from this endogenous source. This, however,
does little to remove the threat posed by septicaemia from external
sources or from organisms which are able to recolonise the intestine
(which may be resistant to antimicrobial agents - see above).
Despite these potential drawbacks, SBD is a useful method for the
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reduction of the incidence of infection.
Removal of endotoxin from blood followed by re-infusion of the blood
has been attempted in an animal model (Cohen jrt al 1987b) and in
endotoxaemic neonates (Togari et al 1983). The animal model involved
plasmapheresis during which endotoxin was removed by adsorption onto
immobilised polymyxin, resulting in removal of endotoxin and removal
of fatal outcome. The neonatal patients were given exchange blood
transfusion, and complete recovery of patients was achieved. These
processes may therefore provide another measure which may have some
application in septicaemia or endotoxaemia, but their effectiveness
in relation to number of patients treatable must be doubtful.
Neutralisation of mediators of endotoxin activity have been shown to
be effective in the treatment of endotoxin shock. Administration of
monoclonal antibodies directed against tumour necrosis factor (TNF)
in animal models resulted in lessening of pathophysiological
alterations and reduction in fatalities (Beutler et_ al 1985;
Mathison et jfL 1988; Shimamoto et al 1988; Tracey e_t al 1987).
Despite their protective capabilities, these agents fail to remove
the initial stimulus of septic shock - endotoxin - but again may
prove to be a useful adjunct to other therapeutic strategies.
Components of serum other than antibodies are also involved in
endotoxin removal and/or neutralisation (see section 1:3). These
factors cannot be ignored as potential therapeutic agents as they
may form part of a future strategy against endotoxaemia. In
addition, precursors and synthetic analogues of lipid A have been
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shown to possess anti-endotoxic activities (Danner et al 1987;
Golenbock ejt ad_ 1987; Golenbock j!t: al 1988; Proctor e_t al 1986) and
may also prove to be therapeutically useful once their activities
are fully assessed.
None of the above strategies have proven to be highly effective in
preventing fatalities from septic shock caused by Gram-negative
bacteria. This occurs as a result of failure to remove or neutralise
the initial stimulant (endotoxin) of the pathophysiological changes
observed in this condition. A great deal of interest has therefore
been directed towards agents which remove and/or neutralise
endotoxin. Anti-LPS antibodies have been given most attention as
they are central in the host response to endotoxin (see section
1 :3).
1;5:3. The Potential of Anti-Endotoxin Antibodies for the Therapy of
Septicaemia.
A great deal of interest has been generated in the potential of
immunoglobulins for the treatment of Gram-negative septicaemia.
Successful protection has been observed in some instances and this
may therefore provide an appropriate therapeutic agent (for recent
reviews see Baumgartner & Glauser 1987b; Cohen 1986; Schedel 1988;
Telzak & Wolff 1985; Young 1984; Young 1985c).
Generally speaking, there are two groups of antibodies which exist
against the bacterial cell: type-specific antibodies and
cross-reactive antibodies. Much of the research with either group of
antibodies has been directed towards vaccination for the production
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of either hyper-immune globulin or of monoclonal antibodies, and
both methods have received much attention.
Antibodies which are type-specific or predominantly type-specific
(both monoclonal and hyper-immune) which are directed against the
O-antigen of a bacterial cell have been proven to possess protective
activities against the organisms to which they are specific, in a
variety of animal models (Antonacci et al 1984; Barclay e_t aL_ 1986;
Colwell el al 1984; Coughlin & Bogard 1987; Dunn e_t al 1985b; Dunn
et al 1988; Griesman et al 1973; Greisman et al 1979; Johns e_t al
1983; Kim €l al 1985; Kim el al_ 1988; Kirkland & Ziegler 1984;
Munford & Dietschy 1985; McCabe e_t jal 1973; Pluschke & Achtman 1985;
Sawada el al_ 1984; Sawada jl al 1985b; Stoll et_ si 1985;
Vuopio-Varkila 1988; Young 1984; Zweerink et_ al 1988b) and in human
patients (Jones e_t al 1981; Zinner and McCabe 1976). Protective
action has additionally been shown through active immunisation of
animals, which results in high levels of anti-O-antigen antibodies
(Cryz et al 1984; Cryz et al 1985; Young 1972; Ziegler el al 1973).
The action of these antibodies is due to enhancement of phagocytosis
and bacteriolysis by complement thereby removing organisms from the
circulation, and this protective activity of anti-LPS antibodies has
been demonstrated even with encapsulated strains of bacteria
(Kauffmann et al 1986).
The bacteriolytic activity of O-specific antibodies may, however,
produce further problems as it results in release of endotoxin,
which could then express toxic activities resulting in activation of
mediators of septic shock. In addition, a wide range of O-serotypes
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and species of Gram-negative bacteria are observed as causes of
septicaemia. Thus despite their obvious protective capabilities,
these type-specific antibodies have limited therapeutic value. It is
possible that a "cocktail" of these antibodies against the most
common species and serotypes may provide effective therapeutic
activity. The combination of several antibodies with different
specificities may, however, result in dilution of antibody against a
particular organism and therefore reduction of efficacy.
Alternatively, combination of these with an anti-endotoxic agent may
prove to be effective.
Furthermore, in many instances, symptoms of septicaemia result from
release of endogenous endotoxin, the bacterial source of which
cannot be identified. Also, all of the clinical signs of septicaemia
may be observed in the absence of an organism being isolated from
the blood. Therefore type-specific antibodies to O-antigen (which
are bacteriolytic or opsonic) would be of little use because of the
diversity of organisms or other possible sources of endotoxin in
septicaemia.
It would thus be advantageous to produce an immunoglobulin
preparation capable of providing protection against a wide range of
Gram-negative organisms, and which enables removal of endotoxin and
neutralisation of LPS toxicity. This requires direction of
activities towards the cross-reactive region of the
1ipopolysaccharide molecule - the core glycolipid (CGL).
The core glycolipid region represents a highly structurally and
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antigenically conserved component of LPS as discussed in section
1:2. It is therefore possible that antibodies directed predominantly
against core region would provide protection from the lethal effects
of septicaemia.
The potential of anti-CGL antibodies as protective agents may be
queried because of the nature of the LPS molecule in vivo (see
section 1:3). In the intact cell the core and lipid A are believed
to be hidden by O-antigen chains which may prevent access of the
antibody molecule to CGL or other conserved components. It has,
though, been demonstrated that full core (R-LPS) or core plus one
O-antigen unit (SR-LPS) can be found on cells, thus anti-CGL
antibodies may be able to bind to intact cells but they appear to
possess only limited opsonic or bacteriolytic activities (see
section 1:3). This problem assumes lesser significance when it is
considered that endotoxic activities of LPS are expressed only upon
release from the cell surface by the means discussed above. This
also results in exposure of the core-glycolipid, and means that
anti-CGL antibodies can therefore obtain access and bind to the
liberated endotoxin. By acting in this manner, anti-CGL antibodies
behave as anti-toxins through neutralisation of LPS activation of
cells and humoral factors by preventing access of LPS to activation
sites, and also by aiding removal of free endotoxin by the RES.
Anti-sera and monoclonal antibodies raised in a variety of animal
species against the core glycolipid or to lipid A itself have been
shown to be highly cross-reactive in a variety of assay systems, and
also effective in protection against the effects of septicaemia
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arid/or endotoxaemia caused by a wide range of bacteria in many
animal models. Protective activity has been demonstrated through
prophylactic, therapeutic, or active immunisation (Braude et_ al
1977; Bruins _et al 1977; Coughlin & Bogard 1987; Dunn & Ferguson
1982; Dunn e_t al 1983b; Dunn jet al 1984b; Dunn et al 1985a; Dunn e_t
al 1985c; Dunn ejj al 1986; Feeley al 1987; Fenwick et^ al 1986;
Galanos et al 1971; Johns et^ al 1977; Johns e_t al 1983; Larrick e_t
al 1987; McCabe 1972; McCabe e_t al^ 1973; McCabe et al 1977;
Rietschel and Galanos 1977; Sakulramrung and Domingue 1985; Teng e_t
al 1985; Warren et al 1987a; Young & Stevens 1977; Young et^ al 1975;
Young e_t al 1982) .
An extensive study has been carried out by Gaffin and co-workers
over a period of several years for the evaluation of a hyper-immune
equine plasma (HIEP). This hyper-immune plasma was shown to possess
anti-bacterial and endotoxin-binding activities (Wells & Gaffin
1987; Wells et al 1987a) and to be protective in a series of animal
models (Gaffin e_t al 1985b; Gaffin _et_ al 1986; Wells et_ al 1987b;
Zanotti & Gaffin 1985), therefore providing a strong indication of
the widely cross-protective activities of antibodies directed to
LPS.
Assessment of the protective activity of passively administered
anti-CGL antisera has been determined in human septic shock
patients. Of particular note is the long series of studies, firstly
in animals with rabbit antiserum (Braude et al 1973; Braude _et al
1977; Davis _et al 1978; Ziegler et al 1973b) then in animals with
human antiserum (Ziegler et_ al 1973a; Ziegler _et al_ 1975), and
78
finally in human patients with the same human antiserum (McCutchan
et_ al 1979; McCutchan & Ziegler 1983; Ziegler et aJ 1978; Ziegler e£
al 1979). This culminated in a study by Ziegler e_t al (1982) for
which antiserum was prepared by pooling antisera from human
volunteers who had been vaccinated with whole heat-killed E. coli J5
cells. Antiserum was administered to patients at risk of
septicaemia, and, in comparison to a control group (which received
no antiserum) a significant degree of protection against mortality
was obtained in patients with bacteraemia (22% in anti-J5 treated
patients versus 39% in pre-immune serum treated controls, p=0.011),
and in patients with profound shock (44% versus 77% mortality,
p=0.003). A further clinical trial with this antiserum was carried
out, and protective activity was confirmed (Baumgartner e_t al_ 1985),
and the protective factor was proven to be anti-CGL antibodies
(Baumgartner ejL jil_ 1987c). Further evaluation of the protective
activity of an anti-E. coli J5 antiserum was carried out by Pollack
et al 1983, with a similar protective activity being obtained.
Some studies for the evaluation of the protective capacity of
anti-CGL antibodies have not, however, been able to show protective
activities in certain in vitro and in vivo experimental systems,
despite the presence of antibodies directed towards core-glycolipid
(Gigliotti and Shenep 1985; Griesman & Johnston 1988; Griesman et al
1978; Greisman et al 1979; Ng etal 1976; Trautmann and Hahn 1985;
Vuopio-Varkila 1988). This shows that antibodies (particularly
monoclonal antibodies) which recognise conserved regions of the LPS
molecule do not all possess protective activities, but that many of
those which have been produced do possess these activities.
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Therefore it is likely that anti-core preparations could provide a
widely protective therapy for septicaemia.
Further evidence for the role of anti-CGL antibodies in protection
against Gram-negative septicaemia has been obtained by the
observation that the presence of high levels of antibodies prior to
infection results in a lower incidence of bacteraemia and an
improved survival rate in patients who do acquire bacteraemia
(Freeman & Gould 1985a; Freeman & Gould 1985b; McCabe e_t al 1972;
Peter et _al 1979; Pollack & Young 1979; Pollack et al 1983; Zinner &
McCabe 1976) - see also section 1:3.
One approach which has only recently been considered as a route of
obtaining protective antibodies to LPS is that of naturally
hyper-immune blood donors (Gaffin 1983; Rivat-Peran e_t al 1983;
Schedel 1985). Screening of blood donor populations has shown that a
wide range of antibody levels to a variety of smooth and rough
lipopolysaccharides and lipid A molecules exists (see section 1:4).
Since it has also been determined that the presence of natural
antibody to endotoxin prior to septicaemia correlates with a better
rate of survival from septic shock (see above), it is highly
probable that appropriately selected donors with high levels of
antibodies to inner core and/or lipid A could provide a readily
available source of protective antibodies for use in the treatment
of septicaemia.
Pooled human sera or IgG fractions which have not been selected for
high levels of anti-LPS have been shown to possess protective
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activity against septicaemia and endotoxaemia caused by a wide range
of organisms in animal models (Abdelnoor e_t al 1982; Bulay e_t al
1986; Collins & Roby 1983; Collins et_ al 1986; Collins e_t al 1987;
Duswald et_ al 1980; Emerson e_t al 1986; Harper et^ jLL 1987; Hill &
Bathras 1986; Iwata e_t al 1987; Peterson e_t 1987; Stephan et al
1985; Stoll et_ al 1987; Stuttman et al 1987), and in patients,
reduction in the incidence of infections was obtained (Duswald j^t ^1
1980) although, in another study, no reduction in sepsis or
mortality was obtained (Glinz et al 1985). It would therefore be
expected that selected high titre donor sera or IgG prepared from
these sera might be a highly effective therapeutic agent for the
prophylaxis and treatment of Gram-negative septicaemia.
The protective capability of normal human sera with high levels of
cross-reactive anti-LPS antibodies has been demonstrated. Sera were
assayed for the presence of antibodies to 12 smooth LPS molecules,
and those with 40ug IgG per ml or higher were pooled and
fractionated. This preparation was shown to contain both
type-specific (anti-O-antigen) antibodies, and cross-reactive
(anti-CGL) antibodies (Gaffin et al 1985). The pooled IgG was shown
to possess antibacterial activity in vitro (Pudifin et_ 1985), and
protective activity in animal models (Gaffin et al 1981; Gaffin e_t
al 1985a), and was assessed in human septic shock patients (Lachman
et al 1984a; Lachman e_t al 1984b). Results of this trial showed
fatality in 40.0% of control patients and in 4.3% of patients
receiving immunoglobulin (p=0.00236). This therefore provides a
highly effective preparation for treatment of septic shock resulting
from septicaemia and endotoxaemia.
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Further clinical trials have been carried out with donor sera
selected for high titre anti-lipid A antibodies, and preliminary
results have shown an improved outcome (Jaspers j^t al 1987; Marget
et al 1985). One other trial is under way in which human sera
possessing high levels of anti-core antibodies are being assessed
for their protective capacity, and, once again, preliminary results
are indicative of protection (Schedel 1988).
Antibodies against core glycolipid (CGL) obtained from selected
blood donors with high levels of antibodies would, therefore, appear
to provide a readily available source of antibodies for the
treatment of septicaemia, as it avoids the process of vaccination to
produce hyper-immune sera (which often produces levels of antibody
no higher than found naturally and also produces unpleasant
side-effects in vaccinees - Rivat-Peran et al 1985; Ziegler et_ a_l
1982). The production of monoclonal antibodies against conserved
epitopes of LPS is another possibility, but this is a time-consuming
process which does not necessarily result in protective antibodies.
Assessment of antibodies from blood donors is therefore an essential
process in the determination of strategies for prevention and
treatment of septicaemia.
From the above evidence it appears that passively administered
normal human sera, IgG fractions of sera, or monoclonal antibodies
selected for a high titre against CGL or lipid A could be an
effective means of treatment and prophylaxis of septic shock caused
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by Gram-negative septicaemia or endotoxaemia. Efforts to produce a
cross-protective immunoglobulin preparation therefore appear
hopeful.
The most effective therapy, however, may include elements and agents
from several current or developing strategies. The essential element
of any treatment is to eliminate endotoxin, thereby removing the
progenitor of septicaemia from the circulation and from organ
stores. It can, however, be seen that anti-endotoxin antibodies are
undoubtedly one of the factors with greatest influence of protection
from the toxic activities of LPS.
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Objectives of the Current Study.
In view of the complexity of the factors involved in septicaemia and
endotoxaemia, this thesis aims to explore several different, though
interlinked, aspects of the potential of obtaining a therapeutic IgG
preparation from the blood donor population.
1. Levels of anti-core-glycolipid immunoglobulins are assessed in an
ELISA system which used as antigens complexes of four rough
lipopolysaccharides with polymyxin. The antigenic relationship
between lipopolysaccharide present in LPS-polymyxin complexes and
other forms of LPS (uncomplexed, outer membrane-bound, and
cell-bound) will be assessed as will the levels of IgG to a wider
range of LPS molecules to determine the relevance of this assay
system for the detection of anti-LPS and in particular anti-CGL
antibodies.
2. The alteration of anti-LPS antibodies in patients in septic shock
has not been determined out in detail so far. It was thus decided
that an assessment was required to determine the presence or absence
of any relationship between particular anti-CGL antibodies with
levels of endotoxin in these patients.
3. The immunoglobulin response to LPS has not previously been
studied in detail. Immunisation of rabbits with a range of
Gram-negative bacteria was carried out to determine the
immunoglobulin response to LPS from different species and genera and
additionally to provide information upon the antigenic relationships
between epitopes present on a variety S-LPS and R-LPS and lipid A
molecules.
4. The availability of CGL epitopes on intact bacteria has been in
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doubt for some time. There was thus a requirement to determine the
extent of binding of anti-core and anti-O-antigen monoclonal
antibodies to an organism of relevance to septicaemia.
5. It has been determined that hyperimmune globulin produced by
vaccination or monoclonal antibodies possessing strong reactivity
with CGL is effective in prevention of fatalities arising from
V.
septic shock. Little evaluation has been made of the protective
capability of normal human serum selected for high levels of IgG to
CGL epitopes. Assessment must be made in vitro and in vivo of the
anti-endotoxin and anti-bacterial capabilities of human sera and IgG
possessing various levels of anti-CGL antibodies both jin vitro and
in vivo.
The results of these studies could therefore provide an indication
of the usefulness of selected human immunoglobulin products for the
treatment of septicaemia. Additionally, other points of contention
currently existing regarding the antigenic presentation of LPS and
structural and antigenic relationships between lipopolysaccharides
will be investigated. Particular regard will be paid to antigenic
relationships between organisms which commonly cause septicaemia




The bacterial strains used included Gram-negative aerobic and
facultative anaerobic rod shaped bacteria with rough or smooth
lipopolysaccharide phenotypes. These organisms were obtained from a
range of sources as mentioned below. When received, all strains were
immediatelly cultured to prepare lyophilised stock cultures.
ORGANISM STRAIN SOURCE
1. S. typhimurium R1542 Ra
2. II ii it R1 19 Rb Dr I.W. Sutherland,
3. II it ii R878 Rc Deptartment of Microbiology,
4. II ii ii R1032 Rd University of Edinburgh,
5. II ii ii R1 102 Re Edinburgh, Scotland.
6. s. minnesota R595 Re
Dr. G Schmidt,
7. s. minnesota R60 Ra Forschungs Institut,
8. II it it R345 Rb Borstel,
9. II ii it R5 Rc Institut fur Experimentalle
10. II it it R7 Rd Biologie und Medizin,
West Germany.
! 1 . K. aerogenes 10B Rb Dr. I. R. Poxton,













































22. E. coli 018;K1
23. " " " 018;K-
24. " " " 016;K1
25. " " " 06;K5 Dr. A. Cross,
26. " " " 04;K? Department of Bacterial Diseases,
27. " " " 012;K? Division of Communicable Diseases,
28. " " " 015;K? Walter Reed Army Institute of Research,
29. " " " 08;K? Washington D.C.,
30. " " " 02;K? USA.
31. " " " 01;K?
32. " " " 08;K?
33. " " " 075;K?
Lipopolysaccharides.
LPS was prepared from smooth organisms by the hot phenol-water
method of Westphal et al ( 1952) and from rough mutant bacteria by
the phenol/chloroform/petroleum method of Galanos et al (1969) (for
both methods see below). Additional LPS was obtained from List
Biologicals Laboratories, Campbell, California, USA:
E. coli 0111 :B4 Product no. 201
it ii ,i kl2 mm294 (complete core) Product no. 303
it ii ii k]2 D3lm4 (Re core) Product no. 302
ii ii ii k,2 D3lm4 (lipid A) Product no. 402
S. minnesota wild type Product no. 220
it ii ii R60 (Ra core) Product no. 312
ii ii ii R345 (Rb core) Product no. 3 10
ii ti ii R5 (Rc core) Product no. 308
ii ii ii R7 (Rd core) Product no. 306
ii ii ii R595 (Re core) Product no. 304
ii ii ii lipid A Product no. 401
Sera and Monoclonal Antibodies.
Samples of human sera were obtained from blood donors at the South
East Scotland National Blood Transfusion Centre in Edinburgh. Sera
were screened after being held at 4°C overnight. Sera were then
stored at -40°C and thawed at 4°C overnight for subsequent assay.
Two monoclonal antibodies, one with high specificity for the
0-antigen of E. coli 0 18:K1 (McAb SZ185/2.5.5), and the other with
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high specificity for the outer core region of E. coli 018:K1 (McAb
SZ27/150.3) were obtained from fusions carried out in the Department
of Surgery, University of Edinburgh Medical School.
Purified IgG prepared from blood donors with high titres (Ps+) and
low titres (Ps-) of antibodies to a P^ aeruginosa vaccine, and IgG
from volunteers vaccinated with this vaccine were obtained from the
Scottisn National Blood Transfusion Service Protein Fractionation
Centre, Edinburgh.
Selected donor sera were used for more detailed analyses. These were
GL+, possessing high levels of anti-CGL and given an arbitrary value
of 100%; GL-, possessing very low levels of anti-CGL (less than 10%
in comparison to GL+); HI-NS, containing a very high titre of
antiCGL (602% in relation to GL+); and MED 1 and MED2 with anti-CGL
values of 60% and 110% respectively in comparison to GL+.
Septic Shock Patients.
Six patients showing symptoms of septic shock from the Intensive
Therapy Unit, Department of Surgery, Western Infirmary, Glasgow were
available for assay. Blood samples were obtained daily, from which
serum was separated. Sera were assayed in ELISA and by Limulus
amoebocyte lysate assay (see below).
Preparation of IgG from Human Sera.
IgG fractions were prepared from sera in a two-step process by
precipitation and ion-exchange chromatography. Immunoglobulin was
precipitated by the addition of crystalline ammonium sulphate
(Sigma) to serum to give 50% saturation (equivalent to a final
concentration of 0.313g/ml). The (NH4)2S04 was allowed to dissolve
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with stirring. The precipitate was harvested by centrifugation (MSE
Hi-Spin) at 10,000j> for 60min. The pellet was resuspended in a small
volume of lOmM potassium hydrogen-phosphate (K2HPO4.3H2O - Sigma),
pH 6.8. After being dissolved, the solution was adjusted to its
original volume with lOmM K2HPO4.3H2O, pH 6.8. This was
re-precipitated, recentrifuged and resuspended as above. Ammonium
sulphate was removed by ultrafiltration.
Ultrafiltration was carried out in Collodion bags (Cat. No. SM
13200E, Sartorius GmbH, Gottingen, West Germany) with a molecular
weight cut-off of 12,400, in a Collodion bag holder (Cat. No. SM
16305, Sartorius GmbH, Gottingen, West Germany) under a vacuum of
50mm Hg, with 3 volumes of lOmM K2HPO4.3H2O. Once ultrafiltration
was complete, samples were adjusted to their original volume.
The second step in the purification process involved the use of ion
exchange DEAE-cellulose (Whatman DE52) . The required volume of
pre-swollen gel was prepared as a slurry by suspending in 6ml of
lOmM K2HPO4.3H2O pH 6.8, for every 1 .0g of DEAE-cellulose. The
cellulose was allowed to settle and the excess buffer was decanted.
These steps were carried out repeatedly until decanted buffer was
also at pH6.8. The slurry was finally allowed to settle and excess
buffer was removed until a final volume of 20% over the volume of
slurry was obtained. This slurry was used to prepare a column (35mm
x 315mm). Buffer was passed through the column at a constant flow
rate (45ml per h per cm^ of column cross-sectional area) until the
column bed height was constant. The column was then equilibrated
until the pH of the eluent was the same as the loading buffer (lOmM
K2HPO4.3H2O, pH 6.8). The ammonium sulphate precipitate was then
passed through the column and elution of IgG was monitored by
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observing a peak of absorbance at 280nm. Other immunoglobulins and
serum proteins were eluted by passing 1.4M NaCl in potassium
phosphate through the column. Elution was again monitored by
measuring absorbance at 280nm. The column was regenerated by washing
the column through with K2HPO4.3H2O buffer, pH6.8.
Purified IgG was then concentrated to its original volume by vacuum
dialysis using the ultrafiltration system previously described.
Culture of Bacteria.
All bacteria were cultured at 37°C in an orbital incubator (Cat. No.
IH-465, Gallenkamp, Widnes, Lancashire, UK). Starter cultures were
prepared by inoculation from blood agar - BA - stocks which were
originally prepared from freeze-dried stocks. Bacteria were
transferred onto fresh BA monthly for a total of four subcultures,
after which time fresh cultures were prepared from freeze-dried
stocks.
Bacteria were inoculated into 10ml nutrient broth to prepare a
starter culture, which could then be inoculated into larger volumes
for further growth. Purity of cultures was determined by
Gram-staining and by plating onto blood agar.
Culture Media.
a) Nutrient broth.
Gibco nutrient broth was prepared at the Blood Transfusion Service
Protein Fractionation Centre. This culture medium was sterilised by
ultrafiltration.
b) Minimal medium.
MALKA minimal medium was prepared as a modification of the medium of
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Robert-Gero e_t a\^ 1970. Stock solutions were prepared as follows.
Solution A: 73.4 mg/ml Na2HP04, 32.4mg/ml KH2PO4, pH 7.2.
Solution B: 20.5 mg/ml MgS04.7H20.
Solution C:20% w/v glucose.
Solution D: 1.83 mg/ml FeS04.7H20 in sterile distilled water, to
which 1 drop of concentrated HC1 or H2SO4 was added.
Solution E: 50.0 mg/ml (1^4)2804.
All solutions were prepared with sterile distilled water and were
filter sterilised. Solutions A and B were stored over CHCI3.
Solution C was filter sterilised. Solution D was not to be
autoclaved.
To prepare 1000ml of MALKA, 20ml A, 20ml B, 20ml C, 1ml D, and 20ml
E were added 919ml of distilled water.
Modifications of this medium were also used in which 10%, 1%, and 0%
of the concentration of magnesium salt (solution B) were present.
c) Nitrogen Deficient Medium (NDM).
This was prepared following the method of Sutherland & Wilkinson
(1965), and contained the following: lg yeast extract (Oxoid); lg
casamino acids (Difco technical grade); lOg Na2HP04; 3g KH2PO4; 0.2g
MgS04.7H20; lg K2SO4; lg NaCl; O.Olg CaCl25 and O.Olg FeS04. This
solution was made up to 1000ml with distilled water and autoclaved.
To this, 20% w/v filter-sterilised glucose solution was added to
give a final concentration of 2% glucose w/v.
d)Trypticase Soy Broth - TSB.
Trypticase soy broth (Prod. No. 152-4980, Gibco Ltd., Paisley,
Scotland) was prepared at 30g/l, to which 1.5% w/v nutrient agar
(Prod. No. 152-3560, Gibco Ltd., Paisley, Scotland) was added.
9 1
e) Sheep serum.
This was obtained from Moredun Animal Research Institute, Gilmerton
Road, Edinburgh. After preparation, serum was filter-sterilised
(0.45um pore size) and stored at -20°C. Samples were thawed
immediately prior to use.
Bacterial Counts.
Viable counts were performed by a modification of the Miles-Misra
method. Serial dilutions of bacteria were prepared in sterile PBS,
and five 20ul volumes were spotted onto BA. Viable count was
calculated from the number of colonies produced after overnight
incubation at 37°C.
Counting of whole cells was performed in a haemocytometer (Improved
Neubauer, depth 0.1mm, l/400mm2, Weber & Sons, Lancing, England).
Chemical Assays.
Assays for carbohydrate and protein were carried out by the methods
of DuBois ejt al^ (1956) with glucose standard and Lowry e_t ad (195 1)
with bovine serum albumin standard respectively.
Preparation of Smooth Lipopolysaccharides.
LPS from organisms of smooth phenotype were prepared by the method
of Westphal j^t j^l (1952). Batches of bacteria were cultured
overnight in nutrient broth as described above. Volumes (8 to 12
times 1000ml) were grown overnight then harvested and washed twice
in phosphate-buffered saline - PBS (0.05M sodium phosphate, 0.15M
sodium chloride, pH7.4). The bacterial pellet was freeze-dried and
weighed. The dried bacterial pellet was resuspended in distilled
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water (dw) to a concentration of 5% w/v, and heated to 65-68°C in a
water bath. To this an equal volume of 90% (w/v) phenol (BDH Analar
- 90g heated to 45°C then made up to 100ml with dw) in distilled
water, also at 65-68°C, was added and the mixture was stirred for 15
minutes. The mixture was then cooled in an iced water bath to
separate the phenol and aqueous phases. Centrifugation at
5000-10000j| for 15 min was applied separate further the two phases.
From this, the upper aqueous layer was removed and the extraction
was repeated on the lower phenol phase. The aqueous phases from both
procedures were pooled and cleared if required ( lOOOOj;, 15 min) then
dialysed overnight (or until phenol was no longer detectable)
against running tap water. After dialysis the sample was cleared
again if required, reduced to approximately 20% of its original
volume in a rotary evaporator, then ultracentrifuged for 3h at
100000j>. This produced a pellet which was resuspended in distilled
water and subjected to further centrifugation. The final pellet was
resuspended in a small volume of distilled water, freeze-dried, then
weighed. This LPS was stored at -20°C.
Preparation of Rough Lipopolysaccharides.
The petroleum ether/chloroform/phenol (PCP) method of Galanos e_t al_
(1969) was used to prepare LPS from rough mutant bacteria. This
required a stock extraction solution containing petroleum ether -
boiling point 40°-60°C (BDH Analar), chloroform (BDH Analar), and
90% phenol (see above) in the ratio 8:5:2 by volume.
Bacteria from an overnight culture were harvested and washed twice
in distilled water, then lyophilised and weighed. Dried bacteria
were resuspended in PCP to 25% w/v, homogenised for 2 min below
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20°C, then centrifuged at lOOOOg for 15min. The supernate was
filtered (Whatman No.l) into a round bottom flask. The pellet was
re-extracted by the same procedure and the filtered supernates were
pooled. The supernate was rotary evaporated to remove the petroleum
spirit and chloroform. LPS was precipitated by the addition of
distilled water in a drop-wise manner (approximately 0.4ml was
required). Once precipitate formed, the solution was left to stand
for lOmin. This mixture was centrifuged at 5000g (Heraeus Christ,
Bactifuge) for 10 min to produce a solid pellet. The supernate was
discarded and, after draining the tubes, the pellet was washed in
80% phenol three times, recovery being obtained by centrifugation.
The final pellet was washed twice in ether and dried in vacuo. Once
dry, the pellet of crude LPS was resuspended in 3-5ml of dw, then
sedimented by centrifugation at lOOOOOg for 4h. The final LPS pellet
was dissolved in dw and lyophilised.
An alternative means of precipitation was required for some of the
R-LPS preparations - particularly P^ aeruginosa R-LPS - as dw was
found to produce an inadequate yield. Qureshi _et al (1982) described
an improved precipitation by addition of six volumes of diethyl
ether/acetone (both analytical grade in the ratio of 1:5 by volume)
to one volume of phenol solution. After addition of diethyl
ether/acetone the mixture was left to stand for 60min to allow
maximal precipitation. The precipitate was then washed and
centrifuged as described
Preparation of Outer Membrane Complex.
This was prepared by a modification of the method of Poxton (1979).
An overnight culture of bacteria was harvested and washed twice in
PBS by centrifugation at 12000g for lOmin. The bacterial pellet was
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resuspended in l/50th of the initial volume in PBS containing lOmM
EDTA (ethylene diamine tetra acetic acid disodium salt, BDH Analar),
and incubated at 45°C for 30-40min. The suspension was then
sonicated for 50sec in an ultrasonic bath (Model 6441A, Dawe
Instruments Ltd., Western Avenue, London W3 OSD, UK) and the
unbroken cells were removed by repeated centrifugation until no
cells were visible in the supernate under phase contrast microscopy.
The supernate contained outer membrane which was assayed for
carbohydrate and protein content.
Proteinase K Digestion of Bacteria.
Proteinase K (Sigma) digestion (Hitchcock & Brown 1983) of both
smooth and rough bacteria was performed to prepare
lipopolysaccharides for analysis by PAGE and immunoblotting.
Bacteria were harvested, washed twice in PBS, then resuspended in
sterile PBS to give an absorbance of between 0.5 and 0.6 at 525nm as
measured in a spectrophotometer. This suspension (1.5ml) was
harvested (3min lOOOg^ Beckman Microfuge B) in a 1500ul Eppendorf
tube (Elkay) and the pellet was suspended in 50ul single strength
PAGE sample buffer (see below). This suspension was boiled for
lOmin. Once cooled, lOul of sample buffer containing 25ug of
proteinase K was added (2.5mg/ml in sample buffer), followed by
incubation in a 60°C water bath for 60min. Samples were stored at
-20°C until required. Samples (lOul) were loaded onto polyacrylamide
gels for electrophoresis.
Polyacrylamide Gel Electrophoresis - PAGE.
Polyacrylamide gel electrophoresis was carried out with SDS-free gel
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buffers following the method of Pyle & Schill (1986), which itself
is an adaptation of the method of Laemmli (1970). Separating gel
contained 17.5ml separating gel buffer (0.75M Tris-HCL pH8.8 - BDH
Analar), 3.5ml dw, and 12.25ml 40% acrylamide stock solution (40g
acrylamide - BDH electrophoresis grade - plus 1.08g
methylene-bis-acrylamide - BDH electrophoresis grade - made up to
100ml with dw). This mixture was de-aerated under vacuum after which
1.75ml ammonium persulphate ((NH4)2S20g BDH Analar - 15mg/ml) and
50ul TEMED (NNN'N'-tetramethyl-1,2-diaminoethane - BDH) were added.
This was prepared as a 160mm x 125mm x 1.5mm slab gel, and was
overlayed with water saturated butan-2-ol until set. After removal
of butanol the stacking gel was poured. This contained 5.0ml
stacking gel buffer (0.25M Tris-HCl pH6.8), 3.5ml dw, and 1.0ml 40%
acrylamide stock solution. After de-aeration, 0.5ml ammonium
persulphate solution and 20ul TEMED were added. The solution was
poured onto the separating gel and a comb inserted.
The electrode buffer consisted of 0.025M Tris (BDH Analar), 0.192M
glycine (BDH specially pure), pH8.3. To this 0.1% by weight SDS
(sodium dodecyl sulphate - Fisons "Primar" grade) was added.
Samples were prepared in single strength sample buffer which
contained 0.0625M Tris pH6.8 (BDH Analar) in which 2% SDS by weight,
10% glycerol (Fisons A.R.) by volume, 1% 2-mercaptoethanol by
volume, and 0.001% bromophenol blue by weight were present.
Lipopolysaccharide and outer membrane preparations were dissolved in
buffer and boiled for 3min prior to loading onto gels. Proteinase K
digestions were loaded directly onto gels.
Samples were electrophoresed through the stacking gel at a constant
60V, and through the separating gel at a constant 150V until the
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front had run 75mm. After electrophoresis, samples could be analysed
by staining for 1ipopolysaccharide or protein or by immunoblotting
after transferrence to nitrocellulose.
Staining PAG for Lipopolysaccharide.
An adaptation of the methods of Tsai & Frasch ( 1982) and Hitchcock &
Brown (1986) was used to visualise LPS in polyacrylamide gels - PAG.
After electrophoresis, the gel was placed in fixative (7% acetic
acid - BDH Analar- and 25% isopropanol - BDH General Purpose - by
volume in dw) overnight. Once fixed, the fixative was poured off and
the gel was oxidised for 5 min in a solution of 1 .05g periodic acid
(H5IO6 - BDH General purpose) in 150ml dw to which 4ml of fixative
was added. The PAG was then washed for 4h in dw with at least four
changes of water. Silver staining was carried out by placing the PAG
in 100ml of staining solution which contained 21ml 0.36% NaOH, 1.4ml
ammonium solution, 4.0ml AgN03, and 73.6ml dw. After staining for
lOmin the gel was washed again for 40min with four changes of dw.
Lipopolysaccharide was visualised by the addition of 0.005g citric
acid (Fisons A.R.) dissolved in 100ml 0.019% formalin (prepared by
dilution of BDH Analar formaldehyde solution. Once colour had
developed sufficiently, the reaction was stopped by washing the gel
in dw 3 to 4 times. The gel was then stored in the dark.
Electrophoretic Transfer of Antigens from PAG to Nitrocellulose.
Lipopolysaccharides and other antigens which had been subjected to
PAGE were transferred to nitrocellulose (0.2um pore size) for
immunochemical analysis. A modification of the method of Towbin
(1979) was used as follows: the gel was removed from its cassette
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and a nitrocellulose sheet soaked in electrode buffer ( 12g Tris -
BDH General purpose, 57.68g glycine, 1000ml methanol - BDH Analar,
and 4000ml dw - pH8.3) was placed on top. The gel and nitrocellulose
were then sandwiched between two Scotchbrite™ pads in a cassette
and the assembly was placed into a gel tank containing electrode
buffer. The gel was placed towards the cathode and the
nitrocellulose towards the anode. A constant current of 40mA was
applied overnight at 4°C.
Immunological Staining of Antigens.
After transfer to NC antigenic reactivity was examined. Sheets of NC
were firstly washed in Tris-buffered saline - TBS (4.84g Tris,
58.48g NaCl, 2000ml dw - pH7.5) for lOmin. At this point NC could be
dried and 2ul volumes of antigen dotted on to act as controls. Dots
were allowed to dry then the sheet was placed in blocking solution
(TBS containing 3% w/v gelatin - Bio-Rad EIA purity grade) for
35-40min. Once blocked, the NC sheet was transferred into antibody
buffer (TBS with 1% w/v gelatin) containing an appropriate dilution
of antibody, and incubated for 3h at room temperature. After
reaction with antibody solution, the sheet was washed in TTBS (TBS
with 0.025% Tween 20 v/v - polyoxyethylenesorbitan monolaurate,
Bio-Rad EIA Purity grade) for 15min then reacted with secondary
antibody. This was either anti-human or anti-mouse Ig Horse radish
peroxidase (HRP) conjugate depending upon the species of the first
antibody. TTBS was again used to wash the NC for a further period of
15min and then the binding of antibody was visualised by addition of
30mg HRP colour reagent (Bio-Rad EIA Purity grade) dissolved in 10ml
ice cold methanol added to 50ml TBS containing 30ul H2O2 • The
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development of colour was stopped after 30min by washing the NC in
dw. The blot was dryed and stored in the dark.
An avidin-biotin adaptation of this method was also carried out. In
this case the secondary antibody was replaced with biotinilated
anti-human IgG (E.Y. diluted 1:1000) which was incubated for 60min.
Nitrocellulose was then washed twice with TTBS for lOmin each, then
avidin-Horse radish peroxidase conjugate at a dilution of 1:1000 was
incubated with the blots for 30min. Sheets were washed again in TTBS
(2 x lOmins) and rinsed in TBS. Colour development was carried out
as above.
A dot blot system was also assessed. In this biotin labelled
anti-human IgG from two sources (E.Y. and Vector) and avidin
labelled Horse radish peroxidase from two sources (BRL and Vector)
were used as probes after reaction of antigens (2ul of a solution
containing lOmg/ml of LPS) with primary antibody.
Alkaline phosphatase labelled secondary antibody was also used in
some instances. All stages were the same except for colour
development reaction. After washing in TTBS, the NC was rinsed in
substrate buffer (0.06M sodium borate pH9.7 with 1.2mg/ml
MgSO^.^O). This was replaced with substrate buffer containing
0.25mg/ml o-dianisidine tetrazotized and B-naphthyl acid phosphate
(monosodium salt), both from Sigma. Once developed for 15min the
blot was washed for 15min in methanol/acetic acid/dw (5:1:5 by
volume) then washed in dw.
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Coating of ELISA Microtitre Strips.
Coating of microtitre strips was carried out following a
modification of the method of Barclay & Scott (1987). Mini-sorb
tubes (Nunc Inter Med, Kamstrup, Roskilde, Denmark) were used
throughout.
a) Coating with LPS-polymyxin complex.
Stock solutions of both polymyxin and LPS were sonicated prior to
mixing. Complexes were formed by adding polymyxin B sulphate (Sigma
chemicals) at a concentration of 0.2mM with lipopolysaccharide at a
concentration of O.lmM and mixing for 30min at room temperature.
This solution was then dialysed in 2000 molecular weight cut-off
cellulose tubing (Spectrum Medical Supplies Industries Inc.)
overnight against dw to remove excess unbound polymyxin. Complex
could be stored at -20°C. Molarity of LPS was calculated from the
estimated molecular weights of LPS as determined by Morrison &
Jacobs ( 1976):
To coat strips (Microwell Immuno Quality F8 Medium binding strips,
Nunc Inter Med), complex was diluted 1:50 into coating buffer (0.05M
carbonate/bicarbonate buffer: 6.2mg/ml Na2C03.H20, 4.2mg/ml NaHC03,
pH9.6 plus 0.05% sodium azide w/v) and lOOul was added to each well.
Strips were incubated overnight at room temperature then washed four
times with wash buffer (Oxoid Dulbecco "A" solution, pH7.2,
containing 0.05% Tween - Sigma). Wells were post-coated with PBS
containing 5% (w/v) bovine serum albumin and 0.05% (w/v) sodium
LPS TYPE MOLECULAR WEIGHT
wild type (smooth)
Ra and Rb type
Rc type








azide (both Sigma), lOOul of which was added to each well. After
overnight incubation at room temperature, strips were washed as
described above then stored at -20°C until required.
b) Coating with Purified LPS.
Coating with LPS was carried out by preparation of O.lmM solution of
LPS, which was diluted 1:50 in coating buffer (as above), and lOOul
was placed into microtitre strip wells. Incubation, washing and
post-coating was carried out as described for LPS-polymyxin coating.
c) Coating with Outer Membrane Complex.
This was coated as above. Molarity of LPS in the sample was
calculated by comparison of carbohydrate concentrations of the LPS
and outer membrane preparations, and determining the volume required
to give comparable carbohydrate (and thus LPS) concentrations. The
protein concentration of this was also measured.
d) Coating with Bacteria - Viable and Heat-killed.
Bacteria were grown overnight in Gibco nutrient broth, harvested,
and washed twice in phosphate-buffered saline. The concentration of
bacteria was determined by counting in a haemocytometer, then the
suspensions were heated in a boiling water bath for lOmin if
required. Viability was determined by plating onto blood agar.
Carbohydrate concentration was determined as a rough indication for
total LPS concentration, and the suspension was diluted in PBS to
give approximately O.lmM LPS. Coating of strips was carried out as
described above.
Enzyme-Linked Immunosorbent Assay - ELISA.
The microtitre strips were coated for ELISA as described above.
Antibody samples were thawed and prepared in dilution buffer (wash
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buffer - see above - containing 0.5% (w/v) bovine serum albumin -
Miles Laboratories - and 4% (w/v) polyethylene glycol 6000 - Sigma).
Dilutions of antibodies were added to plates at lOOul per well.
After incubation for 60min at 37°C, the plates were washed 4 times
with wash buffer (as above). Secondary antibody (sheep anti-human
IgG urease conjugate, rabbit anti-human IgM urease conjugate, goat
anti-rabbit IgG urease conjugate or goat anti-rabbit IgM alkaline
phosphatase conjugate - Commonwealth Serum Laboratories), prepared
in dilution buffer, was added at lOOul per well after plates were
dried. Plates were washed as before after 60min incubation with
secondary antibody at 37°C. Further washing with dw was carried out,
then lOOul urease substrate (Commonwealth Serum Laboratories) was
added per well. After development for up to 60min at room
temperature, the reaction could be stopped by addition of 20ul 1 %
w/v thimerosal (Sigma). Absorbance was read in a Titertek Multiscan
plate reader. A wavelength of 590nm was required for the urease
conjugate.
Absorption of Sera.
Absorption was carried out on fresh and heat-inactivated (56°C,
60min) sera with either viable or heat-killed organisms by the
following method: bacteria were suspended to a concentration of
approximately 10® organisms per ml. Bacterial suspension (400ul) was
placed in a 1500ul Eppendorf tube and bacteria were harvested by
centrifugation. After removal of PBS, bacteria were resuspended in
400ul serum, then re-centrifuged. This step was repeated three times
to ensure maximal absorption of antibodies by bacteria. Samples of
absorbed sera were then assayed in ELISA. For EPICS, absorptions
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were carried out with a bacterial concentration of 10^ organisms per
millilitre of serum for three absorption steps.
ELISA Competition Assay.
This was carried out by a modification of the above-mentioned ELISA
procedure. A doubling dilution series of inhibitor (S. typhimurium
LPS, LPS-polymyxin complex, or outer membrane complex) was prepared
in ELISA dilution buffer. Serum (50ul, diluted 1:50 in dilution
buffer) was added to 50ul of each dilution of inhibitor, and mixed.
Inhibitor-serum mixtures were incubated for various times at 37°C,
then the lOOul was placed onto the appropriate ELISA strips, and
ELISA was carried out as described above.
Chromogenic Limulus Amoebocytyte Lysate Assay.
A microtitre plate adaptation of the CoaTest/Endotoxin kit
(KabiVitrum Diagnostica UK, Uxbridge, England) chromogenic Limulus
amoebocyte lysate assay was carried out. All procedures were carried
out in a sterile laminar flow cabinet, and Dynatech Immulon A
microtitre plates were used throughout. Three different systems were
used for measurement of:
a) endotoxin levels in serum,
b) endotoxic activity of purified
lipopolysaccharides or IgG,
c) inhibitory activity of serum,
IgG, or polymyxin on LPS.
a) Endotoxin Activity in Human Serum.
Serum samples were stored at -20°C, then thawed overnight at 4°C.
Serum was diluted 1:10 into PF-dw to give a final volume of 1.0ml in
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a Mini-Sorb tube held at 70°C in a heating block, and the diluted
serum was held at this temperature for 5min to inactivate LAL
inhibitors and activators. After heating, the tubes were cooled by
placing into an ice-water bath, at which temperature samples remain
stable until assayed. Duplicate serum samples (30ul) were placed in
wells in a microtitre plate, one sample being used for determination
of Limulus amoebocyte lysate activity and the other as a blank. To
each test sample, 30ul of PF-dw was added, and to each blank, 90ul
PF-dw was added. Limulus amoebocyte lysate (LAL) was reconstituted
with PF-dw to the recommended concentration, and after standing at
room temperature for lOmin, 30ul was added to each test sample.
These were mixed, and the plates were incubated at 37°C for
40-45min. LAL chromogenic substrate (S-2423) was reconstituted with
PF-dw as recommended, then diluted 50:50 with LAL substrate buffer.
Buffer-substrate mixture (60ul) was added to each test sample, and
plates were incubated for a further 3min at 37°C. The reaction was
stopped by the addition of 60ul of 50% v/v acetic acid to test and
blank samples, and the absorbance was measured at 405nm. LAL
activity was calculated by relation to a standard curve prepared by
dilution of the endotoxin supplied (E. coli 0111:B4
lipopolysaccharide) in dw.
b) Endotoxic activity of Purified LPS.
LPS was diluted from a stock solution (lmg/ml) with pyrogen-free
distilled water (PF-dw). Mini-Sorb tubes were used to avoid
adsorbance of LPS onto tube walls. LPS solution (30ul) diluted
appropriately was added to 30ul PF-dw in microtitre plate wells.
Limulus amoebocyte lysate (LAL) was reconstituted with PF-dw as
above. LAL (30ul) was added to each microtitre well, and after
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mixing, the plates were incubated at 37°C for 25min. LAL substrate
was prepared as above, then 60ul was added to each well, and this
was incubated for a further 3min at 37°C. The reaction was stopped
by the addition of 60ul of 50% v/v acetic acid, and the absorbance
was measured at 405nm. LAL activity could be calculated by relation
to a standard curve prepared as above.
An adaptation of the method of Piotrowicz and McCartney ( 1986) was
also used. Samples (30ul) were prepared in PF-dw. To samples a
reaction mixture (90ul - containing equal parts by volume of LAL,
chromogenic substrate and substrate buffer) was added. Colour
development could be determined at various time points without
requiring the addition of acetic acid to stop colour development,
c) Inhibition of LAL Activity of LPS.
For evaluation of the inhibitory action of serum, purified IgG, or
polymyxin on LAL activity, the following procedure was carried out:
volumes of the appropriate LPS concentrations (30ul) - prepared as
in (b) - were placed in microtitre plate wells. To these, 30ul of
inhibitor solution was added, and the solution was mixed and
pre-incubated at room temperature if required. To this, 30ul of LAL
was added, and incubation was carried out at 37°C for 25min. LAL
substrate (60ul) was then added, and after 3min further incubation
at 37°C the reaction was stopped by addition of 60ul of 50% v/v
acetic acid. Absorbance was measured at 405nm.
Fluorescent Labelling of Bacteria.
E. coli 018:K~ and E^_ coli 018:K1 were grown under a variety of
conditions as detailed in RESULTS, and 1.0ml samples were removed
and bacteria were harvested (3min, Microfuge B, Beckman) then washed
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three times in phosphate buffered saline. Samples were divided into
three equal volumes in 1500ul Eppendorf tubes; one as a control, and
one for each of two murine monoclonal antibodies (one directed at
the core region and one at O-antigen). After centrifugation, two of
the bacterial pellets were resuspended in one or other monoclonal
antibody (diluted 1:10 in PBS), and incubated at room temperature
for 30min. The third sample of bacteria was retained for incubation
with FITC-labelled antibody. The suspensions of bacteria in
monoclonal antibody solutions were precipitated by centrifugation,
and washed three times in PBS. All three samples of bacteria were
then resuspended in a 1:40 dilution of FITC labelled anti-mouse IgG
(Sigma, F(ab'2)fragment), and incubated for 30min at room
temperature. Samples were washed three times in PBS and finally
resuspended in saline (0.85% w/v NaCl - BDH Analar - in dw)
containing 1% formalin (BDH Analar), in which stability of samples
is retained when stored in darkness at 4°C. Binding of antibodies to
the bacterial surface was determined by flow cytometry. For this, a
Coulter EPICS "C" flow cytometer was used with a laser output of
500mW at 488nm to excite fluorescence. A flow rate of 1000 bacteria
per second was used and 10-40000 cells were analysed. Bacteria were
selected by gating on a one parameter histogram measuring forward
angle light scatter (FALS), and the percentage of cells showing
fluorescence above background levels was calculated.
Longitudinal Immunisation of Rabbits.
A longitudinal immunisation programme in rabbits was carried out.
Samples of blood (1ml) were removed from Dutch rabbits at intervals
(days -30, -12, and -5) prior to immunisation, and were continued at
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7-day intervals after immunisation from days 2 to 163. Rabbits were
immunised with 10® heat-killed bacteria on days 0, 28, 56, 84, 112,
and 140, as detailed in RESULTS. Antibodies (of both IgG and IgM
classes) to 31 lipopolysaccharide antigens (10 S-LPS, 19 R-LPS, and
2 lipid A) were assayed in the polymyxin-LPS ELISA system described
above with anti-rabbit IgG urease conjugate (Commonwealth Serum
Laboratories), and anti-rabbit IgM alkaline phosphatase conjugate
(Commonwealth Serum Laboratories). Absorbances were measured at
590nm and 405nm respectively. Serum was removed from the blood
sample after clotting and centrifugation (4000g, Heraeus Christ
Bactifuge).
Lethality and Protection Studies in Animal Models.
Lethality of purified LPS or viable bacteria was assessed in a
variety of mouse strains. All animals were obtained from the
Department of Bacteriology, University of Edinburgh animal house
where they were bred and where all procedures were carried out. Mice
were given food and water jid 1ibiturn, and lethality was observed for
a period of 3 days.
a) Non-compromised models of endotoxaemia and bacteraemia.
Outbred Swiss white mice (10-12 weeks old), or inbred C57black/6
mice (8-10 weeks old), were challenged intravenously (i.v.) or
intraperitoneally (i.p.) with graded doses of LPS dissolved in PBS
or dw, or viable bacteria prepared by resuspending a washed
overnight culture of bacteria in PBS. Bacterial concentration was
calculated by comparison of absorbance of the washed culture with a
standard curve of absorbance at 600nm versus viable count, and the
appropriate dilution was then calculated. Administration of a
107
variety of immunoglobulin preparations was carried out i.v. or i.p.
as detailed in the RESULTS section.
b) Galactosamine model of endotoxaemia.
Following the method of Galanos et al (1979), inbred C57bl/6 mice
(6-8 weeks old) were challenged with LPS plus galactosamine
(D(+)galactosamine hydrochloride, Sigma - 8mg per mouse) both
dissolved in PBS. LPS and galactosamine were inoculated
intraperitoneally either as a mixture, or with the LPS immediately
following galactosamine. Once again assessment of immunoglobulins
was carried out, as detailed in the RESULTS.
c) Mucin-Haemoglobin model of bacteraemia.
Inbred C57bl/6 mice were sensitized to the lethal effects of
bacteria by the co-inoculation of mucin, haemoglobin, and bacteria.
Mucin (porcine stomach mucin, type II, crude - Sigma) was prepared
as a 4% w/v solution in PBS, and was autoclaved in 50ml samples
which were stored at -20°C until required. Haemoglobin (bovine, BDH
technical grade) was prepared aseptically as a 16% w/v suspension in
PBS, and 25ml volumes were stored at -20°C. Bacterial suspensions
were prepared from overnight cultures in Gibco nutrient broth.
Bacteria were washed twice in PBS, then resuspended in PBS
containing 10% (v/v) glycerol (Fisons A.R.), and stored at -70°C. A
viable count was carried out on the bacterial stock solution, and
bacteria were diluted in PBS to a dose appropriate for challenge.
Mice were challenged i.p. with 0.5ml of a mixture containing mucin
at a final concentration of 6.0%, haemoglobin at a concentration of
1.0%, and bacterial suspension (this was prepared by mixing 0.2ml
mucin stock solution, 0.125ml haemoglobin solution and 0.175ml
bacterial suspension).
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Immunoglobulin preparations were assessed for their capacity to
protect from lethal challenge of bacteria by i.p. inoculation as
detailed in RESULTS.
d) Neutropenic Mouse Model.
Neutropenia was induced in mice by administration of lOmg of
cyclophosphamide (Sigma) dissolved in 0.3ml PBS to 6-8 week old
C57bl/6 mice. Once neutropenia had developed (48h) mice were
challenged with 0.2ml of a mixture of equal parts of bacterial
suspension (E. coli 016:K1) and haematin (0.244% w/v in sterile
PBS). Immediately after bacterial challenge mice were administered
with lOOug of purified human immunoglobulin dissolved in sterile PBS
(0.2ml) or with PBS.
109
RESULTS
3:1. Detection of Anti-Lipopolysaccharide Immunoglobulins.
3:1:1. ELISA Survey of Anti-CGL IgG in the Blood Donor Population.
•N
Assay of blood donor sera for anti-LPS core glycolipid IgG was
carried out as part of a routine screening procedure at the Scottish
National Blood Transfuion Service in Edinburgh. An ELISA system was
used in which a "cocktail" containing equimolar amounts of R-LPS
from four organisms complexed to polymyxin was used as antigen. LPS
from E_^ coli J5 (Rc-type LPS), S_^ typhimur ium R878 (Rc), P.
aeruginosa PAC605 (Rc), and aerogenes M10B (Rb) were each present
at a concentration of 0.025mM, giving a total LPS concentration of
O.lmM. This "CGL-pool" was used to assay human serum, diluted 1:100
as described in "MATERIALS AND METHODS" . Absorbance was. measured at
590nm and calculated relative to a known high titre serum (GL+)
given an arbitary value of 100%. The distribution of results from
this survey are shown in figure 3:1. The results represented a
normal distribution curve with a positive skew. Sera of possible
therapeutic use could be selected on the basis of a relative
absorbance of 200% or greater (approximately 5 times the population
mean absorbance value). Only 20 of the 695 donors (2.85%) had an
absorbance greater than 200%. The majority of donors showed an
absorbance of 80% or less and the mean and mode absorbances were
approximately 45% and 30% respectively.
3:1:2. ELISA Assay of Normal Human Sera against Individual LPS
Antigens.
Selected donor sera were assayed in a single antigen system against
31 purified lipopolysaccharides and lipid As. Nine S-LPS, 20 R-LPS,
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FIGURE 3:1. Distribution of Anti-CGL IgG Antibodies in the
Blood Donor Population.
and 2 lipid A were used in the screen as detailed in figure 3:2.
Three sub-populations of sera were assayed: 10 high (>200%) in
CGL-pool; 8 median (40%) in CGL-pool; and 8 low (less than or equal
to 10%) in CGL-pool. Results for the 31 antigens and the CGL-pool
are expressed in the form of a scatter diagram (figure 3:2) where
absorbance values are representative of IgG levels. Much variation
in levels of anti-LPS IgG in serum was seen within each
sub-population (high, medium and low). In general, increasing mean
absorbance to all antigens was seen with increasing CGL-pool
absorbance. In addition, the range of absorbances showed overlapping
values, but a stepwise increase was obtained against antigens
alongside increasing anti-CGL values. Four rough LPS preparations
showed only small differences in absorbances between the three
sub-populations (S. minnesota Ra and Rb; E. coli R4; and K_^
aerogenes M10B). Other antigens (S. typhimurium Ra, Rb; minnesota
0, Rd, Re; E. coli J5, K12 lipid A, 018:K-, 0111, 086) showed higher
absorbance range and mean in the sub-population with lowest CGL-pool
values, than the median sub-population, but the high CGL-pool group
remained highest.
3:1:3. Persistence of Anti-LPS IgG Levels in Blood Donor Sera.
Levels of IgG in monthly donations from selected plasmapheresis
donors were measured against the previously-mentioned 31 LPS
antigens in ELISA. As can be seen in figures 3:3a to 3:3h, levels of
IgG in the CGL-pool assay and in individual antigen assays remained
fairly stable over the period, and very few large changes in IgG
levels (up or down) were observed. After these alterations IgG
levels stabilised. By comparison of individuals, it can be seen that
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FIGURE 3:2. Key to LPS Antigens.
No. Code Antigen %
1. St 0 S. typhimurium wild type
2. St Ra It If " RI 135
3. St Rb ft ft " RI 19
4. St Rc rt it " R878
5. St Rd rt it " R1032
6. St Re
if n " R1102
7. Mix -cocktail CGL-pool
8. Sm 0 S. minnesota wild type
9. Sm Ra ft It If R60
10. Sm Rb If It If R345
1 1. Sm Rc If ft If R5
12. Sm Rd ft It If R7
13. Sm Re If It If R595
14. Sm lipid A II If
If lipid A
15. Ec C62 E. coli C62
16. Ec J5 If If If J5
17. Ec K12 If if If K 12
18. Ec K12 Re If If If K1 2 Re mutant
19. Ec K12 lipid A II If II K 12 lipid A
20. Ec R1 If If If R1
2 1. Ec R2 If If II R2
22. Ec R3 If It If R3
23. Ec R4 If If If R4
24. Ka M1 OB K. aerogenes Ml OB
25. PaC 605 P. aeruginos PAC605
26. Ec 0 18K-H E. coli 018: K 1
27. Ec 018K- iT it ii 0 18:K~
28. Ec 0 1 11:B4 if if if 0111 :B4
29. Ec 06 if if if 06 :K5
30. Ec 016 if it it 0 16: K 1
31. Ec 086 ii ii it 086: K6 1
32. Pa HABS-1 P. aeruginosa Habs type
Blood Donor IgG antibodies
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FIGURE 3:2. Reactivity in ELISA of three blood donor
sub-populations with low, medium, and high levels of anti-CGL IgG
antibodies (see antigen 7) against thirty one LPS antigens.
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FIGURE 3:3.
Key to antigens in ELISA screen.
Organism ELISA antigen
s. typhimurium wild type St 0 wt
II II R1542 St Ra
II II RI 19 St Rb
If II ' R878 St Rc
II II R1032 St Rd
II II RH02 St Re
S. minnesota wild type Sm 0 (Wt)
If II II R60 Sm Ra (R60)
II II II R343 Sm Rb (R345)
II II II R5 Sm Rc (R5)
II II II R7 Sm Rd (R7)
II II II R595 Sm Re (R595)
II II 11 lipid A Sm lipid A
E. coli R I Ec R 1
II II II R2 Ec R2
II II II R3 Ec R3
II II II R4 Ec R4
II II II J5 Ec J5
II II II K12 Ec K 12 Dm34
II II II Kl2 Re Ec K12 Re
II II II K12 lipid A Ec K12 lipid A
II II II 06 Ec 06
II II II 0 16 Ec 016
II II II 0 18 Ec 0I8K-
II II II 018:K I Ec 018K+
II II II 086 Ec 086
II II II 0 1 1 1:B4 Ec 0 1 1 I: B4
P. aeruginosa PAC605 PaC605
" " " Habs type 1 Pa 0-S1
K. aerogenes M10B KaMlOB
Mix-cocktail CGL-pool
GGL-pooi results presented as percentage value of control
(] = 100%, 2 = 200%). All other results presented as
absorbance values at 590nm.
FIGURE 3:3a. Levels of Anti-Iipopolysaccharide IgG in monthly
serial samples from Plasmapheresis Donor COA-E.
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FIGURE 3:3b. Levels of Anti-lipopolysaccharide IgG in monthly
serial samples from Plasmapheresis Donor GRO-D.
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FIGURE 3:3c. Levels of Anti-lipopolysaccharide IgG in monthly
serial samples from Plasmapheresis Donor CHA-N.
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FIGURE 3:3d. Levels of Anti-lipopolysaccharide IgG in monthly
serial samples from Plasmapheresis Donor LIP-C.
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FIGURE 3:3e. Levels of Anti-lipopolysaccharide IgG in monthly
serial samples from Plasmapheresis Donor GRA-D.
Ka M10BPaC 605Ec K12 Dm3* Ec K12 Re EcK12 lipid* Ec J5 (List]
Ec Oiil:B*Ec 0!BK*
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FIGURE 3:3f. Levels of Anti-lipopolysaccharide IgG in monthly
serial samples from Plasmapheresis Donor PUR-A.
st o wt
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FIGURE 3:3g. Levels of Anti-lipopolysaccharide IgG in monthly
serial samples from Plasmapheresis Donor PAP-J.
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FIGURE 3:3h. Levels of Anti-lipopolysaccharide IgG in monthly
serial samples from Plasmapheresis Donor AIT-N.
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much variation existed in IgG levels to smooth and rough LPS, and to
lipid A antigens, reflecting the variations observed in the CGL-pool
assay. Antibody levels in individuals to both E. coli 018:Kl and E.
coli 018:K~ lipopolysaccharides showed little difference from each
other at all points in all 8 donors. None of E. coli K12, Kl2Re, K12
lipid A, and aerogenes M10B showed major detectable levels of
antibody in any of these 8 donors.
3:1:4. ELISA of IgG Prepared from Blood Donors.
Fractionation of 33 of the 695 sera was carried out to purify IgG
components of sera as described in MATERIALS AND METHODS. After
fractionation, the IgG preparations were subjected to ELISA to
determine levels of antibody against the above mentioned series of
LPS antigens. Histograms of the IgG profiles of 5 of these purified
fractions are presented in figures 3:4a to 3:4e, and histograms for
all 33 IgG fractions are present in appendix 1 . Much variation in
IgG levels existed between individuals and between different
antigens within an individual. Some individuals possess very high
levels of IgG to most antigens (e.g. numbers 5, 6 and 24), while
others possess only low or undetectable levels of IgG (e.g. numbers
16, 26, and 33). In between these extremes a wide spectrum of levels
of IgG was observed.
Of particular note was the different reactivities to Salmonella
R-LPS molecules from S_^ minnesota and S^ typhimurium. The binding of
IgG to R-LPS of the same chemotypes did not produce comparable
absorbance values for the two species.
Generally lower reactivity with LPS of Rb and Rd LPS chemotypes from





S. typhimurium : 0 (Ht) S 0
S. typhimurium : 1542 H a
S. typhimurium : 119 fl b
S. typhimurium : 678 R c
S.typhimurium : 1032 R d
S. typhimurium : 1102 fl e
S.minnesota : 0 (WtJ s a
S.minnesota : P60 fl a
S.minnesota : H345 fl b2
S.minnesota : P5 fl c
S.minnesota : H7 fl d2P
S.minnesota : H595 fl e
S.minnesota : exH595 fl IpA
E.coli 06 : 0 (Ht) S 0
E.cal i 016 : 0 (Wt) s a
E.cali 016 K- : 0 (Wt) S 0
E.col i 016 Kr : 0 (Wt) s a
E.co i i 086 : 0 (Wt) s 0
E.cali QUI : 0 (Wt) s a
E.coli PI :KF 4704 fl a
E. c o 1 i P2 : EH 100 fl 3
E.coli P3 F 673 fl 3
E. ca 1 i P4 F 2513 fl a
E.cali K12 : mm294 fl a
E.cali 062 : 062 fl a'
E.cali J5 J5 fl c'
E.cali (K12) : 031m4 fl e
E.coli (K12) : ex Q31m4 fl IpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 fl b
K.aerogenes : Mi 0b fl b
0 i 2
net 0.0.(590) screening ELISA
FIGURE 3:4a. Reactivity in ELISA of IgG (number 5) purified from
human serum against 31 LPS antigens.
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IgG-i
d 1 lut ion. -
ELISA ANTIGENS (LFS-palymyxin
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 fl a
S. typhimurium : 119 R b
S. typhimurium : 873 a c
S.typhimurium : 1032 a d
S.typhimurium : 1102 a e
S.minnesata : 0 (Wt) s 0
S.minnesata : 360 a a
S.minnesota : 3345 a o2
S.minnesata : 35 a c
S.minnesata : 97 a d2P
S.minnesata : 9595 a e
S.minnesata :exfl595 R IpA
E.cal i OS : 0 (Wt) S 0
E.cali 016 : 0 (Wt) S 0
E.cali 018 K- : 0 (Wt) S 0
E.cali oia Kf : 0 (Wt) S 0
E.cali oas : 0 (Wt)' S 0
E.cali 0111 : 0 (Wt) S 0
E.cali PI ;:KF 4704 a a
E.cali a 2 EH 100 a a
E.cali a 3 F 573 a a
E.cali ,P4 : F 2513 a a
E.cali K12 : mm294 a a
E.cali CS2 CS2 9 a'
E.cali J5 J5 a c*
E.cali (K121 : 031m4 a e
E.cali (K12) : ex D31m4 a ipa
P.aeruginosa : Habs-Qi s 0
P.aeruginosa : PAc605 a b




net Q.D. (590) screening ELISA
FIGURE 3:4b. Reactivity in ELISA of IgG (number 11) purified from
human serum against 31 LPS antigens.
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IgG-iS
dIlut ton 1/ 100
ELISA ANTIGENS (LPS-po1ymyxin complexes)
S. typhimurium : 0 (Wt)
S.typhimurium : 1542
S.typhimurium : 119












































E.cali 086 : 0 (Wt) S a
E.cali QUI : 0 (Wt) S a
E.cali fli : HF 4704 fl a
E.cali R2 : EH 100 fl a
E.cali A3 : F 573 fl a
E.cali :A4 :F 2513 fl a
E.cali K12 :mm294 fl a
E.cali 062 : C62 fl a'
E.cali J5 : J5 fl c'
E.cali (K12) :03im4 a s
E.cali (K12) :ex Q3lm4 A lp A
P.aerug inosa :HaPs-01 s 0
P. aerug inosa :PAc505 a b
K.aeragenes : MlOb A b
1 2
net 0.0.(590) screening ELISA
FIGURE 3:4c. Reactivity in ELISA of IgG (number 16) purified from
human serum against 31 LPS antigens.
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IgG-24
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin
S.typhimurium : 0 (Wfc) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium :1102 R e
S.minnesota :Q (Wt) S 0
S.minnesota : 060 R a
S.minnesata : R345 R b2
S.minnesota : A5 R c
S.minnesata : R7 R d2P
S.minnesota : R595 R e
S.minnesata : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) s a
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli Rl :HF 4704 A a
E.coli R2 :EH 100 R a
E.coli R3 : F 573 R a
E.coli R4 :F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C52 R a'
E.coli J5 :J5 R c*
E.coli (K12) : D31m4 R e
E.coli (K12) : ex 031m4 R IpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
complexes)
0 1 2
net Q.Q. (590) screening ELISA
FIGURE 3:4d. Reactivity in ELISA of IgG (number 24) purified from





S.typhimurium : 0 (Wt) S 0
S.typhimunium : 1542 9 a
S.typhimurium : 119 9 b
S.typhimurium : 378 9 c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota :0 (Wt) S 0
S.minnesota :R6Q R a
S.minnesota :H345 9 b2
S.minnesata : R5 9 c
S.minnesata : fl7 R d2P
S.minnesota : H595 9 e
S.minnesota :exR595 R IpA
E.cali 06 : 0 (Wt) S 0
E.coli 015 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 013 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.cali 0111 : 0 (Wt) s a
E.cali Hi :HF 4704 9 a
E.cali 92 :EH 100 9 a
E.cali 93 :F 573 9 a
E.coli 94 :F 2513 9 a
E.coli K12 :mm294 R a
E.coli CS2 :052 9 a'
E.cali J5 : J5 9 C"
E.cali (K12) :031m4 R e
E.cali (K12) : ex 03im4 R IpA
P.aeruginosa :Hahs-01 S 0
P.aeruginosa :PAc605 9 b











net 0.0.(590) screening ELISA
FIGURE 3:4e. Reactivity in ELISA of IgG (number 33) purified from
human serum against 31 LPS antigens.
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against Ra, Rc and Re chemotypes of LPS. Approximately 50% of the
IgG preparations showed reactivity with Re LPS and Rc LPS, and the
remaining 50% showed far greater reactivity with Rc than with Re
LPS. These two sub-populations of antibodies were shown to be
mutually exclusive in an assay of the 695 sera as detailed by
Barclay and Scott (1987).
3:1:5. Immunoblotting of Immunoglobulins against LPS.
Lipopolysaccharides were separated on 14% SDS-free polyacrylamide
gel as described in MATERIALS AND METHODS. LPS were initially
visualised by silver staining PAGs (figure 3:5). Ladder patterns
were clearly seen for smooth type LPS, and differentiation was
obtained between core LPS of different chemotypes. Various
immunoglobulins as described in MATERIALS AND METHODS were used to
probe these antigens after electrophoretic transfer onto
nitrocellulose.
a) Pseudomonas vaccinees IgG (PsV) was used at a dilution of 1:500
to probe lipopolysaccharides from P. aeruginosa Habs type 1 (S-LPS),
P. aeruginosa PAC 605 (Rc-LPS), E^ coli 086 (S-LPS), E_^ coli J5
(Rc-LPS), K_^ aerogenes M10B (Rb-LPS), S. typhimurium R878 (Rc-LPS),
and S. typhimurium R1102 (Re-LPS) on nitrocellulose. The results are
presented in figure 3:6a. IgG from this preparation bound strongly
to LPS from P_^ aeruginosa Habs type 1 and Sj_ typhimurium R878.
Lesser reactivity was obtained against LPS from E_^ coli J5, K.
aerogenes M10B, and high molecular weight components of E_^ coli 086
LPS. No reactivity was seen with P^ aeruginosa PAC 605 or S.
typhimurium R1102 lipopolysaccharides. This immunoblot was repeated
against typhimurium R1542 (Ra), R1 19 (Rb), and R1032 (Rd) in
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FIGURE 3:5. Silver stain of polyacrylamide gel (containing 14%
acrylamide and no SDS) for lipopolysacchrides ( IOug) from K^_
aerogenes MIOB (track 1), P. aeruginosa PAC 605 (track 2), E. coli
J5 (track 3), S. typhimurium R1 102 - Re (track 4), S. typhimurium
R1032 - Rd (track 5), S. typhimurium R878 - Rc (track 6), Sj_
typhimurium R119 - Rb (track 7), S. typhimurium R1542 - Ra (track
8), P. aeruginosa Habs type 1 (track 9) and E. coli 086:K61 (track
10).
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FIGURE 3:6a-d. Immunoblot of Pseudomonas vaccinees IgG (PsV -
figure a), Pseudomonas positive IgG (Ps+ - figure b), Pseudomonas
negative IgG (Ps- - figure c), and a high titre human donor serum
(RAC+ - figure d) at dilutions of 1:500 against lipopolysaccharides
transferred from a 14% SDS-free polycrylamide gel onto
nitrocellulose. Lipopolysaccharides from S. typhimurium R1 102 - Re
(track 1), S. typhimurium R878 - Rc (track 2), K. aerogenes M10B
(track 3) , E_^_ coli J5 (track 4) , coli 086 :K6 1 (track 5) , P.
aeruginosa PAC605 (track 6), and P. aeruginosa Habs type 1 (track 7)
were used.
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FIGURE 3:6e. Immunoblot of antigens transferred onto nitrocellulose
from a 14% SDS-free polyacrylamide gel with Pseudomonas vaccinees
IgG (PsV) at a dilution of 1:500. The antigens were
1ipopolysaccharides ( lOug) purified from E. coli 086:K6 1 (track 1),
S. typhimurium R1542 - Ra (track 2), typhimurium R 1 19 - Rb (track
3), S. typhimurium R878 - Rc (track 4), S. typhimurium R1032 - Rd
(track 5), Sj_ typhimurium R1 102 - Re (track 6) , E_^ coli J5 (track
7), K. aerogenes M10B (track 8), P. aeruginosa Habs type 1 (track
9), and P. aeruginosa PAC605 (track 10).
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addition to the above antigens. The results (figure 3:6e) show that
PsV once again exhibited wide cross-reactivity.
b) Pseudomonas positive IgG was diluted 1:500 and was reacted as in
(a) against the initial panel of seven LPSs. In this case, only
antibodies directed towards the 0-antigen of P^ aeruginosa Habs type
1 were detectable (figure 3:6b).
c) Pseudomonas negative IgG was used as above, and as shown in
figure 3:6c, no binding to any of the 7 LPS antigens was detectable.
d) A high titre human donor serum (RAC+) was assayed against the
antigens used in (a), (b), and (c) above. Figure 3:6d shows that
this serum contained IgG which bind to LPS from P_^ aeruginosa Habs
type 1, but to no other LPS antigen in this assay.
e) Further immunoblots were carried out against LPS from E_^ coli 086
and J5, P_^ aeruginosa Habs type 1 and PAC605, and Sj_ typhimurium
R1542, R878, R1102, and lipid A (prepared by hydrolysis of R878 LPS
for lh in 1% v/v acetic acid) with sera which were assayed in the
CGL-pool ELISA as either high or low, with the inclusion of antigen
dot (2ul) controls. Little activity to any R-LPS was obtained in
either high or low titre sera. Major binding was observed to LPS
from P_^ aeruginosa Habs type 1 from sera of both high and low titre
which were examined (figures 3:7a and 3:7b). Additionally, binding
to none of the antigens was obtained in certain high and low titre
sera.
f) An avidin-biotin system and an alkaline phosphatase system were
also used in an attempt to increase sensitivity of results, but no
increase was obtained.
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FIGURE 3:7. Immunoblot of normal human sera selected as positive(figures a-d) and negative (figures e-g) in ELISA against
lipopolysac char ides ( 10ug) from S,. typhimurium R1 102 - Re (track 1),p- aeruginosa PAC605 (track 2), typhimuriium R878 - Rc (track 3)]p • C°1 i 35 (track 4), K. aerogenes M1 OB (track 5), S. typhimur ium
R1542 - Ra (track 6), P. aeruginosa Habs type 1 (track 7), and E.
coli 086:K61 (track 8).
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3:2. Endotoxin and Immunoglobulin Assays of Human Shock Patient
Sera.
Six patients were available for study, but from three less than 10
samples of serum were obtained and will not be considered. Endotoxin
concentrations were calculated by use of a Limulus amoebocyte lysate
(LAL) assay, and IgG levels to 31 1ipopolysaccharide and lipid A
antigens were assayed in a polymyxin-ELISA system as described in
MATERIALS AND METHODS. Results are presented as graphs (figures 3:8
to 3:10) of both endotoxin and antibody levels to 12 of the 3 1
antigens plotted against time (the results for the remaining
antigens are presented in appendix 2). Endotoxin levels are
expressed in endotoxin units per millilitre (EU/ml) and IgG levels
as absorbance at 590nm. Also represented in the graphs are the
points at which patients received infusions of blood products (fresh
human plasma or packed red blood cells).
i) Patient BS: Thirty-two samples were obtained over a period of 34
days (figures 3:8a to 3:8d). Low levels of LAL activity were
detectable initially (approx. 2.0EU/ml), which fell over a period of
5 days to levels at or below the detection limit of the assay (0.5
EU/ml, equivalent to 6pg/ml). After day 11, a rise in LAL activity
was obtained, with a peak of 6.9EU/ml (82.8pg/ml) on day 14. Levels
of endotoxin remained detectable at approximately 1.5EU/ml from days
16 to 23 with a small peak of activity (2.0 EU/ml) on day 22. After
this point, endotoxin levels remained at the lower limit of
detection except for a further small peak on day 32.
Anti-LPS IgG levels to all antigens examined showed considerable
fluctuation from days 0 to 10, during which period the patient was
receiving infusions of blood products. The first eleven days
134
FIGURES 3:8 to 3:10. Key to LPS Antigens.
A JL minnesota Rc R5
B ii ii ii Re R595
C ii ii ii lipid A (from
D ii it if smooth
E ii ii ii Ra R60
F E. coli R 1
G ii n it R2
H ii if if R3
I ii n ii R4
J it ii ii K12
K ii ii if 06
L ii ii ii 016
M ii ii ii 018
N ii ii ii 086









































FIGURE 3:8. Activity in Limulus Amoebocyte Lysate Assay in serum
from a Patient with Septic Shock (graph a) with relevant infusions
of blood products, and Levels of IgG antibodies to 15 LPS antigens
(graphs b-e). LPS antigns are described on the page opposite.
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produced simultaneous rises and falls in IgG to rough
lipopolysaccharides and to coli 086 LPS. Antibodies to E_^ coli
O-serotypes 06, 016, 018 and 0111 remained fairly high and
relatively stable from day 0 to day 10.
Between days 1 1 and 14 a general depression of IgG levels to rough
LPS (with the exception of S_^ minnesota Ra) was observed, coinciding
with the large peak of endotoxin activity. IgG levels to all E. coli
smooth LPS increased over this period. Levels of anti-S. minnesota
Re became noticeably depressed prior to each peak of LAL activity,
and rose as levels of endotoxiin fell.
With the reduction in endotoxin from day 15, an increase was
obtained in IgG to all rough LPS and to lipid A. The only exception
to this was IgG to S^ minnesota Re which remained depressed until
day 24. IgG to Ra and to smooth LPS remained reasonably stable until
the final sample, although a small drop in anti-Ra to moderate
levels was obtained between days 21 and 27 with levels recovering by
day 28, while IgG versus Re, Rc and lipid A showed larger
fluctuations. A rising trend could, however, be seen after a second
depression of IgG to Re and Rc on day 27.
ii) Patient MCC: Figures 3:9a-e indicate that this patient had high
levels of LAL activity initially (12 EU/ml), falling to
approximately 5 EU/ml on days 2 and 3, followed by a return to 12
EU/ml on day 5. After this point levels of endotoxin fell with a
small peak of 4 EU/ml on day 9. Reduction of endotoxin levels
corresponded approximately with infusion of packed red blood cells.
Levels of IgG to lipopolysaccharides were initially low to
negligible, with the exception of E. coli R2 and R4 which were























































































FIGURE 3:9. Activity in Limulus Amoebocyte Lysate Assay in serum
from a Patient with Septic Shock (graph a) with relevant infusions
ofblood products, and Levels of IgG antibodies to 15 LPS antigens
(graphs b-e). LPS antigens are described opposite page 135.
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high levels with IgG to coli Rl, R2 and R4 reaching plateaux on
day 5. Antibodies to E. coli LPS (rough and smooth) show steep rises
during the second peak of endotoxin, followed by a drop as endotoxin
levels fall. From this point onwards (day 7), antibodies climb
again.
For the Salmonella minnesota mutants, the rise in IgG is slower,
with anti-Re being the last to recover as the peak of endotoxin on
day 5 falls.
iii) Patient MCM: No endotoxin was detectable until day 5 of the
study (figure 3:10). Levels of endotoxin fluctuated after this
point, reaching a low of 1.0 EU/ml on days 10 and 13, and rising to
a peak on day 15. Levels remained elevated although a small fall was
seen between days 15 and 21.
Antibodies to ^ minnesota rough LPS were detectable only at low or
negligible levels between days 0 and 6 with the exception of IgG to
Rc LPS which was present at moderately high levels. A small peak
also occurred for lipid A prepared from S_^ minnesota corresponding
with the first detectable LAL result. IgG levels to E_^ coli rough
LPS were far more variable but remained approximately constant. E.
coli 06, 016 and 0111 IgG showed declining trends from moderate to
low levels, and IgG binding to 086 became negligible. E. coli 018,
on the other hand, showed IgG levels increasing from moderate to
high levels by day 3, after when stabilisation occurred. Between
days 6 and 9 all IgG increased to moderate or high levels
concomitant with infusion of packed reb blood cells on day 6. Days
10 and 11 produced a depression of IgG to near baseline levels just
prior to a large rise in LAL activity from day 14 onwards. After
































































FIGURE 3:10. Activity in Limulus Amoebocyte Lysate Assay in serum
from a Patient with Septic Shock (graph a) with relevant infusions
of blood products, and Levels of IgG antibodies to 15 LPS antigens
(graphs b-e). LPS antigens are described opposite page 135.
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as did those against E_^ coli K12, R2, R3, 06, 018 and 086. IgG
against E_^ coli Rl and R4 remained moderate but large fluctuations
were visible. E. coli 016 recovered to moderate levels followed by a
gradual decline after day 18, and after a temporary depression
anti-0111 IgG increased by a small increment during the large peak
of endotoxaemia. Rises to high and moderate levels were obtained in
IgG to E. coli R2 and 018 respectively on days 21 and 22.
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3:3. Longitudinal Study of Immunoglobulin Response to LPS of Rabbits
Immunised with Bacteria.
Dutch rabbits were challenged intravenously at 28 day intervals with
approximately 10® heat-killed bacteria suspended in 1.0ml of sterile
PBS. The immunisation schedules were carried out as detailed in
table 3:1. Lipid A bacteria were prepared by hydrolysis of cells in
1% acetic acid by heating for 90 min at 100°C, followed by three
washes in PBS to remove acetic acid and hydrolysed components.
Serum samples were assayed in the ELISA system described in
MATERIALS AND METHODS for anti-lipopolysaccharide IgG and IgM. Serum
was diluted 1:100 in antibody buffer, and anti-rabbit IgG-urease was
used for detection.
3:3:1. RABBIT 130.
This rabbit was immunised with a series of rough type cells from S.
typhimurium in ascending LPS size from lipid A to Ra. Figure 3:lla-g
indicate the alterations in levels of IgG.
Pre-immunisation levels of IgG to all 26 antigens examined were
negligible. Immunisation with lipid A cells produced small rises
against S_^ minnesota lipid A; S^ typhimurium Ra and Rc; E. coli Rl,
R2, R4, K12Re, K12 lipid A, 0-types 2, 6, 18, 75, 86, and 111; and
S. typhimurium wild type. Most of these responses were boosted upon
immunisation with Re cells, although E^ coli Kl2Re, Rl, 06, and 018
remained unaltered. Immunisation with Re resulted in IgG to all S^
mlnnesota R-LPS becoming detectable at low levels, and large
increases appearing against S_^ typhimurium Ra and Re LPS. Lipid A
response was also boosted slightly. Rises from baseline levels to
moderate levels were observed versus P_^ aeruginosa PAC605; K.




















































































































































FIGURES 3:11 to 3:15.
Key to immunogens and antigens.
Organism ELISA antigen
s. typhmurium wild type WTST
ft it i R1542 RAST
ii it i RI 19 RBST
ii ii i R878 RCS'T
ii it i R 1032 RDST
ii ii i Rl 102 REST
ii ii i lipid A N/A*
s. minnesota R60 RASM
ii II II R345 RBSM
II II If R5 RCSM
ii If If R7 RDSM
II ii ii R595 RESM
II ii ii lipid A LASM
E. coli Rl ECR1
If ii ii R2 ECR2
If ii ii R3 ECR3
fl ii if R4 ECR4
ii ii ii J5 ECJ5
If ii ii F5 15 N/A
ft ii ii K 12 ECK12
fl ii ii K12 Re ECREK 12
ft ii ii K12 lipid A ECLAK12
ii ii ii 01 N/A
ii ii ii 02 EC02
If ii ii 04 N/A
ii ii ii 06 EC06
ii ii ii 012 ECO 12
II ii ii 016 ECO 16
It It tl 018 ECO 18
ii tl It 075 EC075
ft ii ii 086 EC086
ii ii ii 0111 EC01I 1
P. aeruginosa PAC605 PAC605
ii II " Habs type 1 PAS 1
K. aerogenes M10B KAM10B






































N/A* : not used as antigen









ELISAANTIGENS( PS) RASM RBSM RCSM RDSM RESM
days
Immunizing bacteria































O.D.(IgG) 2.00- 1.75- ' . 1.50- 1.25- 1.00- 0.75- 0 .50- 0.25- 0 .00
RabbitIgGanti—LPSresponses Rabbit130














0 .D(IgG) 2.00 1.75 4 * 1.50 1.25 1 .ooH
RabbitIgGanti—LPSresponses Rabbit130
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The next immunisation (with Rd) produced only a slight homologous
response. No alteration was caused versus E. coli LPS from J5, R3,
K12 lipid A and 0111, while IgG versus 02, 012, and 018 IgG fell. A
minor response was obtained to S. minnesota R-LPS, and modest to
significant increases in absorbance were seen to all other antigens.
S. typhimurium Rc produced an increase versus homologous antigen and
against the parental 0-antigen containing strain from low to
moderate levels. Transient rises were induced versus coli 0111
and K_^ pneumoniae M10B. Other antigens developed little response,
and for many a declining trend was obtained.
Largest responses produced by immunisation with Rb were against S.
typhimurium Ra and E_^ coli 075 and 086, with a smaller rise in
homologous IgG from low to moderate levels. Similar modest rises
were seen to E_^ coli Kl2Re and Rl; S. typhimurium Rc, Rd and Re; and
to all minnesota preparations. Large fluctuations were observed
for E^ coli 02, 012, 016, 075, 086, 0111, R2, and R4, though the
last two showed a rising trend.
The final immunisation with Ra bacteria produced no homologous
response. Little change was obtained versus typhimurium Rd, P.
aeruginosa Habs type 1, or E_^ coli Rl and R3. Moderate to large
responses were seen versus all other antigens, although versus four
E. coli (J5, K12, 018, and 0111), three ^ minnesota mutants (Rb,
Rc, and Re) and .K^ aerogenes MlOB this was followed by a fall to
pre-Ra immunisation levels.
3:3:2. Rabbit 131.
This animal was also immunised with a series of rough heat-killed S.
typhimurium bacteria, but in descending size from Ra chemotype to
lipid A. Figure 3:12a-g shows the response of IgG antibodies versus
149














































O.D.(IgG) 2.00-| 1.75 * 1.50- 1.25- 1.00- 0.75- 0.50- 0.25- 0.00-
RabbitIgGanti-LPSresponses Rabbit131









































































0 .D(IgG) 2.00-I 1.75H '4 1.50H
RabbitIgGanti—LPSresponses Rabbit131
ELISAANTIGENS( PS) A:ECR1 B:ECR2 C:ECR3 D:ECR4 E:RAST
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O.D.(IgG) 2.00- 1.75- 1.50H
RabbitIgGanti—LPSresponses Rabbit131
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O.D.(IgG) 2.00- 1.75- 1.50- 1.25- 1.00 0 .75 0.50- 0.25- 0.00-
RabbitIgGanti-LPSresponses Rabbit13
























































































O.D.(IgG) 2.00-i 1.75 * 1.50- 1.25- 1.00 0.75- 0 .50- 0.25- 0.00_JIT"—iH -28-14 Immunizing bacteria
RabbitIgGanti—LPSresponses Rabbit131
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the LPS antigens in ELISA.
Prior to immunisation, levels of IgG were negligible or not
detectable. Immunisation on day zero produced a marked rise in IgG
titre to the homologous antigen (S. typhimurium Ra) and to Ej_ coli
R2 and R4. Modest rises to S_^ typhimur ium wild type, S_^ minnesota
lipid A, and E_^ coli 075 and 086 were also produced. Minimal
response was obtained to other antigens.
Immunisation with Rb boosted all IgG induced previously,
particularly large rises being seen to ^ typhimurium wild type and
Ra, and to E. coli 086, R2, and R4. Smaller responses were obtained
to the homologous antigen, S. minnesota lipidA, and to E_^ coli 075.
Initial responses were obtained to several antigens: those to S.
minnesota Ra and P. aeruginosa PAC605 were modest while those versus
E. coli 02 and 012 were large.
Rc LPS from S^ typhimurium produced only small rises to homologous
LPS and to S. typhimurium Rb and E. coli 075, with larger increments
to S^ typhimurium wild type and to P^ aeruginosa PAC605. IgG to
other antigens remained reasonably stable.
After challenge of rabbits with Rd there was a sharp fall in IgG to
S. typhimurium Ra, P. aeruginosa PAC605, and to E. coli 012, R2 and
R4. Modest increases followed by return to pre-Rd immunisation
levels occurred with typhimurium Rc, E^ coli 075, and K.
aerogenes M10B. Once again IgG to the remaining LPS remained fairly
stable.
Heat-killed S_^ typhimurium Re produced modest rises to S. minnesota
lipid A and E^ coli 02, 012, and 018. Activity of IgG against E.
coli R2 and R4 continued to decline slowly as did that against
strain 086.
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The final immunisation resulted in moderate to large increases in
IgG versus S_^ typhimurium R-LPS except Rd which did not alter.
Similarly, IgG to coli 075 and 086 were obtained. Activity
directed towards coli R2 and R4, S_^ minnesota lipid A, and P.
aeruginosa PAC605 increased, but then returned to levels found prior
to this immunisation. Large fluctuations were observed in IgG to the
remaining E. coli 0-types, though an underlying upwards trend was
observed. All other IgG levels remained stable.
3:3:3. Rabbit 132.
Although most IgG levels (figure 3:13a-g) were negligible, low
levels of IgG to S_^ minnesota Ra and Rb, typhimurium wild type,
P. aeruginosa PAC605, and to E. coli 075 and 086 were observed to be
present before the initial immunisation. This rabbit was immunised
with a range of rough type organisms initially of Rc chemotype
followed by Re chemotype.
The initial immunisation with S. typhimurium Rc produced modest
increases in S. typhimurium and S. minnesota Ra lipopolysaccharides,
and to those from E^ coli J5, Rl, R3, 06, 012, and 0111. Larger
increment were observed versus S. typhimurium Rc and wild type, and
E. coli R2, R4, 02 and 086.
E. coli J5 mutant resulted in sharp rises to _S_^ typhimurium Rc, S.
typhimurium wild type, and to six E^ coli LPS (R3, R4, 02, 06, 075,
and 086). A small, but transient, rise was seen to the homologous
antigen. Similar small, though persistent, increases were obtained
to minnesota Rc and lipid A, S. typhimurium Re, P. aeruginosa
PAC605, K. aerogenes M10B, and E. coli Rl, R2, K12, 016 and 018.



















































































O.D.(IgG) 2.00 1.75 1.50 1.25 1.00- 0.75- 0.50- 0.25- 0.00
RabbitIgGanti—LPSresponses Rabbit132
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to typhimurium Ra and Re, and to E. coli J5, 06, 018 and 075,
though the rise to Ra and 018 were delayed. Moderate rises were
observed to the M10B itself, to S_^ typhimurium Rc and Rd, and to E.
coli Rl, R2, R3, R4, and 086.
P■ aeruginosa PAC605 produced transient rises to typhimurium Ra
and wild type, to _Sj_ minnesota Re and lipid A, and to E_^ coli J5,
K12, K12Re, K12 lipid A, 012 and 018, although levels remained
moderate after falling. IgG directed towards E. coli 02 and R3, the
remaining S_^ typhimurium, and minnesota Rb, Rc, and Rd LPS were
unchanged. The remaining LPS, including that from the immunising
strain, showed more persistent increases.
Re type LPS from E_^ coli F515 produced little change in IgG levels
to P^ aeruginosa Habs type 1 and to E_^ coli K12 and 086 after an
initial drop. Many other LPS showed increases in reactivity varying
from moderate (S. typhimurium wild type, Rb and Rc, all S^ minnesota
antigens, P. aeruginosa PAC605, and E. coli J5, R3, K12, K12Re, K12
lipid A, 02, 06, 016, and 018); to large (S. typhimurium Ra, Rd and
Re, and E_^ coli R2 and 075). Those versus S. typhimurium Rd and wild
type, P. aeruginosa PAC605, and E. coli J5, K12, 02, 06, 012, and
016 were all transient. All other IgG levels remained stable.
The final immunisation with S_^ minnesota R595 Re caused an early
drop in IgG to LPS from E_^ coli R2, R3, 02, 06, 012, and 016, but
levels to all but R3 recovered by the end of this study (day 156).
Large increases to S. minnesota lipid A, S. typhimurium Ra, Rc and
Re, P_^ aeruginosa PAC605, and E^ coli Rl and K12 were obtained.
Smaller, though significant, rises were obtained to E. coli J5, K12
lipid A, K12Re, 075, and 0111, aerogenes M10B, S_^ minnesota
R-LPS, and to Rb and Rd LPS from S. typhimurium. Declining IgG
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levels were obtained after initial increases to S. typhimurium Rb
and Rd, P_^ aeruginosa PAC605, and E_^ coli J5, Rl, R3, 02, and 06.
Other LPS antigens showed no increase or decrease in IgG.
3:3;4. Rabbit 133.
The intention was to challenge this animal with a range of rough
strains from E. coli. Unfortunately, this rabbit died after the
third immunisation as antibody levels were beginning to show
increases. As a result of the short course of this immunisation,
results are not indicated.
3:3:5. Rabbit 134.
This received as immunogens a series of E_^ coli of O-serotypes
predominant in cases of bacteraemia and septicaemia. IgG levels to
most antigens before immunisation were negligible to low with the
exception of S. typhimurium Re, E. coli R3, and E_^ coli K12, which
all showed rising titres towards the first immunisation (figure
3:14a-g) .
Challenge of rabbits with heat-killed E. coli 018 produced little or
no response to most antigens, though moderate increases in IgG to E.
coli 02, 075, R2, and R4, as well as S. typhimurium Ra and wild type
LPS were detected.
E. coli 06 resulted in a massive immediate rise against the
homologous LPS and to E. coli 016 and S. typhimurium Ra LPS. A large
increase was also seen versus S. minnesota lipid A, but IgG returned
to lower levels. IgG to S_^ typhimurium Rb, Rc, and Rd; S. minnesota
Rb, Rc, Rd, and Re; P_^ aeruginosa Habs type 1; and E^ coli Rl, J5,
K12Re, and 018 remained unaltered, and the remainder showed moderate
167
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Inoculation with coli 04 produced little alteration versus most
antigens, the exceptions being E_^ coli 016 (which showed large
fluctuations within an underlying rising trend), 02 and 06 (which
rose from high to very high levels), and 012 (which showed a
transient rise to moderate levels.
Following immunisation with E. coli 02 a large increase was observed
to homologous LPS from moderate to high levels, at which point IgG
stabilised. This was paralleled by E_^ coli 018, but at very low
levels. LPS from E. coli 016 again showed large fluctuations in IgG.
Stability or small reductions were observed for many of the other
antigens with the exception of S_^ typhimurium Rc, S_^ minnesota Rc,
Rd, and Re, and E^ coli R2, R3, and R4 which all showed falling
titres following transient rises.
The next immunisation (E. coli 01) resulted in modest increases in
IgG to all S_^ minnesota R-LPS and to E_^ coli 06, 018, and 012.
Reduction in IgG occurred versus S. minnesota lipid A and S.
typhimurium Ra, Rc, and Re. The remaining antigens showed relatively
stable IgG reactivities.
Inoculation of the last immunogen (E. coli 016) produced a marked
rise in only anti-S. typhimurium Ra IgG, although smaller increments
were obtained versus several other LPS (S. typhimurium Rb, Rc, Rd,
and Re; P. aeruginosa PAC605, S. minnesota lipid A; and E. coli Rl,
R2, R3, R4, K12, K12Re, K12 lipid A, 02, 016, and 018). Other S-LPS
and R-LPS showed either little alteration or a modest fall in IgG.
3:3:6. Rabbit 135.
A range of O-antigen-containing organisms associated with
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septicaemia from different genera were used to immunise this animal.
Before the first immunisation (figure 3:15a-g), low levels of IgG
were detected against E_^ coli R2 and R4, P. aeruginosa Habs type 1
and PAC605, and to S. typhimurium Ra and wild type.
Inoculation with coli 018 produced no significant homologous
response, although moderate responses (E. coli 02, 075, and 086, and
S. typhimurium wild type) and small responses (E. coli 06 and 0111)
to other antigens were obtained. Some rough antigens also showed
increased recognition by IgG, with very steep rises observed to S.
typhimurium Ra and E_^ coli R2 and R4 (which all showed detectable
IgG before immunisation) . A sharp rise was also observed versus S.
typhimurium Rb, but this occurred 16 days after immunisation.
Moderate rise were obtained to E_^ coli R3 and S_. minnesota lipid A.
On subsequent immunisation with 018 cells, a very small transient
rise was obtained to 018 LPS. Recognition of LPS from E. coli 012,
075, and 086 and S_^ typhimurium wild type were sharply and rapidly
boosted to high levels though IgG then gradually fell in the period
to the next immunisation. This immunisation also induced more modest
rises in IgG recognising E. coli K12, 02 and 0111, and P. aeruginosa
Habs type 1, with IgG stabilising at moderate levels. E. coli 06 and
016 showed small but significant increases, and IgG to E. coli R2
and R4 and to S^ typhimurium Ra were boosted to maximal levels, at
which point they remained until the final immunisation. Significant
and persistent increases were seen to S. typhimurium Rb and Rc, and
non-persistent responses were seen to S. typhimurium Rd and Re, S.
minnesota Ra and lipid A, and E_^ coli Rl, R3, K12, K12Re, and K12
lipid A. Smaller increments were obtained versus most other
antigens.
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P. aeruginosa Habs type 1 produced a massive homologous response,
with IgG remaining at maximal levels until the final immunisation.
Lipid A from minnesota also showed IgG boosted to high levels,
and transient increases were obtained against E_^ coli K12 lipid A,
S. minnesota Re, and S_^ typhimurium Rb, Rc, and Rd. Small increments
versus S. typhimurium wild type and E. coli 012 and 075 were
obtained. The only other major change was observed with E. coli 086,
against which massive fluctuations occurred.
E. coli 06 provoked a massive response to 06 LPS and to E. coli 016
and 086 LPS, although against 086, large fluctuations were present
after the initial rise. A slower rise was observed versus E_^ coli
02, and a small response occurred to 0111. In contrast, IgG versus
S. typhimurium wild type and E_^ coli 012 fell gradually. IgG to
other S-LPS remained unaltered. Reduction in IgG levels also
occurred for S. typhimurium Ra and Rb LPS. Little change was seen to
S. typhimurium Rc and Rd, S_^ minnesota Ra and Rd, and E_^ coli R2,
R4, K12, K12Re and K12 lipid A. Against other rough LPS, moderate
increases were obtained, though these were not sustained.
The third immunisation with E. coli 018 initiated a moderate gradual
rise to homologous LPS, and a modest rise wad obtained to 0111 LPS
from this species. Once again lipopolysaccharide from E. coli 075
and 086 showed massive fluctuations in IgG and other IgG to smooth
LPS remained relatively stable. After an initial sharp reduction at
immunisation, anti-S. minnesota lipid A antibodies returned to
previous levels. Boosted responses occurred to LPS from S.
typhimurium Rb and S. minnesota Ra, but the former response showed
large fluctuations. Smaller rises were obtained to P_^ aeruginosa
PAC605, S. typhimurium Rd, and E. coli Rl, R3, and K12 lipid A. All
184
other LPS showed unaltered IgG levels.
The final immunisation with K_^ aerogenes M10 resulted in a moderate
but transient rise versus its O-antigen deficient mutant M10B.
Moderate increases were also obtained versus E_^ coli 02 and S.
typhimurium Rd, with larger, more sustained increases against E.
coli Rl, R3, J5, 018 and 0111, and typhimurium Re apparent. In
contrast to most immunogens, this one caused large reductions in IgG
to P^ aeruginosa Habs type 1, minnesota Ra and lipid A, S.
typhimurium Ra, and E. coli R4, 06, 016, 075 and 086, and also more
moderate reductions to P_^ aeruginosa PAC605 and E_^ coli K12 and 012
were also observed. Only anti-R4 and anti-012 IgG showed signs of
recovery from these reductions. IgG to other antigens remained
unaltered from previous levels.
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3:4. Antigenic Presentation of LPS-polymyxin in ELISA.
3:4:1. Assay of 4 Normal Human Sera in ELISA.
ELISA was carried out on four normal human sera (NHS) selected for
high (GL+), medium (MED1 and MED2), and low (GL-) levels of IgG in
the previously described CGL-pool assay. ELISA strips were prepared
as described in MATERIALS AND METHODS with a variety of preparations
from S. typhimurium R878 (Rc chemotype). The preparations used were:
i) purified LPS, ii) LPS-polymyxin complex, iii) outer membrane - OM
- extracts, and iv) heat-killed bacteria. All antigens were coated
onto plates with approximately equivalent concentrations of
carbohydrate, and a control was prepared which was coated with
post-coat only. Each NHS was prepared in a doubling dilution series
from 1:25 to 1:1600 plus a non-antibody control for assay against
each antigen. Results were obtained as absorbance at 590nm, which
gave an indication of levels of IgG.
The ELISA results are presented in figures 3:16a-d. For each of the
four NHS, blank strips produced negligible absorbances at all
dilutions, as did control wells for each antigen with no serum. The
one exception to this was the heat-killed cells with MED 1 but, as
all other heat-killed cells controls possessed only minimal
absorbance, this was probably due to a stray contaminant.
By comparing the profiles of each NHS in figure 3:16, it can be seen
that GL+ possessed the highest overall levels of IgG, MED 1 and MED2
both possessed more moderate IgG levels, and GL- possessed the
lowest. The absorbances obtained against LPS-polymyxin at a dilution
of 1:100 (the dilution used in the assay) were 0.191 (100%) for GL+,
0.046 (24%) for GL-, and 0.062 (32%) and 0.212 (111%) for MED 1 and
186
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FIGURE 3:16. Binding activities of four human sera against four LPS-containing
antigens (as described in the legend) from typhimurium R878 and a blank in
ELISA. A doubling dilution series of serum from 1:25 to 1:1600 plus a control
containing no serum was used. Figures (a), (b), (c), and (d) represent the







MED2 respectively. The results reflected reasonably closely those
obtained for these four NHS in previous assays: GL+ 100%; GL- <10%;
MED 1 approximately 60%; and MED2 approximately 110%.
Of the four antigens, purified LPS and OM produced the highest
absorbances with all sera, both antigens producing very similar
absorbances at all points. Heat-killed bacteria represented the next
most reactive antigen with LPS-polymyxin producing the lowest
absorbance values.
3:4:2. Effect of Absorption with Bacteria on IgG Levels to LPS.
A series of absorptions was carried out on each of the 4 NHS with S.
typhimurium R878 bacteria. NHS and heat-inactivated (56°C for 30min)
HNHS were absorbed with heat-killed and viable organisms
respectively. Heat-killed bacteria were used to absorb untreated
serum as complement is strongly bacteriolytic for organisms with
R-LPS on their surface, and viable organisms can be used to absorb
heat-inactivated serum as the complement activity is removed by
heating.
a) Absorption of NHS with heat-killed bacterial cells.
The results obtained by absorption of 4 NHS with heat-killed
bacteria were graphed (figures 3:17, 3:18, 3:19, and 3:20). Four
solid-phase antigens (LPS-polymyxin, LPS, OM, and heat-killed
bacteria) from S_^ typhimurium R878 in addition to a control were
used for detection of IgG in ELISA.
The results with unabsorbed sera were similar to those achieved
previously (see figure 3:16). Four cycles of absorption were carried
out for each NHS, and the results are presented for each. IgG in
each serum can be seen to fall after each absorption step. Little
188
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Figure 3:17d
FIGURE 3:17. Binding activities of GL+ serum against five antigens in ELISA
before absorption 'and after four consecutive absorptions with heat-killed S.
typhimurium R878 bacteria. A doubling dilution series of serum from 1:50 to
1:3200 plus a control containing no serum was used. Figures (a), (b), (c), (d),
and (e) represent results obtained with LPS-polymyxin complexes, uncomplexed LPS,
outer membrane, heat-killed bacteria and blank solid phase antigens respectively.
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FIGURE 3:18. Binding activities of GL- serum against five antigens in ELISA
before absorption and after four consecutive absorptions with heat-killed S ■
typhimurium R8?8 bacteria. A doubling dilution series of serum from 1:50 to
1:3200 plus a control containing no serum was used. Figures (a), (b), (c), (d),
and (e) represent results obtained with LPS-polymyxin complexes, uncomplexed LPS,
outer membrane, heat-killed bacteria and blank solid phase antigens respectively.
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FIGURE 3:19. Binding activities of MED 1 serum against five antigens in ELISA
before absorption and after four consecutive absorptions with heat-killed S.
typhimurium R878 bacteria. A doubling dilution series of serum from 1:50 to
1:3200 plus a control containing no serum was used. Figures (a), (b), (c), (d),
and (e) represent results obtained with LPS-polymyxin complexes, uncomplexed LPS,
outer membrane, heat-killed bacteria and blank solid phase antigens respectively.
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FIGURE 3:20. Binding activities of MED2 serum against five antigens in ELISA
before absorption and after four consecutive absorptions with heat-killed S.
typhimurium R878 bacteria. A doubling dilution series of serum from ]:50 to
1:3200 plus a control containing no serum was used. Figures (a), (b), (c), (d),
and (e) represent results obtained with LPS-polymyxin complexes, uncomplexed LPS,
outer membrane, heat-killed bacteria and blank solid phase antigens respectively.
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further reduction in IgG was obtained after the third absorption
step had been performed.
b) Absorption of HNHS with viable bacterial cells.
This produced the changes in IgG as shown in figures 3:21, 3:22,
3:23, and 3:24. Reactivity of heat-inactivated sera (before and
after absorption) with ELISA antigens showed far greater fluctuation
than fresh sera. Reduction in IgG levels at each step is noticeably
less obvious than obtained above with the exception when purified
LPS was used as antigen, although large fluctuations in IgG were
noticeable.
The ELISA strips containing only post-coated wells showed far higher
absorbances at a serum dilution of 1:50 than obtained with fresh
serum, but by a dilution of 1:100 this difference was removed and
absorbances for HNHS were close to baseline.
3:4:3. Inhibitory Activity of Soluble LPS-containing Antigens on the
Binding of Anti-LPS IgG in ELISA.
a) Effect of time of incubation of IgG and inhibitor.
Inhibition of GL+ NHS was assayed as described in MATERIALS AND
METHODS. GL+ at a final dilution of 1:100 was incubated at room
temperature with doubling dilutions of inhibitor typhimurium
R878 LPS) from 8 times the concentration of carbohydrate initially
loaded into ELISA strips for coating (i.e. doubling series of
inhibitor from 1.6xlO-^mM carbohydrate per well). Samples of
inhibitor-NHS mixture were removed at lOmin intervals for assay in
ELISA against purified LPS. Absorbances obtained were graphed in two
ways: i) concentration of inhibitor versus absorption for each time
point (figure 3:25a), and ii) time of co-incubation versus
193
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FIGURE 3:21. Binding activities of heat-inactivated GL+ serum against five
antigens in ELISA before absorption and after four consecutive absorptions with
viable S. typhimurium R878 bacteria. A doubling dilution series of serum from
1:50 to 1:3200 plus a control contining no serum was used. Figures (a), (b), (c),
(d), and (e) represent results obtained with LPS-polymyxin complexes, uncomplexed
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FIGURE 3:22. Binding activities of heat-inactivated GL- serum against five
antigens in ELISA^before absorption and after four consecutive absorptions with
viable S. typhimurium R878 bacteria. A doubling dilution series of serum from
1:50 to 1:3200 plus a control containing no serum was used. Figures (a), (b),
(c), (d), and (e) represent results obtained with LPS-polymyxin complexes,
uncomplexed LPS, outer membrane, heat-killed bacteria and blank solid phase
antigens respectively.
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FIGURE 3:23. Binding activities of heat-inactivaated MED I serum against five
antigens in ELISA before absorption and after four consecutive absorptions with
viable S. typhimurium R878 bacteria. A doubling dilution series of serum from
1:50 to 1:3200 plus a control containing no serum was used. Figures (a), (b),
(c), (d), and (e) represent results obtained with LPS-polymyxin complexes,
uncomplexed LPS, outer membrane, heat-killed bacteria and blank solid phase
antigens respectively.
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FIGURE 3:24. Binding activities of heat-inactivated MED2 serum against five
antigens in ELISA before absorption and after four consecutive absorptions with
viable typhimurium R878 bacteria. A doubling dilution series of serum from
1:50 to 1:3200 plus a control containing no serum was used. Figures (a), (b),
(c), (d), and (e) represent results obtained with LPS-polymyxin complexes,
uncomplexed LPS, outer membrane, heat-killed bacteria and blank solid phase
antigens respectively.
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absorbance for each concentration of inhibitor (figure 3:25b).
All time points produced greatest absorbance with no inhibitor
present, with the exception of the sample removed after 60min
co-incubation of inhibitor with GL+, which showed only very low
levels of IgG. All other time points showed rapidly declining
reactivities (i.e. increasing inhibition) with increasing
concentration of inhibitor. At a concentration of 4.0xl0--^mM
carbohydrate (2x concentration in well), however, a rise in
absorbance was obtained for Omin pre-incubation, though at lower
concentrations the absorbance again fell.
As inhibition could be observed in ELISA with no prior incubation of
antibodies and inhibitor, a series of inhibitions was performed in
this manner i.e. inhibitor and NHS were mixed J_n situ in ELISA
microplates, then incubated for 60min to permit binding of
antibodies to inhibitor and solid-phase antigen. The same serum
(GL+) was used throughout because of its high reactivity in ELISA to
all five antigenic preparations.
3:4:4. Activities of Three Inhibitors on Binding of IgG to ELISA
Antigens.
Lipopolysaccharide and outer membrane (OM) were prepared in a 7 step
doubling dilution curve from 8 times carbohydrate concentration in
well (1.6xlO-^mM downwards) for use as inhibitors. Complexes of LPS
with polymyxin were prepared in a doubling dilution series from
twice the concentration in the well (8.0xl0~^mM carbohydrate). The
appropriate concentration of inhibitor (50ul) and GL+ at a dilution
of 1:50 (50ul) were placed in microplate wells containing each of
198
Figure 3:25a Figure 3:25b
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FIGURE 3:25. Inhibition of ELISA reactivity of GL+ serum against S. typhimurium
R878 LPS with purified LPS from the same organism. Figure (a) represents the
activities obtained with a range of inhibitor concentrations for each period of
co-incubation (as described in the key), and figure (b) represents the activities
obtained with each concentration of inhibitor (as described in the key) after
each period of co-incubation.
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the antigenic preparations. This gave a final serum dilution of
1:100, and a dilution series of inhibitor from 8.0xl0~3mM
carbohydrate for LPS and OM, and from 4.0xl0~^mM for LPS-polymyxin.
After 60 min incubation, strips were washed and incubated for 60 min
with lOOul of a 1:500 dilution of anti-human IgG-urease conjugate.
Further washing was carried out and substrate was added to wells
(lOOul). Absorbances were read at 405nm.
a) Inhibition with uncomplexed LPS:
Results obtained after 30, 45, and 60 min colour development
(figures 3:26a-c) indicate that results were similar at all times
and that addition of purified LPS to serum inhibited the binding
activity of antibodies to lipopolysaccharide itself and to
heat-killed organisms, but not to outer membrane. The blank control
strips showed only neligible binding by NHS. Very low levels of
binding were seen to LPS-polymyxin complex even in absence of
inhibitor, thus ELISA results for this antigen must be disregarded.
Inhibition was obtained only between 1.OxlO-^ and 0.125xl0~3 mM
inhibitor against LPS, and between 0.5x10"-^ and 0.125xl0~^mM
inhibitor against bacteria. Above these concentrations binding to
LPS and bacteria was greater than when no inhibitor was present.
This reflects the previous inhibition results (figure 3:25). At
concentrations of greater than 2.0xl0--^mM and 4.0xl0~3mM against LPS
and bacteria respectively, results show a drop towards inhibition
once again.
b) Inhibition with outer membrane (OM).
The greatest reduction in absorbance at all time points was
obtained versus LPS and OM at all concentrations of inhibitor
(figure 3:27a-c). The results for blank strips remains on the axis
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FIGURE 3:26. Inhibition of ELISA reactivity of GL+ serum against four S.
tvphimurium R878 LPS-containing antigens and a blank (as described in the key)
with a doubling dilution series of purified LPS from this organism and a control
containing no inhibitor. Colour development was carried out for 30min (figure a),
45min (figure b) and 60min (figure c).
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FIGURE 3:27. Inhibition of ELISA reactivity of GL+ serum against four S.
typhimurium R878 LPS-containing antigens and a blank (as described in the key)
with a doubling dilution series of outer membrane from this organism and a
control containing no inhibitor. Colour development was carried out for 30min
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FIGURE 3:28. Inhibition of ELISA reactivity of GL+ serum against four SN_
typhimurium R878 LPS-containing antigens and a blank (as described in the key)
with a doubling dilution series of LPS-polymyxin complexes from this organism and
a control containing no inhibitor. Figures (a) and (b) represent repeat assays
carried out under indentical conditions.
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of the graph. Absorbances versus bacteria varies little over the
range of concentrations of inhibitor. With LPS-polymyxin only one
concentration (0.125xlO~^mM) produced an absorbance lower than in
absence of inhibitor. Other points against LPS-polymyxin show large
deviations.
c) Inhibition with LPS-polymyxin complexes.
1. New strips containing LPS-polymyxin were prepared for this in
view of the low absorbances obtained above. For this, LPS-polymyxin
complex at a final concentration of 4.0xl0_-^mM was used for coating
strips. Inhibitor was therefore produced at a final concentration in
wells from 4.0xl0~^mM in a doubling dilution series.
Inhibition was clearly demonstrable versus all four antigens (figure
3:28a). The greatest inhibition occurred against LPS-polymyxin, and
significant inhibition was also observed versus LPS, bacteria, and
OM for all concentrations of inhibitor.
2. Repetition of this inhibition in an identical manner produced the
results indicated in figure 3:28b. Although the results show
inhibition of binding of IgG to all antigens, the absorbance values
and position if the curves is at variance with those in figure
3:28a. Once again inhibition was most noticeable with LPS-polymyxin
coated wells, although with inhibitor at a concentration of
3.125xlO_^mM absorbance was higher than with no inhibitor present.
Inhibition versus LPS and OM also occurred, again at significant
levels. With heat-killed bacteria as the solid-phase antigen, much
variation was obtained between consecutive points on the graph, with
some lying above and some lying below the absorbance where no
inhibitor is present.
d) Inhibi tion was repeated once more with each of the three
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FIGURE 3:29. Inhibition of ELISA reactivity of GL+ serum against four S.
typhimurium R878 LPS-containing antigens and a blank (as described in the key)
with doubling dilution series of three inhibitors. Figures (a), (b) and (c)
represent the results obtained by inhibition with LPS-polymyxin complexes,
uncomplexed LPS and outer membrane respectively.
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inhibitors against the five solid-phase antigens (LPS,
LPS-polymyxin, OM, bacteria, and blank). Inhibitors were prepared
from 8.0xl0~^mM in a doubling dilution series. Results are presented
in figures 3:29a-c as absorbance versus dilution of inhibitor. These
indicate variance from results obtained previously. With each
inhibitor, LPS-polymyxin coated strips showed absorbances
approaching baseline values with the exception of three points (at
0.5x]0~3 and 8.0xl0~3mM for LPS and at 0.5xl0~3mM versus OM).
Reactivity of NHS with bacteria showed much variability in absence
of inhibitor. The results obtained for the final series of
inhibitions can be summarised as follows:
i) LPS-polymyxin complexes, with both LPS and OM, showed decreases
in antibody binding to LPS and OM with increasing concentration of
inhibitor. All dilutions of LPS-polymyxin produced small decreases
in absorbance versus bacteria. Binding of antibodies to LPS in
absence of inhibitor produced a far higher absorbance ( 1 . 10) than
against LPS in the other two assays (0.78 and 0.76).
ii) Uncomplexed LPS showed inhibition of antibody reactivity with
LPS, OM and bacteria. Marked inhibition occurred to LPS. Lower
concentrations of inhibitor showed some inhibitory activity versus
OM, but large fluctuations were obtained in absorbance between
consecutive points. Similarly, inhibition of binding of antibodies
to bacteria occurred, but only at a very low level. The increase in
binding to solid phase antigen previously obtained with high LPS
inhibitor concentrations (figures 3:25 and 3:26) was less noticeable
in this experiment. Reactivity of serum in absence of inhibitor was
low versus OM (0.416) in comparison with the other two inhibitions
(with values of 1.138 and 1.231).
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iii) OM produced a similar reduction in binding activity to LPS with
increasing concentration. Very high binding of GL+ to OM in absence
of inhibitor was obtained (1.23 compared with 0.42 and 0.46 for LPS
and LPS-polymyxin respectively), thus this may be due to the
presence of a contaminant in this well. Strong inhibitory activity
of OM was clearly demonstrated versus OM, LPS and bacteria.
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3:5. Alteration of Expression of Lipopolysaccharide Epitopes under
Different Nutrient Conditions.
3:5:1. Effect of Nutrient Conditions upon LPS Expression.
a) coli 018:K1 was inoculated into 10ml nutrient broth and
incubated at 37°C for 4h after which time 0.5ml was removed for
inoculation into 10ml of the media detailed in table 3:2. Bacteria
were cultured for 18h as described in MATERIALS AND METHODS,
harvested by centrifugation (4000g,, lOmin, Heraeus Christ bactifuge)
and washed twice in sterile PBS, then finally resuspended in 10ml of
PBS. Absorbances of suspensions were measured in a spectrophotometer
at 525nm (A525)and were tabulated (table 3:2). Concentrations of
bacteria in several of the suspensions were adjusted to give an A525
of 0.5 - 0.6. Proteinase K digestions were performed on these, and
lipopolysaccharides were visualised by PAGE ( 14% acrylamide
separating gel) followed by silver staining. Results of silver
staining are presented in figure 3:30.
The results in table 3:2 indicate that strong growth was observed in
media numbers 1, 2, 3, 4, 6, 8 and 9. Less, though significant,
growth occurred in all other media except number 12 (PBS).
Silver staining of PAG (figure 3:30) revealed little difference
between high molecular weight bands of 0-antigen. Heavier staining
of the first major band of core, running at the front, was obtained
with bacteria grown in the presence of serum at a concentration of
20% or greater in NB. Growth in NB and in NB-serum mixtures resulted
in production of a minor band running in front of the first major
core band. Expression of this component appeared to increase with
increasing concentration of NB.
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TABLE 3:2. Absorbance at 525nm after 1 8h of E. coli 018:K1


















































TABLE 3:3. Absorbance at 525nm after 18h of E . coli 018: K
Grown in Different Nutrient Conditions.
N o CONCENTRATION IN MEDIUM a525
















































* Sheep serum inactivated by heating at
56-60°C for 45min, then stored at
-20°C until required.
** Gibco nutrient broth
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FIGURE 3:30. Silver stain of proteinase K digests from overnight
cultures of E■ coli 0 18:K1 grown in media as described in Table 3:2.
Growth media were: track 1 - medium 1; track 2 - medium 2; track 3 -
medium 4; track 4 - medium 6; track 5 - medium 8; track 6 - medium
9; track 7 medium 10; and track 8 - medium 11.
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FIGURE 3:31. Silver stain of proteinase K digests from overnight
cultures of E. coli 018:K~ grown in media as described in Table 3:3.
Growth media were: track 1 - medium 1; track 2 - medium 2; track 3 -
medium 3; track 4 - medium 4; track 5 - medium 5; track 6 - medium
6; track 7 - medium 7; track 8 - medium 8; track 9 - medium 9; track
10 - medium 10; track 11 - medium 11; and track 12 - medium 12.
2 1 1
b) The same growth conditions were applied to an isogenic mutant of
the above organism which produces little or no capsular material (E.
coli 018:K~). Once again, A525 was measured (table 3:3) and adjusted
to 0.5 - 0.6 for proteinase K digestion followed by PAGE and silver
staining for LPS (figure 3:31). Significant growth was obtained
under all conditions (including PBS) as determined by measurement of
optical density of bacterial suspensions. In figure 3:31, it can be
seen that staining of high molecular weight lipopolysaccharide was
very heavy, but little difference was obtained under different
growth conditions. Growth of organisms in 100% serum and in
dilutions of serum in PBS, produced heavier staining of medium
molecular weight bands than under other conditions. Staining of
these medium molecular weight bands became less prominant as serum
was diluted in NB. Staining of low molecular weight components of
LPS was fairly uniform in all media. Some media ( 100% serum, 50%
serum:50% NB, 5% serum: 95% NB, and 100% NB) induced the production
of a fast-migrating band as seen with E. coli 018:K1.
3:5:2. Alteration of LPS during Growth of E. coli 018:KZ.
An overnight culture in NB (5ml) was used to inoculate 100ml of NB.
This was incubated as described previously. Samples were removed at
30min intervals for measurement of A525 against a nutrient broth
blank. After measurement of optical density, bacteria were
harvested, washed twice in PBS and resuspended to give an A525 of
0.5 to 0.6. Proteinase K digestion was then carried out, and samples
were subjected to PAGE. The alteration in A525 was graphed versus
time of sample after inoculation (figure 3:32), and shows that
bacteria entered logarithmic phase of growth very rapidly, and
2 12
Figure 3:32
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FIGURE 3:32. Growth of E. coli 018:K in Nutrient Broth as
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FIGURE 3:33. Silver stain of proteinase K digests of E. coli 0l8:K-
grown in Nutrient Broth. Samples were removed at 30min intervals
from Omin incubation (track l) to 360min incubation (track 12). The
corresponding growth curve is presented in Figure 3:32.
2 14
continued to proliferate rapidly until stationary phase was reached
by 240 min after inoculation. Silver staining of PAG (figure 3:33)
revealed that incomplete proteinase K digestion had occurred for
samples removed at times 120, 210, and 240, but that LPS was not
obscured. Increased staining of high molecular weight bands was
observed over the course of growth. Increased staining of the first
and second fast migrating bands occurred also with maximal staining
occurring between 120 and 150 min. In addition, a third fast
migrating band appeared behind these two at 60 min, and remained
constant throughout after this point. Over and above these
alterations, staining becomes apparent of material in front of the
fastest migrating band after 90 min incubation - this may represent
material observed previously.
3:5:3. Effect of Density of Bacterial Suspension on LPS Staining
Intensity.
In view of the differences observed above between different LPS
profles, a determination was made of the effect of density of
bacterial suspension and volume of proteinase K digest loaded onto
gel on the resultant LPS profile. For this, E. coli 018:K~ was
cultured overnight. After harvesting and washing, the absorbance of
the suspension was measured and adjusted to give three values
between 0.50 and 0.65. The final A525 values obtained were 0.54,
0.58, and 0.64. Proteinase K extracts were prepared for each
suspension, and two volumes (lOul and 20ul) of each were loaded onto
PAG for electrophoresis. The results of silver staining (figure
3:34) show incomplete proteinase K digestion, but LPS profiles and
staining density remained more or less constant in all samples.
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12345678 9
FIGURE 3:34. Silver stain of proteinase K digests of overnight
cultures of E. coli 0l8:K-. Bacterial suspensions of different
optical densities (A525 of 0.54 - tracks 1, 2, and 7; A525 of 0.58 -
tracks 3, 4, and 8; and A525 of 0.64 - tracks 5, 6, and 9) and
different volumes of proteinase K digest were loaded ( lOul in tracks
1 to 6 and 20ul in tracks 7 to 9).
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3:5:4. Growth of E. coli under Different Nutrient Conditions.
Growth curves were carried out for coli 018:K~ cultured in four
media to assess growth phase of cells and thus relevant time points
for analysis of LPS. Figure 3:35 shows the results obtained for
growth in NB, MALKA (minimal medium), NDM (nitrogen deficient
medium), and HSS (heat-inactivated sheep serum). The lag phases in
NB and NDM were very short, and A525 had doubled within 60min.
Bacterial growth in NB continued for 180min, after which point
growth slowed down and stationary phase was reached by 300min after
inoculation. In NDM growth continued at a rapid rate for 240min, at
which point proliferation ceased abruptly. The lag phases for both
MALKA and HSS were longer. When grown in HSS log phase was entered
by 90min, and continued until 210min, at which point growth a slower
rate of growth was apparent. Stationary phase was apparently entered
by 270min. MALKA resulted in entry into logarithmic growth only
after 120min incubation. Multiplication of bacteria continued
rapidly until 360min, at which point growth ceased abruptly.
3:5:5. Growth of E. coli under Magnesium Limitation.
Modifications of MALKA containing 10% and 1% of the concentration of
magnesium (M10 and MO 1 respectively) were used as growth media for
E. coli 018:K~. Samples were removed every 30min for determination
of A525• Results of A525 were graphed versus time for both M10 and
MO 1 and were compared to the previously obtained growth curve for
unmodified MALKA. Figure 3:36 indicates that a lag phase of
approximately 150min was present under both nutrient conditions.
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FIGURE 3:35. Growth of E. coli 018:K~ in four media - NB, MALKA,
ISS, and NDM (as detailed in the text) as determined by measurement
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FIGURE 3:36. Growth of E. coli 018:K in three minimal media (as
detailed in text) as determined by measurement measurement of
absorbance of bacterial suspension at 525nm.
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slower rate than for any other medium. Growth continued at these
rates until 300min, from which time a slower rate of growth
continued until 450min. After overnight incubation (24h) the A525
readings for M10 and MO 1 were 1.45 and 1.8 respectively.
3:5:6. Effect of Growth Medium and Growth Phase on LPS Expression
and Binding of Monoclonal Antibodies to Core and O-antigen.
In view of the above results it was decided that hourly samples
would be sufficient to cover all phases of growth for proteinase K
extraction to visualise LPS, and flow cytometry analysis to
determine binding of monoclonal antibodies to core and O-antigen.
An overnight culture of Ej_ coli 018:K~ was harvested and washed.
Bacteria were then resuspended to their original volume in PBS.
After measurement of A525 ( 1 .45) 5ml of suspension was inoculated
into each of three media (NB, MALKA, and HSS). Samples were removed
hourly for determination of A525, for preparation of proteinase K
extracts, and for incubation with monoclonal antibodies.
Figure 3:37 indicates that the growth curves produced in these media
are similar to those obtained previously (figure 3:35).
LPS profiles of bacteria grown in NB is also similar to that
obtained previously. Both NB and MALKA (figures 3:38a & b) show
heavy staining of large bands of components running at the front,
while heat-inactivated serum (figure 3:38c) produced a smaller more
discrete band. Little alteration in LPS appeared to occur in
bacteria cultured in MALKA, but in NB and HSS heavier staining
appeared in later samples. Growth in serum induced rapid formation
of a very high molecular weight component which was not observed in
other samples including inoculum. The expression of this component,
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Figure 3:37
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FIGURE 3:37. Growth of E. coli 018:K~ in three media (see text
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FIGURE 3:38. Silver stain of proteinase K digests (5ui) of E. coli
0l8:K- grown in nutrient broth (figure a), heat-inactivated sheep
serum (figure b), and MALKA minimal medium (figure c). Samples were
removed at 60min intervals from 60min incubation (track l) to 360min
incubation (track 6) plus a sample from overnight incubation.
Inocula for (a) and (b) are represented in track 8 figure (b), and
for (c) in track 0 of figure (c).
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however, diminished as time progressed.
Analysis of the binding of monoclonal antibodies to core and
O-antigen of this organism by flow cytometry produced the results
presented in table 3:4 after subtraction of background fluorescence
(bacteria incubated with only FITC-labelled anti-mouse IgG - see
MATERIALS AND METHODS).
The results showed that growth in NB produced negligible binding of
an anti-core monoclonal antibody with a mean of 1 .0% of cells
fluorescently labelled, while the anti-O-antigen monoclonal IgG
showed high binding at all points of the growth curve (a mean of
54.1% of cells labelled). MALKA produced similar results to NB with
means of -1.1% and 69.2% of bacteria labelled with core and
O-antigen monoclonal antibodies respectively. Growth of bacteria in
serum produced contrasting results because significant binding was
obtained with both monoclonal antibodies during active growth (means
of 33.9% and 47.4% with core and O-antigen monoclonal antibodies
respectively). Two exceptions from this occurred at 60min after
inoculation, and after overnight culture, where results were
comparable to those obtained with NB and MALKA.
Overnight culture of this organism in NB was repeated, and results
were similar to those obtained previously with -0.05% of cells
binding core monoclonal and 48.28% of cells binding O-antigen
specific monoclonal antibody (table 3:5).
Growth overnight in modified MALKA media containing 10% and 1% of
the magnesium concentration (M10 and MO 1 respectively) produced
results similar to those obtained for overnight growth in unmodified
MALKA (table 3:5).
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TABLE 3:4. Percentage of E. coli 018:KZ Binding Monoclonal




Percent of E. coli binding Monoclonal Antibody in:
Nutrient Broth MALKA Serum
core 1 0--antigen2 core O-antigen core 0-antig
0 0.01 43.76 0.01 43.76 0.01 43.76
60 6.16 57.84 0.58 51.19 4.65 29.02
120 2.09 49.23 -11.81 29.69 40.30 38.85
180 -0.84 35.50 0.52 43.51 56.87 58. 16
240 0.06 80.37 0.48 23.78 28.06 43.00
300 0.20 80.53 0.83 86.98 24.77 50.53
360 0.07 69.79 -4 . 18 77.75 19.48 46.66
o/n 0.38 15.53 0.94 65.30 2.89 23.08
1. McAb SZ27/ 150 .3, anti-core.
2. McAb SZ184/2.5.5, anti-018 Oantigen.
TABLE 3:5. Percentage of E. coli 018:KZ Binding Monoclonal
Antibodies to Core and O-antigen after Overnight Growth in
Magnesium Limiting Media.
MEDIUM PERCENTAGE E^ coli BINDING TO:
CORE1 O-ANTIGEN2
NB 01 48.24
M10 2.68 61 .60




3;5:7. Comparison of Capsulate and Non-capsulate E. coli 018 Grown
in Untreated and Heat-inactivated Sheep Serum.
E. coli 018:K1 and 018:K~ were prepared as described previously, and
optical densities of suspensions were measured (K1 = 1.18, and K- =
1.10). Two 5ml volumes of each suspension were inoculated into 100ml
of sheep serum (SS) and heat-inactivated sheep serum (HSS) from the
same source, and subjected to the culture conditions mentioned
above. Samples were removed every 60 min for determination of A525,
proteinase K digestion followed by PAGE, and analysis of binding of
antibodies to core and 0-antigen epitopes by flow cytometry.
The growth curves of the two organisms under each condition (figure
3:39) showed that both organisms divided more rapidly in HSS than in
SS. Both growth curves and final optical density readings for
organisms grown in HSS were similar to those obtained previously
under the same conditions. Optical densities of both K1 and K~ grown
in HSS were within 0.05 units at all points.
When grown in untreated serum E_^ coli 018:K1 grew at a steady slow
rate throughout, with A525 at 360min of approximately 60% of that in
HSS. In contrast, 018:K~ shows only a small increase on cell number
followed by a decline. From 240min onwards very rapid cell division
was observed, matching the growth rate in HSS.
The lipopolysaccharide profiles (figure 3:40a-d) show that in
untreated serum both organisms produced increasing staining of core
and 0-antigen bands of LPS with time. In HSS increased staining of
0-antigen was noted to occur, but this was more pronounced in E_^
coli 018:K1. Staining of core components of bacteria grown in HSS
did not change markedly from the inoculum.
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FIGURE 3:39. Growth of Ej_ coli 0 18 :K_ and coli 0 18:K1 in
untreated sheep serum (SS) and heat-inactivated sheep serum (HSS) as







FIGURE 3:40. Silver stain of proteinase K digests of E. coli 0 18:K1
(figures a & c) and E. coli 018:K~ (figures b & d). Bacteria were
cultured in untreated sheep serum (figures a & b) and in
heat-inactivated sheep serum (figures c & d). The inocula for each
is shown in track 1. Samples were removed at 60min intervals from
60min incubation (track 2) to 360min incubation (track 7) plus a
















































































































































































results presented in table 3:6 showed one or two anomalous points,
but overall they indicated once again that coli when grown in HSS
permitted access of a core-specific monoclonal antibody as well as
an O-antigen specific monoclonal antibody. Similar binding
characteristics were also obtained with this organism grown in
untreated serum. E_^ coli 018:K1 grown in SS showed much lower
binding to both core and O-antigen, although from times 60min to
180min limited binding was observed by the anti-core monoclonal
antibody. After this point, binding to both core and O-antigen was
very low. In HSS binding to core generally produced negative values
(i.e lower than control), but binding to O-antigen occurred for a
mean of 29.7% of bacteria cultured for between 60min and 360min.
3:5:8. Growth of E. coli in Absorbed and Non-Absorbed Serum, and
Effect on Binding of Monoclonal Antibodies to Core and O-antigen.
Absorption of serum was carried out with organisms of identical and
unrelated O-antigen structures (E. coli 018:K~ and E_^ coli 086:K6i
respectively) to that of the bacterium under analysis. Washed
suspensions of each organism were prepared in PBS at a concentration
of 10 '^cells/ml. A volume (1.0ml) of each was placed in clean
sterile Universal bottles and bacteria were pelleted by
centrifugation. After removal of supernate, bacteria were
resuspended in 10ml of untreated sheep serum, giving a final
concentration of 10^cells/ml. The suspension was immediately
centrifuged then serum was decanted and used to resuspend a fresh
bacterial pellet. Suspensions were immediately centrifuged as this
was determined previously to effectively remove LPS-specific
antibodies as shown in an ELISA system (section 3:4). Centrifugation
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TABLE 3:7. Percentage of E. coli 018:KZ and 018:K1 Binding
Monoclonal Antibodies to Core and O-antigen in Absorbed
and Non-absorbed Serum.
Absorbant Time Percent of bacteria binding Monoclonal antibody
E. coli 018:K~ E. coli 018:K1
core' O-antigen^ core O-antigen
2h 5.27 45.57 3.16 61.48
nil 4h -15.81 26.46 0.02 40.58



















1 and 2: monoclonal antibodies as before.
*: nd, not done.
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was again carried out and the serum was used once more for
absorption. The absorbed serum (ASS) was stored at 4°C overnight
until required.
Inocula for growth in SS and ASS were prepared as previously
described, and 0.2ml of suspension was inoculated into 4.0ml of each
serum preparation: a) untreated serum; b) serum absorbed with 018:K~
cells; and c) serum absorbed with 086:K6I cells. After inoculation,
bacteria were incubated at 37°C and 1.0ml samples were removed every
120min. Once washed, bacteria were reacted with monoclonal
antibodies followed by fluorescein-labelled anti-mouse IgG at a
dilution of 1:80.
Table 3:7 indicates the percentage of bacteria binding monoclonal
antibodies for each growth condition. Many values were below those
obtained in control samples reacted with only secondary antibody,
although most of these were less than 5.0% below control. Three
results were obtained with percentage values of 15.0% or more below
controls. E_^ coli 018:K~ showed very low binding by anti-core
monoclonal antibody in contrast to previous results, but binding to
0-antigen occurred at reasonably high levels in absorbed and
non-absorbed sera. Culture of Ej_ coli 018:K1 in non-absorbed serum
produced similar results to those obtained previously with
anti-O-antigen monoclonal antibody, but binding with core monoclonal
antibody was negligible. Growth of the capsulate strain (018:K1) in
serum absorbed with either 0-serotype of bacterium resulted in
negligible binding to core (as obtained in non-absorbed serum) and
only very low binding by monoclonal antibody to 0-antigen.
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3:6. Activation of Limulus Amoebocyte Lysate by Lipopolysaccharide
and Inhibition with Immunoglobulins.
3:6:1. Measurement of Limulus Amoebocyte Lysate Activity of Purified
Lipopolysaccharides.
Comparisons were made of the capacity of purified LPS from several
genera of bacteria to activate Limulus amoebocyte lysate in a
chromogenic assay as described in MATERIALS AND METHODS. The assay
was repeated several times for the measurement of endotoxins.
a) Lipopolysaccharides from one smooth and one rough organism (E.
coli 018 and typhimurium R878 Rc respectively) were assayed. A
5-fold dilution series of each LPS was prepared in sterile
pyrogen-free distilled water from a concentration of lOng/ml
downwards. Results were graphed as shown in figure 3:41a. At the
highest concentration, both LPS showed comparable activities. The
activity of R878 LPS fell rapidly from this point to give a minimal
reactivity with LAL at 3.2xl0~^ng/ml. Endotoxin from E_^ coli 018
retained activity at 2.0ng/ml, but activity fell rapidly to a
minimal value at 1.6x10~2ng/mi.
b) A comparison was made between a variety of S-LPS from E_^ coli
(018, 016, and 06) and from P. aeruginosa Habs type 1 (figure
3:41b). A similar activity curve to that above was obtained with 018
LPS with a plateau at high concentrations and a baseline at
approximately 3.2xl0--^ng/ml LPS. Similar curves were obtained with
all E_^ coli LPS, but LPS from P_^ aeruginosa Habs type 1 showed a
lower activity at all points, with minimal activity occurring
between 1.6xl0~2 an(j 8.0xl0-2ng/ml LPS.
c) Rough LPS from three mutants of S. typhimurium were assayed in
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FIGURE 3:4 la. Activity of a smooth LPS (from E. coli 018) and a
rough LPS (S. typhimurium R878, Rc) in a chromogenic Limulus




NO LPS 6 5 4 3 2 1 0
LPS CONCENTRATION (5"nx1 Ong/ml)
—*— E. coli 018
—I— E. coli 016
—X— E. coli 06
—0— P. aeruginosa Habs type 1
FIGURE 3:4 lb. Activity of four smooth Lipopolysaccharides (as
described in the legend) in a chromogenic LAL assay.
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NO LPS 6 5 4 3 2 1 0
LPS CONCENTRATION (5"Vl Ong/ml)
-*— E. coli 018
-i— S. typhimurium R1542
S. typhimurium R878
-4— S. typhimuriurn R1102
Figure 3:41c
FIGURE 3:41c. Activity of three rough £U_ typhimurium
iipopolysaccharides (as detailed in legend") in comprison to E. coli
018 LPS in a chromogenic LAL assay.
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Figure 3:41 d
NO LPS 6 5 4 3 2 1 0
LPS CONCENTRATION (5"nx1 Ong/ml)
E. coli 018 X 1 E. coli J5
E. coli R2 0 S. minnesota R595J
FIGURE 3:4 Id. Activity of three rough LPS (as described in the





















NO LPS 6 5 4 3 2 1 0
LPS CONCENTRATION (5~VI Ong/ml)
E. coli 018
E. coli J5
-H- S. minnesota R5953
FIGURE 3:4le. Activity of Sj_ minnesota R595 LPS and coli J5 LPS
in a chromogenic LAL assay in comparison to E. coli 018 LPS.
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NO LPS 6 5 4 3 2 1 0
LPS CONCENTRATION (5"nx1 Ong/ml)
Assay 1 —*— Assay 3 —B— Mean
h— Assay 2 0 Assay 4
Figure 3:42
1.6 _
FIGURE 3:42. Activity of E. coli 018 LPS in repeated LAL assays
(see figure 3:41a-e) plus a curve representing the mean values of
all assays.
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LAL and compared with 018 LPS. Figure 3:4 1c indicates that R1542
(Ra) LPS possessed low activity at high LPS concentrations and that
activity fell sharply to a baseline value at 4.Ox10~'ng/ml.
Endotoxin from R878 (Rc) had a similar activity to 018 LPS at
lO.Onn/ml, but activity dropped sharply to a minimal value at
1.6-8.OxlO'^ng/ml. Rough LPS from R1102 (Re) showed activity almost
identical to that of 018 at both 10.0 and 2.0ng/ml. A marked decline
in activity was observed only below 4.0x10"'ng/ml with baseline
activity being approached at 1.6xl0~2ng/ml.
d) Two rough LPS from E_^ coli (J5 and R2) and one from minnesota
R595 (Re) were assayed for LAL activities. In this instance, 018 LPS
produced no plateau at high concentrations (figure 3:4 Id), but the
curve retained a similar shape to that obtained previously. LPS from
R595 produced very high activity at lO.Ong/ml, which resulted in a
gradual decline to 4.0x10"'ng/ml after which point activity fell
more rapidly, although a high activity was seen at 1.6x10~2ng/ml. R2
LPS had low activity followed by a sharp fall to a low at
4.0x10"'ng/ml. J5 LPS had the lowest activity at lO.Ong/ml and this
fell gradually to minimal activity at 4.Ox 10"'ng/ml.
e) As a result of the anomalous result with R595 LPS in (d), LAL
activity of this was re-assessed along with that of J5. Results
(figure 3:41e) showed that once again J5 possessed very low
activity, while R595 possessed greater activity than LPS from 018,
with baseline values achieved at 3.2x10~^ng/ml.
f)The results obtained in the above assays with LPS from E. coli 018
were compared in a single graph (figure 3:42) along with a curve of
the mean values of LAL activity at each LPS concentration. All
curves were sigmoid and values were reasonably similar, although
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test-to-test variation was evident.
3:6:2. Inhibitory Action of Human Sera on LAL Activity of
Lipopolysaccharides.
An initial attempt was made to inhibit LAL activity of LPS from E.
coli 018 with the control sera from ELISA assays (GL+ and GL-). A
doubling dilution series of LPS from a concentration of 2.0ng/ml
downwards was prepared and mixed with each serum (undiluted).
Measurement of A405 produced the results indicated in figure 3:43.
LPS alone showed saturation of activity above a concentration of
l.Ong/ml and below this point activity fell sharply. In the presence
of undiluted serum (both GL+ and GL-) LAL activity was completely
abolished.
3:6:3. "Endotoxic" Activities of Purified IgG.
The initial attempt at inhibition of LAL activity of LPS from E.
coli 018 with IgG purified from blood donor sera (figure 3:44a)
indicated that the two IgG preparations used possessed massive LAL
activity of their own (approximately equivalent to 2.0ng 018 LPS/ml)
when used undiluted. A titration curve of IgG was used to determine
at which point LAL activity of IgGs became negligible.
A doubling dilution series of five IgG preparations was carried out,
and the results (not shown) indicated no reduction of LAL activity
at the final dilution (1:64) compared to the initial dilution (1:8).
A five-fold dilution series was then carried out with 3 IgG
preparations. The results (figure 3:44b) indicated that all three
IgGs assayed possessed very high LAL activities, which was reduced









FIGURE 3:43. Inhibitory activities of two human sera with high
(GL+) and low anti-CGL (GL-) activities in ELISA upon activation of
LAL by LPS from Ej^ coli 018.
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FIGURE 3:44a. Inhibition of the LAL activity of E. coii 018
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Dilution of IgG (1 in 5n)
'
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FIGURE 3:44b. Titration of three purified human IgG
preparations in a LAL assay. A five-fold dilution series from
undiluted IgG (I in 5^) to 1:15625 (1 in 5^) plus a control
containing no IgG was used for each IgG.
3:6:4. Determination of LAL Activator Present in Purified IgG.
a) Inhibition of LAL activity of IgGs with polymyxin was carried out
to determine whether the LAL activity of IgGs was
polymyxin-inhibitable (i.e. resided in lipopolysaccharide
contaminants). A doubling dilution series of one IgG (no. 7) was
prepared from undilute to 1:64 for use as a control curve. Similarly
a doubling dilution series of polymyxin was prepared from an initial
concentration of 4.0mg/ml. Inhibition was attempted with IgG at a
1:10 dilution versus each concentration of polymyxin. Results
indicated once again that activity of IgG in LAL assay was not
reduced by a dilution factor of 1:64. Polymyxin at all
concentrations appeared to possess no inhibitory activity against
IgG.
b) The above experiment (a) was repeated with five IgGs. Polymyxin
was used at concentrations of 4ng/ml and 40ng/ml, and IgG was
diluted 1:50, 1:100, 1:200, and 1:400. An adaptation of the previous
LAL assay was used as described in MATERIALS AND METHODS.
The mean absorbances in this assay of distilled water and polymyxin
solutions were all within 0.01 units of each other, therefore
polymyxin possessed no LAL activation capacity. Addition of
polymyxin to IgGs produced only limited reduction of LAL activation
(figures 3:45a-e).
c) IgGs were also subjected to digestion by proteinase K, and
samples were separated by electrophoresis through 14% acrylamide
separating gel followed by silver staining for visualisation of LPS.
No indication of the presence of either R-LPS or S-LPS was obtained
by this method.
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—I— Polymyxin at 4.0ng/ml
—*— Polymyxin at 40.0ng/ml
FIGURE 3:45. Inhibition of LAL activity of five purified
human IgG preparations with polymyxin. Immunoglobulins were
used at dilitions of 1:50, 1:100, and 1:200 against three
concentrations of polymyxin. Figures (a), (b), (c), (d), and
(e) represent assays carried out with IgG5, IgG11, IgG 16,
IgG24, and IgG33 respectively.
3:6:5. Inhibition of LAL Activities of Purified LPS with IgG.
a) Attempts were made to inhibit LPS activation of LAL with IgG
purified from human sera. IgG was diluted 1:500 and was mixed in
situ with LPS in a microtitre plate. Lipopolysaccharides from E.
coli 018 and S. typhimurium R878 and IgG were incubated for 75min at
room temperature prior to addition of LAL. The assay was carried out
as described in MATERIALS AND METHODS. Even at this dilution some
IgG showed reasonably high LAL activity calculated as equivalent
amounts of LPS from E_^ coli 018 present in undiluted IgG
preparations:
IgG 5 - approximately O.lOng/ml
IgG 6 - " 0.35ng/ml
IgG 7 - " 1.25ng/ml
IgG11 - " 0.08ng/ml
IgG24 - " 0.30ng/ml
Despite this, inhibition was readily demonstrable by IgGs 5 and 11
versus both LPSs (figure 3:46 a & b). IgG24 also showed possible
inhibition of R878 LPS when LPS was present at high concentrations
(i.e. LPS activity higher than IgG activity in LAL). Similar
inhibitory activity in LAL assay was obtained with IgG6 against 018
LPS. IgGs 7 and 24 produced greater LAL activity with 018 LPS at all
concentrations than in absence of IgG. A similar increase was
observed for IgGs 6 and 7 with R878 LPS.
b) To reduce LAL activity of IgG further, a dilution of 1:1000 was
used for IgG5 to inhibit the activities of LPS from P. aeruginosa
Habs type 1, and E_^ coli 018, 016, and 06. LPS and IgG were
incubated for 3h prior to being assayed. LAL activity of IgG was
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FIGURE 3:46. Inhibition of the LAL activities of lipopolysaccharides from E. coli




NO LPS 2 1 0
LPS CONCENTRATION (2"nx 2.0ng/mi)
—E. coli 018 + lgG5
—'— E. coli 016 + IgG5
-X- E. coli 06 + lgG5
—0— Mean E. coli curve
—B— P. aeruginosa Habs type 1 + lgG5
—B— P, aeruginosa Habs type 1
FIGURE 3:47. Inhibitory activity of a purified human IgG (lgG5 at a
dilution of 1:1000) on LAL activity of four smooth
1ipopolysaccharides (as detailed in the legend) in comparison to the
activity of Pj_ aeruginosa LPS and the mean activity of coli LPS
as shown in diagram 3:41b.
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negligible. No significant differences were observed in activities
of LPS from the coli strains, but minimal inhibition was seen
against P. aeruginosa (figure 3:47).
c) Ej_ coli 018 and 016 were used initially with 7 IgGs. Inhibition
was carried out with LPS present at final concentrations of 2.0, 0.4
and 0.08ng/ml and IgG at a dilution of 1:500. Pre-incubation of LPS
and IgG was carried out for 3h at room temperature before addition
of LAL. Inhibition of 018 was produced by IgGs 5, 11, 16, and 33,
while IgGs 6 and 7 increased LAL activity of this LPS (figure
3:48a). With 016 LPS, only IgGs 5 and 11 exhibited inhibitory
activity (figure 3:48b). The other IgGs had little effect of LAL
activity, except IgG6 which caused increased activation of LAL.
d) Inhibition of E. coli 06 and S. typhimurium R1542, R878, and
R1102 lipopolysaccharides was attempted with five IgGs. A dilution
of 1:500 of IgGs was used throughout versus a variety of LPS
concentrations (figure 3:49a-d). 06 was inhibited significantly only
by IgG5. R1542 and R878 were inhibited to some extent by all IgGs,
but anomalous results occurred at some points (these anomalies were
removed upon repetition - figure 3:50). The activity of R1102 was
inhibited by all IgGs, with IgG5 being the least effective.
e) A final inhibition was carried out with IgGs at a dilution of
1:500, and LPS at concentrations giving approximately 75% of their
maximum activity. The LAL values obtained indicted that many of the
predictions of 75% values were inaccurate, but an overall mean of
66.3% of maximum activation was obtained. The inhibitory activities
of IgGs in this assay are presented as bar charts (figure 3:51a-g)
where 100% represents complete removal of LAL activity by IgG and 0%









NO LPS 2 1 0
LPS CONCENTRATION (2""x 2.0ng/ml)
NO LPS 2 - 1
LPS CONCENTRATION (Zn
FIGURE 3:48. Inhibition of the LAL activities of lipopolysaccharides from E. coli 018
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FIGURE 3:49. "inhibition of the LAL activities of lipopolysaccharides from E. coli 06
(figure 3:49a), S. typhimurium RI542 (figure 3:49b), R878 (figure 3:49c) and R1 102
(figure 3:49d) with five purified IgG.
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FIGURE 3:50. Repetition of inhibitions shown in Figure 3:49 carried out under
identical conditions.
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FIGURE 3:51. Inhibition of Limulus Amoebocyte Lysate




















possessed inhibitory activity against most LPS, with much variation
present between IgGs.
3:6:6. Inhibition of LPS Activation of LAL with Polymyxin.
The inhibitory capacity of polymyxin on LPS in the LAL assay was
determined by addition of various concentrations of polymyxin to LPS
in microtitre plate wells as described above for IgG.
a) The activity of coli 0 18 and 016 LPS were assessed in the
presence of three concentrations of polymyxin. Polymyxin and LPS
were incubated for 180min at room temperature prior to determination
of LAL activity. The results (figure 3:52 a & b) clearly show that
polymyxin inhibited LPS activation of LAL. Little difference was
observed between polymyxin at 4.0 and 40.0ng/ml, but a concentration
of 400ng/ml was more noticeable as an inhibitor, especially at
higher LPS concentrations.
b) Inhibition as described in (a) but with 10-fold higher polymyxin
concentrations was carried out on R-LPS from S. typhimurium (R1542,
R878, and R1102). Figure 3:52 c, d, and e demonstrates that
inhibition occurred with all LPS. All concentrations of polymyxin
removed totally the activity of R1542 LPS. For both R878 and RI 102,
increasing concentrations of inhibitor resulted in increased
expression of inhibition, and total removal of LAL
activity of LPS was not obtained.
253
Figure 3:52c
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FIGURE 3:52. Inhibition of LAL activities of lipopolysaccharides from E. coli 018
(figure. 3:52a) and 016 (figure 3:52b), and S. typhimurium R154 2 (figure 3:52c), R878
(figure 3:52d) and R1102 (figure 3:52e) with polymyxin. Polymyxin was present at
4.Oug/ml, 40.Oug/ml and 400.0ug/ml for figures (a) and (b), and at ten-fold higher
concentrations for figures (c), (d) and (e).
Key co figures a 4 b.
-*— Polymyxin at 4.Oug/ml
-o— Polymyxin at 40.0ug/m
-E— Polymyxin at 400.Oug/ml
No Polymyxin
Key to figures c, d 4 e.
-*— Polymyxin at 40.Oug/ml
Polymyxin at 400ug/ml
-B— Polymyxin at 4000ug/ml
No polymyxin
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3:7. In vivo Activities of Anti-LPS Immunoglobilins.
3:7:1. Determination of Lethal Doses of Bacteria in Swiss White Mice
and the Protective Activities of Immunoglobulins.
i) Swiss white mice were initially used for determination of lethal
doses of various bacteria. Bacteria were cultured overnight in NB
then harvested and washed twice in sterile PBS. The optical density
at 600nm (Aggo) was determined and bacterial counts were calculated
by comparison with a standard curve of Aggg versus colony forming
units. A dilution series in PBS was prepared for challenging
animals. Swiss white mice were challenged intravenously with 0.1ml
of bacterial suspension.
A comparison of the lethal doses of P^ aeruginosa Habs type 1 and
rough mutant PAC605 was made. The results .obtained are presented in
the table below.
TABLE 3:8. Comparison of Lethal Doses of P. aeruginosa Habs
type 1 and P. aeruginosa PAC605 in Swiss White Mice (groups
of 3) .
a) P_^ aeruginosa Habs type 1 b) aeruginosa PAC605
Challenge Cumulative Deaths Challenge Cumulative Deaths
Dose Dayl Day2 Day3 Dose Dayl Day2 Day3
1.9xl08cfu 1 3 - l.lxl010cfu 022
9.5xl07cfu 0 3 5.50xl09cfu 0 0 1
4.8xl07cfu 000 2.25xl09cfu 000
2.4xl06cfu 000 1.13xl09cfu 000
These results clearly showed the difference in virulence between
smooth and rough forms of bacteria. The rough strain of P.
aeruginosa (PAC605) required greater than 10organisms to produce
even 67% lethality, while Habs type 1 (with 0-antigen) required
approximately 9.5xl07 organisms for 100% lethality.
ii) The protective activities of three IgG preparations (Pseudomonas
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TABLE 3:9. Protective Activity of Immunoglobulins in Mice
against Lethal Challenge with P. aeruginosa Habs type 1.
a) Pseudomonas vaccinees IgG (PsV).







no IgG 3 - -
b) Pseudomonas positive IgG (Ps+).
IgG Dilution Cumulative Deaths* after
challenge with I.SxlO^cfu
Day 1 Day2 Day3
10° 0 2 2
101 3 5 -
102 4 5 —
103 1 3 3
no IgG 2 3 -
c) Pseudomonas negative IgG (Ps-).





102 5 - -
103 5 - -
no IgG 1 3
*: five mice in each immunoglobulin group
three per control group.
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vaccinees IgG - PsV, Pseudomonas positive IgG - Ps+, and Pseudomonas
negative IgG - Ps-, see MATERIALS AND METHODS) were assessed versus
Habs type 1 challenge. Animals were challenged with 15 to 70 times
the dose required to kill 100% of animals. Immediately following
bacterial challenge, immunoglobulin (0.1ml) at a range of dilutions
were inoculated intravenously. Table 3:9 indicated that limited
protective capacity was observed with all IgG preparations. Most
activity was obtained with PsV, Ps+ was slightly less effective, and
Ps- was least protective.
3:7:2. Assessment of Lethal Bacterial Doses and Protective
Activities of Immunoglobulins in C57bl/6 Mice.
The lethal doses of bacteria were also assessed in C57bl/6 mice,
which were determined to be more sensitive to Gram-negative
bacterial challenge. Bacterial suspensions were prepared as
described previously, and mice were challenged intraperitoneally
( 1.0ml).
P. aeruginosa Habs type 1 was used as challenge organism, after
growth into log phase (6h) in two media (NB and MALKA). Table 3:10
presents the data obtained.
TABLE 3:10. Comparison of Lethality of P. aeruginosa Habs type 1
Grown in NB and in MALKA Tgroups of 4 mice).
a) Nutrient Broth Grown
Challenge Cumulative Deaths
Dose Dayl Day2 Day3






Dose Dayl Day2 Day3
1.40xl08 4 - -
3.50x107 4
8.75xl06 0 1 1
2.19xl06 000
Calculation of LD50 values by the method of Reed and Meunch (1938)
257
indicated that growth of organisms in minimal medium (MALKA - LD50
of 1.39xl07 organisms) permitted lethal challenge at a dose lower
than organisms grown in NB (LD50 of 4.63xl07 organisms),
iv) A series of determinations of lethal doses of a range of
bacteria was carried out in C57bl/6 mice. In addition, attempts were
made to protect mice with a human donor serum selected for very high
levels (602% of GL+ value) of IgG to core glycolipid in the ELISA
screen of blood donors (HI-NS). Groups of five mice were challenged
i.p. with 0.5ml of graded doses of bacteria in suspension. Bacterial
challenge was followed within 5min with 0.25ml of PBS or serum at a
dilution of 1:10.
Tables 3:11 a—i indicate the results obtained with nine organisms.
TABLE 3:11. Protective Activity of a High Titre Donor
Serum (HI-NS) Against Intraperitoneal Challenge with
Gram-negative Bacteria.
a) P^ aeruginosa Habs type 1.
Cumulative Number of Deaths
Challenge PBS--treated HI-NS-treated
Dose Day 1 Day2 Day3 Day 1 Day2 Day3
2.09x1010 5 - - 4 5 -
4.18xl09 4 5 - 1 1 1
8.36xl08 0 0 0 0 0 0
1.67xl08 0 0 0 0 0 0
3.34x107 0 0 0 0 0 0
b) E^ coli 018:K~.
Cumulative Number of Deaths
Challenge PBS-treated HI-NS-treated
Dose Day 1 Day2 Day3 Day 1 Day2 Day3
approx. lO^ 4 4 4 2 5 -
2xl08 0 5 - 0 2 3
4xl07 0 1 2 0 0 0
8xl06 0 0 0 0 0 1
1.6xl06 0 0 0 0 0 0
258
c) E. coli 06:K5.
Cumulative Number of Deaths
Challenge PBS-treated HI-NS-treated
Dose Dayl Day2 Day3 Dayl Day2 Day3
3.80xl09 4 4 4 5
7.68x108 5 - - 5
].52xl08 1 5 - 25-
3.04xl07 1 5 233
6.08xl06 000 Oil
d) coli 0 16:K1.
Cumulative Number of Deaths
Challenge PBS-treated HI-NS-treated
Dose Dayl Day2 Day3 Dayl Day2 Day3
4.21xl09 5 - - 5 - -
8.40xl08 5 - - 5 - -
1.68x108 3 5 - 15-
3.36x107 034 111
6.72xl06 111 000
e) E. coli 01:K?.
Cumulative Number of Deaths
Challenge PBS--treated HI--NS-treated
Dose Day 1 Day2 Day3 Day 1 Day2 Day3
8.70xl09 4 5 - 4 5
1.74x 109 5 - - 4 5
3.48xl08 0 3 4 0 1 3
6.96x107 0 0 0 0 0 0
1.39xl07 0 0 0 0 0 0
f) E. coli 012:K?.
Cumulative Number of Deaths
Challenge PBS--treated HI-NS-treated
Dose Day 1 Day2 Day3 Day 1 Day2 Day3
7.70x108 3 5 - 3 5 -
1.54xl08 1 3 3 1 2 2
3.08xl07 0 0 0 0 0 0
6.16xl06 0 0 0 0 0 0
1.23x108 0 0 0 0 0 0
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g) E. coli 015:K?.
Cumulative Number of Deaths
Challenge PBS-treated HI-NS-treated
Dose Dayl Day2 Day3 Dayl Day2 Day3
4.25x109 5 5
8.50x108 444 5












Day 1 Day2 Day3 Day 1 Day2 Day3
4 4 4 5 - -
0 0 0 0 0 1
0 0 0 0 0 0
0 0 0 0 1 1
0 0 0 0 0 0
i) E_^ coli C62.
Cumulative Number of Deaths
Challenge PBS-treated HI-NS-treated
Dose Dayl Day2 Day3 Dayl Day2 Day3
1.30xl010 134 122
2.60xl09 011 022
5.20x108 0 0 0 0 0 0
1.04x108 0 0 0 0 0 0
2.08x107 0 0 0 0 0 0
These results indicated that in most cases fatalities could be
prevented or at least delayed by the application of a normal donor
serum with a high titre of IgG to core-glycolipid epitopes.
Protective activity was most obvious for doses between approximately
107 and 108 smooth E_^ coli, and for doses between 109 and 10
smooth P^ aeruginosa. E. coli of O-serotypes 18, 6, and 16 showed
slightly lower lethal doses than those of O-serotypes 1, 12, and 15.
The rough strains of E. coli (K12 and C62) both showed a far higher
dose required to result in death of C57bl/6 mice, (greater than 10
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bacteria) and no protection was obtained for these strains with this
serum.
3:7:3. Lethal Doses of Bacteria in C57bl/6 Mice with Mucin and
Haemoglobin, and Protection with Immunoglobulins.
The lethal dose of bacteria in C57bl/6 mice was assessed with the
mucin-haemoglobin model of infection as detailed in MATERIALS AND
METHODS. Mice were challenged intraperitonealy with 0.5ml containing
bacteria, haemoglobin, and mucin.
TABLE 3:12. Comparison of Lethal Doses of Bacteria
in C57bl/6 Mice - groups of 5 - with and without
Mucin and Haemoglobin (Mu/Hb).
a) P_^ aeruginosa Habs type 1.
Cumulative Number of Deaths
Challenge - Mu/Hb +■ Mu/Hb
Dose Day 1 Day2 Day3 Day 1 Day2 Day3
5.08xl09 5 - - 5 - -
I .02xl09 4 4 4 5 - -
2.03xl08 0 0 0 5 - -
4 .06xl07 0 0 0 4 4 4
8.I3xl06 0 0 0 0 0 0
b) E. coli 016:K 1 .
Cumulative Number of Deaths
Challenge - Mu/Hb + Mu/Hb
Dose Day 1 Day2 Day3 Day 1 Day2 Day3
1.20x1011 5 - - 5 - -
1.20x1010 5 - - 5 - -
1.20xl09 1 3 3 5 - -
1.20xl08 0 0 0 5 - -
1.20xl07 0 0 0 3 5 —
c) E. coli 018:K~.
Cumulative Number of Deaths
Challenge - Mu/Hb + Mu/Hb
Dose Day 1 Day2 Day3 Day 1 Day2 Day3
3.5x10 10 0 0 0 5 - -
3.5x109 0 0 0 0 1 2
3.5x108 0 0 0 2 2 2
3.5xl07 0 0 0 0 1 2
3.5xl06 0 0 0 0 0 0
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d) coli 0 18 :K 1.
Cumulative Number of Deaths
Challenge - Mu/Hb + Mu/Hb
Dose Day! Day2 Day3 Dayl Day2 Day3
2.54x105 5 - -
2.54xl09 2 5 - 5
2.54x108 1 5 5
2.54x107 0 5 - 5
2.54xl06 034 4 5-
The results pointed to a reduction in the dose of bacteria required
to produce fatalities when bacteria were administered in conjunction
with mucin and haemoglobin. Non-capsulate coli 018 possessed a
very high lethal dose in both the absence (greater than 3.5x10
bacteria) and presence (approximately 3.5x10'® bacteria) of Mu/Hb.
E. coli 016 was only slightly more virulent than 018:K~ without
Mu-Hb, but the lethal dose was markedly reduced when bacteria were
co-inoculated with Mu/Hb. A reduction in lethal dose of P■
aeruginosa Habs type 1 of 25-fold was obtained with Mu/Hb. The
capsulate strain E_^ coli 018:K1 was the most virulent of these
bacteria, requiring 2.54x10^ bacteria for 100% lethality without
Mu/Hb. In the presence of Mu/Hb, a bacterial count of less than
2.54xl06 was required to cause death of all mice.
vi) In view of the low lethal dose of E_^ coli 018:K1 when
administered with Mu/Hb, a more extensive determination was carried
out. The results of this are presented in table 3:13 below. These
results indicated that approximately 12 organisms were sufficient to
produce 100% lethality with Mu/Hb, although at two points above this
(2.95x10^ and 5.9xlo') only 80% lethality was achieved.
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TABLE 3:13. Determination of the Lethal Dose of E. coli
018:K1 in the Presence of Mucin and Haemoglobin.
Cumulative Number of Deaths
Challenge - Mu-Hb + Mu-Hb
Dose Day 1 Day2 Day3 Day 1 Day2 Day3
5.76xl08 nd* nd nd 5 - -
1 .15xl08 nd nd nd 5 - -
2.30x10? nd nd nd 4 5 -
4.61xl06 nd nd nd 3 5 -
9.22xl05 nd nd nd nd nd nd
1 .84xl05 nd nd nd nd nd nd
3.69xl04 5 - - nd nd nd
7.37xl03 4 5 - nd nd nd
1 .48x103 5 - - nd nd nd
2.95x102 1 4 4 nd nd nd
5.90x10' 2 4 4 nd nd nd
1 .18x101 1 5 - nd nd nd
2.36x10° 1 3 3 nd nd nd
4.72x10"' 1 1 1 nd nd nd
9.44xl0-2 0 0 0 nd nd nd
nil 0 0 0 0 0 0
* nd - not determined
vii) The protective capacity of various immunoglobulin preparations
was assessed in the Mu-Hb model of infection with E. coli 018:K1 -
Mice were challenged with five times minimum lethal dose - 5xMLD (59
organisms) and 25xMLD (295 organisms). Protection was attempted with
four normal human sera (GL+, GL-, MED 1, and MED2 - see MATERIALS AND
METHODS).
TABLE 3:14. Protective Activity of Four
Human Sera Against Intraperitoneal
Challenge with E. coli 018:K1
Cumulative Number of Deaths
with challenge dose of
5xMLD 25xMLD
Serum Day 1 Day2 Day 1 Day2
GL+ 0 5 5 -
GL- 2 5 3 5
MED1 4 5 2 5
MED2 5 - 4 5
nil 2 5 3 5
The results obtained indicated that little significant protective
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capacity was demonstrable by these human sera in this model,
although a limited prolonging of life was produced by GL+ against
5xMLD.
viii) Protection was attempted with GL+ at two dilutions as
summarised in table 3:15.
TABLE 3:15. Protective Activity of a Normal Blood Donor
Serum (GL+) Against Intraperitoneal Challenge with
E. coli 018:K1 in the Mucin and Haemoglobin Model.
Cumulative Number of Deaths
with challenge dose
Serum 5xMLD 25xMLD
Dilution Dayl Day2 Day3 Dayl Day2 Day3
1:8 4 5 - 4 5-
1:32 4 5 - 5
no serum 4 5 - 5
No significant protective capacity was observed, but one mouse from
a total of five showed extension of survival with a dilution of 1:8
of GL+ against a challenge of 25xMLD.
ix) Two purified IgGs and a monoclonal antibody (versus O-specific
antigen) were used to protect C57bl/6 mice against 4 challenge doses
of bacteria. IgG were diluted 1:5 to give a concentration of
approximately l.Omg/ml protein, of which lOOug was administered i.p.
after bacterial challenge.
From the results presented in table 3:16, it could be determined
that both purified IgG preparations showed limited protective
capacity against challenge with 1.2x10' and with 4.8x10' bacteria.
The monoclonal antibody specific for the 018 0-antigen produced
greater protection than the IgGs at all but the lowest challenge














































































































































































































































































x) The protective activity of purified human IgG was assessed in a
neutropenic mouse model of infection. Neutropenia was induced as
described in MATERIALS AND METHODS. The challenge organism was E.
coli 016:K1, and the results presented in table 3:17 indicate that
in comparison to saline-treated controls, a slight decrease in
lethality was observed with administration of lOOug of IgG16, IgG24,
and IgG33 in mice challenged with 1.24x10^ cfu. No other group
showed any benefit in administration of IgG.
3:7:4. Lethal Toxicity of Bacterial Lipopolysaccharides.
i) Toxicity of LPS from Ej_ coli 086:K61 was assessed in Swiss white
mice. Galactosamine was co-inoculated with LPS as described in
MATERIALS AND METHODS. Five mice were present per group and each
mouse was administered 0.1ml i.v. The results indicated that with no
galactosamine, lethality was not obtained even with lOOOug of LPS.
When galactosamine was mixed with LPS, two of five mice died when
given lOOOug of LPS, and one of five when administered 500ug LPS. No
mice died with 500 or 250ug LPS without galactosamine, or at 250ug
with galactosamine.
ii) A comparison was made between different solvents and their
effect upon toxicity of S_^ typhimurium R878 LPS in Swiss white mice
in the absence of galactosamine. Three days after challenge, four of
five mice administered 2.5mg LPS and 2 of 5 given 1.25mg LPS
dissolved in distilled water were dead. Of the mice administered LPS
dissolved in PBS, only one of five receiving 2.5mg of LPS died. No
other mice died.
iii) Administration of galactosamine (8.0mg/mouse i.p.) to C57bl/6


























































































































































































































































































105-fold increase in sensitivity to LPS. Two milligrams was required
to cause death in mice which did not receive galactosamine. A
ten-fold lower dose caused no deaths, but in mice administered
galactosamine, 2.0ng of LPS was sufficient to kill 100% of mice.
iv) Protection against LPS challenge was carried out with coli
018 LPS (mixed with galactosamine - final volume 0.5ml) in C57bl/6
mice. A normal human serum (MED2) was used initially and dilutions
(0.25ml) were administered i.p. immediately following LPS challenge.
Table 3:18 presents the data obtained. Two mice were present per
group.
These data show that some protection was produced through
administration of serum diluted 1:10 in male mice. Protection was
also obtained with serum diluted 1:100 against lOOng of LPS in
female mice.
v) Further protective studies were carried out with a high titre
anti-core glycolipid serum (HI-NS). Five male mice were used per
group as summarised in the table below (table 3:19a), and was
repeated in male (3:19b, four mice per group) and in female (3:19c,
5 per group) mice.
Much variability was obtained between each of these sets of data.
While protection occurred in some situations, other conditions
produced greater lethality in groups receiving serum than in those
receiving PBS. For two of the groups of data, lethality of LPS in




4:1. Detection of Human Antibodies against Core Glycolipid Epitopes
of Lipopolysaccharide.
There have been two recent reports (Fomsgaard e_t jiL 1987; Gaffin
1983) of the presence of high levels of anti-LPS immunoglobulins in
the blood donor population. Both report similar proportions (5% by
Fomsgaard and 7% by Gaffin) of individuals in their surveys who
possessed 'therapeutically useful' levels of IgG for the treatment
of septic shock, defined as the presence of greater than or equal to
40ug of anti-LPS immunoglobulin per millilitre of plasma. In the
present survey, in which the 'therapeutically useful' level of
immunoglobulin is defined differently (see below) there are 2.85% of
donors who possess 'therapeutically useful' levels of anti-LPS Ig.
The assay system used here differs in two major respects:
i) the ELISA system used herein does not directly
measure the amount of IgG in micrograms per
millilitre. Selection of "therapeutically useful"
levels of IgG was made on the premise of selection
of hyper-immune globulin, that is individuals
possessing five or more times the mean levels of
IgG in the population (as determined by measurement
of absorbance.
ii) this ELISA system was set up to detect only
cross-reactive anti-CGL IgG and not immunoglobulin
to O-antigen as in the other reports.
Since it is the core glycolipid which contains the toxic component
(lipid A) of LPS responsible for the pathophysiological alterations
associated with septicaemia, it would appear that determination of
antibodies to this region would provide a more effective
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anti-endotoxin. It has also been shown in many studies (see section
1:5:3) that anti-CGL produced by immunisation provides protection
against Gram-negative septicaemia, therefore detection of
predominantly cross-reactive antibodies would also be advantageous
from this point of view. Despite their use of 11 smooth LPS, it was
determined that the system used by Gaffin did detect cross-reactive
immunoglobulins (Gaffin et al 1985a).
The distribution of IgG to LPS in the current population and in that
of Fomsgaard are very similar (figure 3:1).
This LPS-polymyxin ELISA was shown to provide a generally good
indication of IgG levels to many 1ipopolysaccharides and LPS-derived
antigens (figure 3:2). It can be seen that sera with high
absorbances in the CGL-pool assay tend to possess overall higher
antibody levels to other LPS antigens than those sera with lower
absorbances in the CGL-pool assay.
The relationship between CGL-pool results and general levels of
anti-LPS IgG is also reflected in the results presented in figures
3:3 and 3:4 with serum and purified IgG respectively. Additionally,
both sets of data show the wide range within and between individuals
in levels of antibodies against many lipopolysaccharide molecules.
Immunoblotting of sera selected for "high" and "low" levels of IgG
in the CGL-pool assay produced unexpected results. Certain sera
which were determined as "high" showed little or no reactivity with
any of the antigens transferred to nitrocellulose, and certain sera
designated as "low" possessed antibodies which bound to many of the
antigens. Similar lack of reactivity with LPS antigens transferred
onto nitrocellulose was obtained by Mutharia _et al (1985).
Determination of binding characteristics of anti-LPS antibodies in
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serum by immunoblotting does not, therefore, match that obtained in
ELISA, possibly through alteration of the antigenic conformation of
LPS during the processes involved in the electrophoretic transfer.
When applied to eighteen of the thirty-three purified preparations,
immunoblotting revealed that no binding was detectable even when the
more sensitive alkaline phosphatase and avidin-biotin systems (see
MATERIALS AND METHODS) were used. Binding of IgG did, however, occur
to dot antigens applied to nitrocellulose, therefore showing that
the antigens are either altered during the electrophoresis steps, or
that separation of LPS by PAGE effectively reduces the concentration
of antigen below the point at which the low levels of antibodies
present in sera or IgG preparations can be detected.
Immunoblotting did, though, prove sensitive enough for the detection
of antibodies to the O-antigen of P. aeruginosa Habs type 1 in IgG
prepared from Pseudomonas vaccinees (PsV - see MATERIALS AND
METHODS), Pseudomonas positive donors (Ps+ - see MATERIALS AND
METHODS), and from one high titre blood donor serum (RAC+ - see
MATERIALS AND METHODS) but not in Pseudomonas negative donors (Ps- -
see MATERIALS AND METHODS). Immunoglobulins were also detectable to
the O-antigen of E^ coli 086 in PsV. This O-antigen has been shown
to be highly immunogenic and elicits a strong specific response in
rabbits (see section 4:3), and would be expected to produce positive
results in immunoblotting if antibodies were present.
It must thus be concluded that immunoblotting as described here does
not provide a sufficiently sensitive system for the detection of
anti-LPS in normal human sera, although it has proven useful for
analysis of reactivity of monoclonal with various LPS (de
Jongh-Leuvenink e_t aJ^ 1985; de Jongh-Leuvenink e_t al 1986; Sidberry
273
^et ad 1985). The ELISA CGL-pool assay, however, provides a sensitive
indication of the presence or absence of IgG to many LPS, and
provides a good basis for the selection of blood donors for
production of potentially therapeutic serum and IgG products for the
treatment of septicaemia.
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4:2. Endotoxin and Anti-endotoxin in Patients with Septic Shock.
No extensive survey has been carried out so far for the
determination of levels of endotoxin and anti-endotoxin present in
patients during septic shock, although several reports which cover
either the aspect of endotoxin levels (see beolw) or of antibodies
to a limited range of LPS (Brauner et al 1986; Brauner et all987;
Johns e_t al 1983; Pollack e_t a_l 1983a; Pollack e_t al 1983b; Young
1972) exist. Endotoxin, as measured by Limulus amoebocyte lysate
assays, has previously been shown to be present at various levels in
shock patients and in "normal" individuals, with shock patients
showing generally higher levels than the more healthy individuals
(van Deventner et^ al 1988b; McCartney e_t al 1987; Shenep e_t al
1988). The levels of endotoxin present in shock patients can be seen
to vary from day-to-day and even over shorter periods(McCartney et_
al 1987).
This survey confirms the presence of high LAL activity in serum from
patients with septic shock, and also reflects the variability in
endotoxic activity in consecutive daily samples.
Two of these three patients (BS and MCC) were repeatedly blood
culture negative while patient MCM showed the presence of
pneumococcal septicaemia and signs of septic shock on admission.
These results indicate that the presence of Gram-negative bacteria
is not an essential requirement for endotoxaemia and the production
of septic shock. The observation of "aseptic" endotoxaemia and
Gram-positive induced endotoxaemia is supportive of results obtained
by other groups (Miller & Wenzel 1987; McCartney _et al 1987).
When endotoxin levels are considered in conjunction with antibody
levels, a complex series of interactions was seen to occur, as many
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of the anti-LPS antibody levels detected could be seen to alter with
changing endotoxin levels. Of major note was an inverse relationship
between many of the IgGs and the levels of LAL activity, and the
IgGs to LPS from minnesota R5 (Rc) and R595 (Re) appeared to be
most intimately associated with the presence or absence of
endotoxaemia. The involvement of Re and Rc type LPSs reflects the
results obtained in one aspect of the survey of blood donors
presented in section 4:1. It has been demonstrated by Barclay and
Scott (1987) that two distinct sub-populations, representative of
the 'smallest common denominator' of LPS molecule recognised, are
present. In a survey of 763 blood donor sera it was found that
individuals directed cross-reactive antibodies to either an epitope
within the Re core glycolipid - as with patients BS and MCC
(comprising lipid A and KDO) or to an epitope within the Rc core
glycolipid - as with patient MCM (comprising lipid A, KDO, heptose,
and a hexose), but not present in the Re CGL.
Taking the results from patient BS (figure 3:8), it could be seen
that levels of IgG to S_^ minnesota Re were moderate to high
throughout the first ten days as endotoxin levels remained low.
During the peak of endotoxaemia anti-Re levels fell, reflecting
consumption of these antibodies by endotoxin, and as levels of
anti-Re fell endotoxin could rise. Antibodies would be produced
during this phase, and as levels of IgG increased, endotoxin fell.
Between days 17 and 31 there appeared to be a constant flux between
anti-Re and endotoxin with IgG levels sufficient to keep levels of
endotoxic activity below l.OEU/ml, and sufficient endotoxin to cause
consumption of IgG. Only from day 31 onwards did anti-Re show signs
of recovery to levels seen at admission to this study, as endotoxin
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remained low. This patient thus showed recovery in levels of IgG,
and removal of endotoxin, but this was not reflected in the clinical
outcome as the patient died from the pathophysiological changes
associated with septicaemia.
The two other patients showed similar relationships between anti-Re
(MCC) or anti-Rc (MCM) with levels of endotoxin in the blood. The
levels of Rc-reactive IgG in patient MCM plummeted as endotoxin
appeared and remained low throughout endotoxaemia. Antibodies
binding to Re were not initially present and levels remained low.
This patient showed signs of recovery despite high endotoxin levels
and was discharged to a general ward where death occurred the
following week. It is possible that death resulted from continued
endotoxaemia, but serum samples were not continued after discharge,
although clinical indications are supportive of death through septic
shock induced by endotoxin.
The final patient (MCC) showed continually falling levels of
endotoxin in the face of rising levels of antibodies. As IgG against
Re LPS was last to recover this suggests that this is the most
intimately involved in neutralisation and removal of endotoxin as it
continued to be consumed by LPS as other IgG recovered. The
increased IgG levels and reduced endotoxin levels were reflected in
this patient by complete recovery from septicaemia.
The role of IgM in these interactions has not been assessed because
the aim of this group is to provide an intravenous IgG for the
therapy of septicaemia, therefore it was relevant to assay only IgG.
It is undoubted that IgM must play some role in neutralisation of
endotoxin, and this is supported through the protective ability of
anti-endotoxin IgM monoclonal antibodies.
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The reduction in levels of antibodies to CGL (particularly to LPS
from E_^ coli J5 and S_. minnesota R595) and also O-antigen during the
acute phase of septicaemia and the recovery in patients who survived
are similar to those obtained previously (McCabe et al 1972; McCabe
et al 1973; Nys al 1987; Nys al 1988; Young 1972). Further
support is provided by Baumgartner and colleagues (Baumgartner e_t jal
1987a) who determined that the protective agent in an anti-endotoxin
antiserum resided in anti-R595 immunoglobulins.
To clarify further this issue, it will be necessary to subject
control patients (trauma or surgical patients with no indications of
septic shock) as well as further patients with septicaemia to the
above series of endotoxin and antibody assays. However, from the
study of these three patients, it seems that repletion of septic
shock patients with preparations containing high levels of
immunoglobulins to the inner core region of LPS would aid in the
neutralisation and removal of the trigger of septicaemia - endotoxin
- and thus reduce the mortality rate associated with septic shock.
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4:3. Immunoglobulin G Response to Lipopolysaccharides.
The longitudinal study of development of IgG to LPS in rabbits
immunised with heat-killed bacteria produced a complex series of
ELISA results (see section 3:3). Most immunisations produced a
noticeable increase in IgG to homologous LPS. In addition,
immunisations produced heterologous responses, in part arising
through the production of cross-reactive antibodies to conserved
epitopes and to some extent as a result of the action of LPS (which
would be present in the boiled cell preparations) as a polyclonal
B-cell mitogen. This study is longer and more extensive (in both the
range of immunogens and the range of antigens in the assay) than any
carried out to date (Johns e_t 1977; Johns e_t a_l 1983; Mackie e_t
al 1982; Michael & Mallah 1982; McCabe 1972; McCabe e_t _al 1972;
McCabe e_t a_l 1973; McCabe j^t aJ 1977). The results for each rabbit
can be summarised individually:
a) Immunisation of rabbit 130 (figure 3:11) clearly showed the
production of homologous IgG at each immunisation step, though that
produced by S^ typhimurium Rd was small in relation to the others.
The small rises provoked by hydrolysed bacteria to many antigens
(possibly through polyclonal B-cell activation) were boosted with Re
immunisation. Each immunisation (particularly Re and Rb) produced
increases in Ra reactive IgG, which reached maximal levels by the
penultimate immunisation (Rb). This would tend to indicate that Ra
and Rb possess a dominant common epitope within the sugar units
distal from lipid A.
The responses to R-LPS of identical chemotypes from S. typhimurium
and S. minnesota show marked differences with little response
detectable to minnesota antigens. This indicates that the rough
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lipopolysaccharides from these two species are not antigenically
identical, and their structures must therefore differ. This
contradicts a wide body of accepted literature which states that
rough LPS molecules from all Salmonella spp. are identical. The
small increases obtained to S^ minnesota R-LPSs could, however, have
appeared through production of a cross-reactive anti-lipid A
response after the initial immunisation which increases following
all immunisations. The obvious antigenic differences between these
two species are reflected in the results obtained in screening of
the blood donor population for anti-CGL where once again levels of
IgG to S_^ typhimurium and S_^ minnesota were not equivalent. These
antigenic differences may reside in the quantity and quality of
ethanolaminyl and phosphoryl groups present on the mutants of each
species.
b) Rabbit 131 produced results (figure 3:12) indicating that the Ra
core from S_^ typhimurium R1542 and those from coli R2 and R4 are
antigenically very similar. This is borne out through reference to
the accepted structures of these lipopolysaccharides as presented in
figure 1:4.
Ra-type bacteria induced a specifically outer core response as well
as a slight anti-lipid A response, indicating that the lipid A of
both S. minnesota and S. typhimurium may be similar structurally and
antigenically.
The increase in IgG to many S-LPS as well as that of S_^ minnesota Ra
tends to follow closely the production of lipid A reactive IgG, with
the exception of S. typhimurium wild type which more closely follows
its Ra mutant. This pattern seems to indicate that access of
anti-lipid A antibodies is not restricted by the presence of
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O-antigen in purified lipopolysaccharides, and reiterate the
cross-reactivity observed between S_^ typhimurium R-LPSs and S.
minnesota lipid A.
Immunisation with Rb once again increased IgG levels to Ra, thereby
providing support for the existence of a cross-reactive
immunodominant epitope present on both LPS types. Immunisation with
lipid A produced a low level, widely reactive response but other
R-LPS produced little homologous or heterologous response although
immunisation with Rb and Rc produced a small degree of reactivity to
P. aeruginosa PAC605 LPS. This may occur through the terminal
glucose present on all three of these molecules (see figures 1:3 and
1:4).
These results indicate that the response to the initial immunogen
(Ra) was the only major response which occurred, little being
observed to many other R-LPS and S-LPS except two E_^ coli core
types.
c) The third rabbit (number 132) showed noticeable levels of IgG
prior to immunisation to several antigens coli 02, 075, 086 and
0111; P. aeruginosa PAC605; S. typhimurium wild type; and S.
minnesota Ra and Rb), therefore response to these would be expected
to be a rapid and immediate anamnestic response. These secondary
responses were observed for four of these antigens (E. coli 02, 075,
and 086; and S_^ typhimurium wild type) with above baseline values
before immunisation, and appear to have occurred through the
induction of cross-reactive IgGs although the homologous response
was modest.
E. coli J5 was seen to possess epitopes which boost responses to the
R2, R3, and R4 core types of this species, but the structure of J5
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(reviewed by Barclay & Scott 1987 - see figure 1:3) is dissimilar to
the accepted structures of R2 and R4 and appears to possess an
unique immunodominant epitope (Appelmelk et_ al_ 1986a; Appelmelk et_
al 1986b; Baumgartner & Glauser 1987a; Sakulramrung & Domingue 1985;
Schwartzer et al 1987). The cross-reactivity observed with J5 LPS
may thus result from induction of antibodies which bind to
Re-chemotype LPS (Baumgartner & Glauser 1987a). Cross-reactivity of
J5 LPS was also observed with several E^ coli O-antigens (02, 06,
075, and 086). Relation of the sugar compositions of these LPS
molecules (Orskov et^ a1_ 1977) indicate similar sugar compositions
and therefore possible cross-reactive sites, but polyclonal
activation of B-cells appears to be a strong possibility.
The response to the core oligosaccharide of aerogenes rough
mutant (M10B) indicated that cross-reactivity exists with S.
typhimurium Rc and Rd, as well as E_^_ coli Rl, R2, R3, and R4.
Because of the reactivity with Rd, this indicates that the
cross-reactivity results from the heptose region and thus the inner
core region of this LPS appears to be similar to that of other
enterobacteria.
The presence of unique epitopes on P^_ aeruginosa PAC605 LPS
determined by structural analysis (Rowe & Meadow 1983 - see figure
1:4) was supported antigenically through production of a mainly
specific response, though some cross-reactivity was observed with
cores from K^_ aerogenes, S. minnesota Ra, and Ej_ coli Rl, R2, and R4
though this is not reflected structurally.
Immunisation with two Re type LPSs (E^ coli F515 and S^ minnesota
R595) produced much polyclonal response with cross-reactivity to
many rough LPS evident, thus epitopes present in these Re molecules
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(or similar epitopes) are present on LPS from S_^ minnesota, S.
typhimurium, E. coli, K. aerogenes, and aeruginosa.
d) In the fourth rabbit (number 143 - figure 3:14) E_^ coli 018:K~
produced very little antibody response to any LPS.
Lipopolysaccharide from E. coli 06 was highly immunogenic, producing
a strong response to the homologous antigen and that from serotypes
02, 016, and 075 as well as S. typhimurium wild type. This
cross-reactivity is not borne out by previously reported
cross-reactions (Orskov et al 1977). Since responses to S.
typh imurium Ra, S^ minnesota lipid A, E_^ coli R2 and R4, and to a
lesser extent R3, it appears likely that many of these reactions are
occurring through production of anti-CGL antibodies, though strong
reactivity has been observed between 06 and 016 with a monoclonal
antibody raised against 016.
All other immunisations produced mainly homologous responses
although some cross-reactivity with other 0-serotypes and some core
types was obtained. E. coli 016 did, however, produce a large
anti-core response to S. typhimurium Ra probably through
cross-reactivity with E^ coli R2, R3, and R4, which were also
increased.
e) Once again LPS from E. coli 018 was shown to be of low
immunogenicity following even two consecutive immunisations, a
similar occurrence to that found by Elkins and co-workers (Elkins et^
al 1987a; Elkins et al 1987b) where certain 0-antigens were found to
be only weakly immunogenic in mice, and for which a mechanism was
proposed. Some heterologous responses were obtained to S.
typhimurium Ra, Rb, and wild type; S. minnesota Ra and lipid A; E.
coli R2, R4, 02, 012, 075, 086, and 0111; P. aeruginosa PAC605. The
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reactivity with core types R2 and R4 would seem to point to 018
possessing one or other of these, or a core glycolipid with an
epitope which is common to both. The presence of many cross-reactive
IgG would seem to be responsible for many of the reactivities
observed.
Lipopolysaccharide from P^_ aeruginosa Habs type 1 was highly
immunogenic, producing a predominantly homologous response. Similar
strong immunogenic activity has been observed previously through
immunisation of mice with P. aeruginosa (Mackie et al 1982).
The cross-reactivities observed by immunisation with E_^ coli 06
between O-serotypes 02, 06, and 016, as determined above, were
confirmed.
The reduction in IgG following the final immunisation may point to
the presence of viable organisms in this preparation, though levels
recover.
In conclusion, the results produced by this study are summarised as
follows:
i) Sj_ typhimurium Ra and Rb possess a strongly cross-reactive
epitope common to both LPS.
ii) LPS from equivalent rough mutants of S. minnesota and S.
typhimurium are not antigenically identical.
iii) The rough LPS from S. typhimurium Ra and Re possess a common
cross-reactive epitope through lipid A and/or KDO.
iv) The cores of coli R2 and R4 are strongly cross-reactive
with the Ra core of S. typhimurium and are therefore antigenically
similar.
v) Rough LPS from P. aeruginosa PAC605 and K. aerogenes Ml OB are
cross-reactive with certain enterobacterial cores.
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vi) The O-antigen from E. coli 018 is non-immunogenic in rabbits,
vii) Ej_ coli 06 and 016 possess strongly antigenically
cross-reactive O-antigenic structures.
viii) Pj_ aeruginosa Habs type 1 has a strongly immunogenic and
immunodominant O-antigen.
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4:4. Antigenic Presentation of Lipopolysaccharide in ELISA.
A series of absorptions followed by ELISA, and inhibition of ELISA
reactivity with soluble antigens were carried out to determine
whether LPS-polymyxin complexes presented an antigenic configuration
which was comparable to those observed in other LPS preparations.
This determination is necessary firstly because polymyxin may bind
to antigenic sites of LPS (Moore et al 1986) thereby obscuring
potentialy reactive sites, and secondly to indicate whether use of
these complexes is an appropriate means of identifying antibodies
which are reactive with LPS as presented in intact organisms. This
would therefore indicate the relevance of this assay for
determination of anti-CGL antibodies in the blood donor population,
a) The results from the titration of the four sera against four
LPS-containing antigen preparations indicated that uncomplexed LPS
and OM were most reactive in ELISA. It might have been expected that
OM would produce greater reactivity with sera because of the
presence of outer membrane proteins to which antibodies could bind.
This may indicate a less efficient binding of OM to ELISA strips
because of its higher solubility than LPS but as protein-containing
antigens are known to bind very efficiently to polystyrene ELISA
strips, the lower reactivity with OM may be the result of
underestimation of LPS content in OM by the carbohydrate assay. A
further surprising result was the relatively low absorbances
produced with heat-killed cells as antigen as these again contain
many antigens other than LPS. One possibility would be that LPS
content was under-estimated by the carbohydrate assay, or that
heating of the bacteria at 100°C for lOmin alters the antigenic
structures on the surface thereby preventing interaction with
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immunoglobulins. It is also suggested that binding of whole bacteria
to ELISA strips is more efficiently facilitated by centrifugation of
plates (B. Scott, personal communication), thus providing a further
possibility for improvement. Finally, LPS-polymyxin complexes were
the least reactive with sera, possibly resulting from their high
solubility, and thus lower deposition onto well surfaces. Despite
the lower absorbance values observed, LPS-polymyxin was shown to
present a more stable antigen in ELISA than purified LPS (Scott &
Barclay 1987), and thus the high values obtained against LPS may not
have re-occurred upon repetition of coating.
b) The absorption of sera with heat-killed Sj_ typhimurium R878
bacterial cells (section 3:3) showed that all forms of antigen
reflected the reduction in IgG levels after each absorption. Similar
patterns of reduction in IgG were observed for each antigen
preparation.
The marked reduction in IgG reactive with uncomplexed LPS showed
that LPS-specific immunoglobulins were present in each serum at
reasonable concentrations, and it must be assumed that removal of
anti-LPS during absorption accounts for some reduction of IgG seen
against OM and heat-killed bacteria.
One serum (GL-) produced low reactivity against all antigens, and
reduction in IgG was low after absorption, therefore this serum
appears to possess generally low levels of IgG to all S_^ typhimurium
R878 antigens and not only the LPS.
Reduction in IgG was less noticeable with LPS-polymyxin than with
uncomplexed LPS, but this may be accounted for by lower
concentration of complex being deposited in the wells during the
coating process. This would imply that LPS-polymyxin is in a form
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which may differ from all other forms of LPS in this assay. However,
the relative absorbances produced against each antigen with each
serum at all dilutions produced similar relative values in
comparison to that of LPS-polymyxin. It can thus be said that the
complex presents LPS in a manner which is appropriate for the
measurement of anti-LPS antibodies.
c) Absorption of heat-inactivated sera with viable organisms
(figures 3:2] to 3:24) also showed reductions in IgG levels
following absorption, but large fluctuations were obtained between
consecutive dilutions and between successive absorptions, thus
reduction in levels of IgG were less well defined than above.
At a serum dilution of 1:50, high absorbances were observed on
strips which received only post-coat (and thus contained no
antigen). Heat-inactivation of serum must therefore alter the
binding characteristics of immunoglobulins thereby permitting
non-specific binding to ELISA strips. It is, however, possible that
the heat-inactivation process may have altered the IgM present in
the sera, thus allowing its binding to microplates either directly
of via antigens and it is possible that the heating may also have
permitted recognision of IgM by the secondary antibody (anti-human
IgG). Further possible contributors to this non-specific binding may
be proteins or lipoproteins which bind LPS and which may precipitate
onto microplate wells once complexed with LPS.
Reduction of non-specific binding to background levels occurred by a
dilution of 1:100, indicating that the components responsible for
non-specific binding are present at fairly low levels.
As a result of the problems encountered with heat-inactivated serum
in these absorptions, it is recommended that untreated sera are used
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for all absorption studies.
d) Inhibition of ELISA was carried out to determine whether antigen
present in the aqueous phase could prevent the binding of
immunoglobulins to solid-phase rough LPS antigens. Attempts were
made to inhibit binding of antibodies to four solid phase antigens
(LPS-polymyxin, uncomplexed LPS, OM, and heat-killed bacteria) with
three inhibitors (LPS-polymyxin, uncomplexed LPS, and OM).
The initial time-course experiment indicated that co-incubation of
inhibitor (LPS) with serum (GL+) was not required for the
demonstration of inhibition.
When uncomplexed LPS was used as the inhibitor, two of the three
assays (figures 3:25, 3:26, and 3:28b) produced an increased
absorbance at high concentrations of inhibitor. These concentrations
of LPS may permit the formation of macromolecular structures or
micelles of low solubility and relatively high density which may
deposit in wells causing an increased concentration of solid phase
antigen, and consequently greater binding of antibody in wells. The
absence of this increase in the "blank" well would, however, seem to
preclude this. Another possibility is that the increase may have
occurred through deposition of LPS-Ig complexes onto microtitre
plates through interaction of antibodies in the complexes with solid
phase antigens thereby resulting in increased concentration of both
LPS and IgG in these wells, and therefore increased absorbance
values.
The drop in absorbance with even higher LPS concentrations may
represent an alteration of LPS towards a more soluble macromolecular
form through increased association of lipid A units and thus a
reduced hydrophobicity. Since this drop was also observed with OM
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and bacteria as solid phase antigens, LPS at this concentration
(8.0uM) may form a structure which causes LPS to be presented in a
conformation as found on OM and bacteria.
There is also a possibility that the structures formed by LPS at
these concentrations in this system may represent occurrences as
observed in individuals with endotoxaemia. Insoluble complexes may
deposit in tissues and on blood vessel walls where they could
contribute to localised tissue damage as determined by Cybulsky et_
al (1988) and Ohshio et_ al_ (1988), while soluble forms could
continue to circulate resulting in more generalised damage.
Outer membrane (OM) was highly effective at inhibiting binding of
IgG to OM, uncomplexed LPS, and bacteria. Lipopolysaccharide as
presented on OM is thus similar, if not identical, in antigenic
presentation of LPS to bacteria. This OM fraction could thus
represent a similar structure to that observed in blebs or
extracellular toxic complexes (ETC) which are shed from bacteria
during growth (Gankema et_ &L_ 1980, Rothfield & Pearlman-Kothencz
1969; Straus 1987; Straus e_t^ al_ 1985; Straus jrt al^ 1988).
Little inhibition was observed in binding of IgG to LPS-polymyxin
with OM, but results were highly variable and absorbances were
generally higher when inhibitor (OM) was present than in absence of
inhibitor (figure 3:27) while in figure 3:29c, no binding to
LPS-polymyxin was obtained.
LPS-polymyxin complexes were shown in these assays (figures 3:28,
and 3:29a) to possess strong inhibitory activity in binding of IgG
to all antigenic preparations. Complexes in solution thus appear to
represent a form of LPS which is capable of preventing binding of
IgG to LPS in three other forms (uncomplexed, OM, and bacterial),
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and would thus seem to present LPS in a "natural" antigenic
conformation.
This inhibition system produced similar results to those from the
absorption studies, although variability was seen in the stability
of solid phase antigens and in the activity of each inhibitor in
repeated assays. Much of the problem encountered with LPS as
inhibitor could perhaps be overcome by the use of a highly soluble
ionic form of lipopolysaccharide (for example the triethylamine salt
form prepared after electrodialysis).
It thus appears that cross-reactivity of anti-lipopolysaccharide
antibodies present in blood donor sera (and also IgGs, hyper-immune
sera, or even monoclonal antibody preparations) between different
preparations from the same organism, or between LPS from different
organisms, can be determined by either absorption or inhibition
experimentation, although refinement of techniques may be required.
The objective of this study has been fulfilled in that LPS-polymyxin
complexes have been shown to represent a form of LPS which is
antigenically related to that present on the bacterial surface, and
therefore the CGL-pool assay with LPS-polymyxin complexes is a
relevent means for the accurate detection of anti-CGL
immunoglobulins in blood donor sera.
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4:5. Expression of Lipopolysaccharide Epitopes on Viable Bacteria.
Many studies have been undertaken to determine the binding of
anti-O-antigen and anti-CGL antibodies to viable bacteria with
equivocal results (Colwell-Ward et al 1988; Crowley et al 1982; van
Dijk £t. _al 1981; Elkins & Metcalf 1985; Gigliotti & Shenep 1985;
Mehta et al 1988; McCallus & Norcross 1987; Vreede et al^ 1986; see
also section 1:3:3). In addition, a wide range of growth conditions
as well as use of strains of organisms not commonly associated with
septicaemia have been applied. The current study involved the use of
a strain of E_^ coli of known clinical relevance (018:K1 and its
isogenic mutant 018:K~) grown in a range of media for determination
of alteration of LPS composition (analysed by PAGE) and binding of
anti-CGL and an anti-O-antigen monoclonal antibodies (determined by
flow cytometry).
a) An initial quantitative assessment of the proteinase K method for
analysing LPS was made by determining the effect of variation of
density of bacterial suspension upon the intensity of staining of
different LPS components as all suspensions might not be of exactly
the same density for preparation of proteinase K extracts. The
results (figure 3:34) showed that various optical densities from
0.54 up to 0.64 produced little difference in staining intensities
even when two different volumes of sample (lOul or 20ul) were loaded
onto polyacrylamide gels. This means, therefore, that any
differences observed in staining intensity occur as a result of
alteration of LPS rather than through differences in the density of
bacterial suspension used to prepare lipopolysaccharide samples.
b) The initial experiments with E. coli 018:Kl and 018:K~ indicated
that the twelve media produced little alteration in expression of
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high molecular weight components of LPS. Bands of medium molecular
weight showed increased staining for the non-capsulate strain, with
the increase occurring stepwise with increasing concentration of
serum. Growth of the capsulate strain in 100% serum produced heavier
staining of core epitopes, while 018:K~ produced uniform staining of
core under all conditions.
These results appear to reflect the differing requirements and
different virulence factors of these two strains of E. coli.
Overnight culture of the non-capsulate strain in serum induced
greater expression of medium molecular weight components while
018:K1 showed only greater expression of CGL components. This could
reflect greater expression of capsular material by 018:K1 enabling
survival of partially R-type bacteria when grown in serum, whereas
non-capsulate variants of the same strain (018:K~) produce greater
substitution of 0-antigen units onto CGL.
In addition to these alterations, a minor fast-migrating band
appeared when either strain was incubated in nutrient broth or
mixtures of broth and serum. This would appear to represent either a
by-product of growth or possibly the presence of small peptide
fragments produced during proteinase k digestion.
c) Growth of E. ££li 018:K~ in nutrient broth produced greater
substitution of 0-antigen onto core and also increased expression of
naked CGL (as represented by increased staining density of high and
low molecular weight bands) throughout the logarithmic phase of
growth. This pattern of staining occurred early in the growth phase,
and appears to indicate a move from organisms containing a wide
range of 0-antigen substituents to organisms containing either very
long 0-antigen units or one or no 0-antigen units at the expense of
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medium length O-antigen chains. The presence of the fast-migrating
band which appeared previously (see above) was noted after 90 min
incubation.
d) The next stage involved assessment of expression of LPS epitopes
on bacteria grown under different nutrient conditions. Growth
kinetics of E. coli 018:K~ were firstly determined in six media.
Most rapid growth was obtained in nitrogen deficient medium (see
figure 3:35) and in nutrient broth, although growth in broth slowed
after 150 min. The minimal medium (MALKA) also produced rapid
growth, but a longer lag phase was present. The final medium
(heat-inactivated sheep serum - HSS) produced the lowest growth
rate.
Reduction of magnesium concentration in MALKA (see section 3:5:5)
produced a marked reduction in the rate of division of bacteria. Lag
phases were very long (approximately 150 min for both MO 1 and M10),
and growth occurred at a low rate after this point.
The differences in the growth kinetics and the final optical
densities of bacterial suspensions appear to rely on the
availability and accessibility of carbon sources as well as the
extent of limitation of cations in the media. The results obtained
with magnesium limitation indicate that E_^ coli requires to adjust
its metabolism to the low Mg2+ concentrations before it can divide,
and the slow rate of growth achieved suggests that the enzyme
systems involved in metabolism operate less efficiently under
limitation of this cation (reviewed by Brown & Williams 1985).
The importance of magnesium in the replicatory processes of E_^ coli
implied above reflects the previously reported importance of this
ion (as well as other cations) in the metabolism and virulence of
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Grain-negative bacteria (see for example Brown & Williams 1985).
e) It was decided that samples removed hourly for a period of 6h
would be appropriate for further analysis of structural and
antigenic expression of LPS. As indicated in section 3:5:6, E. coli
018:K~ was grown under three conditions (NB, MALKA, and HSS) .
Differences were obtained in expression of core epitopes as growth
in NB and MALKA produced a strongly staining R-LPS/SR-LPS region
(figure 3:38a&b) while culture in HSS produced a more discrete core
band (figure 3:38c). Little alteration occurred in expression of
other LPS bands in organisms grown in MALKA, but when grown in NB
and HSS staining of O-antigen units became heavier as time
progressed. In addition, growth in HSS induced formation of a very
high molecular weight component - this is possibly a form of
capsular material as it has been determined that this
"non-capsulate" isogenic mutant of of E. coli 018:K1 reacts with an
anti-sialic acid (the component of Kl capsule) monoclonal antibody
(A. Bathgate, Honours degree thesis 1988). These responses in LPS
once again reflect the selective pressures upon the organisms under
different growth conditions.
Determination of the binding of monoclonal antibodies to core and
O-antigen (see MATERIALS AND METHODS for description), assessed
through fluorescent labelling and flow cytometry (table 3:4),
indicated that organisms grown in NB or MALKA showed very high
reactivity with SZ184/2.5.5 (anti-O-antigen), but only negligible
binding with anti-core monoclonal antibody (SZ27/150.3). Similar
results were obtained with bacteria cultured overnight in magnesium
limiting conditions (table 3:5). These results tend to indicate that
culture of this organism in these media permits greater substitution
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of O-antigen onto core units (although only NB produced greater
staining of O-antigen), thereby preventing access of monoclonal
antibodies to core epitopes.
When cultured in HSS, markedly different results were obtained for
all samples removed during active growth of bacteria. Binding of
anti-core monoclonal antibody was seen to occur at almost equivalent
level to that of anti-O-antigen monoclonal antibody. Growth of E.
coli 018:K~ in HSS thus alters the antigenic expression of
lipopolysaccharide to permit binding of a monoclonal antibody to the
core despite the increased expression of high molecular weight LPS
components observed in the silver stained PAG (figure 3:38c). After
overnight culture there was a marked reduction in percentage of
bacteria binding to the anti-core monoclonal antibody, therefore
alteration of antigenic expression termindtes between 6h and 24h or
culture.
f) The effect of growth of bacteria in serum was extended by
comparison of capsulate and non-capsulate strains of Ej_ coli 018
grown in untreated and in heat-inactivated sheep serum (SS and HSS
respectively).
The growth kinetics (figure 3:39) produced markedly differing
results. Both organisms when grown in HSS showed rapid division and
increased expression of both core and O-antigen (figure 3:40). When
grown in SS differences between bacteria were more obvious as 018:KI
grew at a slower rate than in HSS (possibly through alteration of
virulence factors resulting from the presence of complement which
possesses bacteriolytic activity against Gram-negative bacteria)
while the non-capsulate strain showed a reduction in density until
240min (through the direct activation of complement by
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lipopolysaccharide resulting in bacteriolysis or through antibody
dependent lysis by complement) after which point division was rapid,
probably through selection of serum resistant variants. Both strains
when grown in SS showed increased substitution of O-antigen units
onto core-glycolipid therefore showing selection of factors which
could increase resistance to the bactericidal activity of serum
(Goldman j^t al 1984; Grossman et al 1987; Porat et al 1987; Taylor &
Robinson 1980; Tomas et al 1988).
Growth of E_^ coli 018:K~ in SS and HSS followed by reaction with
monoclonal antibodies produced results (table 3:6) similar to those
obtained previously for growth of this organisms in HSS showing that
CGL epitopes are accessible in this organism despite increased
expression of O-antigen.
E. coli 018:K1 produced different results for binding of monoclonal
antibodies (table 3:6) for growth in SS and HSS. In HSS binding to
O-antigen occurred at high levels, but to core at only very low
levels, while in SS, binding to both core and O-antigen were fairly
high during the early log phase, but fell fell to very low levels
over the course of growth.
As growth in SS progresses, however, it appears that the capsule is
altered in some way (perhaps through increase in density) and access
of the monoclonal antibodies to LPS epitopes is restricted despite
increased expression of O-antigen as shown by silver staining. A
similar alteration of capsular structure could therefore occur in
vivo and could thus affect bacterial virulence.
These results appear to indicate that the presence of capsule does
not preclude the binding of anti-lipopolysaccharide antibodies. This
result is supportive of the data described by Williams jrt al (1988)
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who produced a similar finding with K. aerogenes in a different
system, and also those of Kaufman e_t aj. 1986 who showed that an
anti-O-antigen antibody could protect mice against lethal challenge
with the capsulate organism E_^ coli 018:Kl. Pluschke & Achtman
(1985) have also achieved protection against capsulate orga^insms by
use of an anti-O-antigen monoclonal antibody, therefore access must
be gained to O-antigen in both of these _rn vivo systems. Also
indicated by these results is the ability of anti-core monoclonal
antibodies to bind to viable organisms under certain culture
conditions, thereby firmly supporting the argument in support of the
ability of anti-CGL to bind to intact organisms (McCallus & Norcross
1987; Williams et. ail 1988) although the results obtained with the
capsulate strain indicate that anti-CGL may not be opsonic (as has
already been observed by Gigliotti & Shenep 1985; Mehta et al 1988;
Vreede e_t a_l 1986) - but they may be able to gain access to
epitopes. This is particularly relevant _in vivo where mainly
capsulate strains are encountered, and where the precise phase of
growth and expression of virulence factors remains a matter of
conjecture.
g) Because of the strong binding of the anti-core monoclonal
antibody under a variety of conditions (even when increased
substitution of O-antigen was evident) it was decided to determine
whether binding of natural sheep antibodies which recognise the 018
O-antigen were permitting access of anti-CGL as postulated by Frank
et al (1987). To carry this out, untreated serum was absorbed with
either E_^ coli 018:K~ or the organism with the unrelated O-antigen
E. coli 086:K61 (see section 4:3 for antigenic relationship).
Bacteria (E. coli 018:K1 or 018:K~) were then cultured in the two
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absorbed sera and in untreated serum. The results produced (table
3:9) were at variance with those obtained previously, as both
organisms grown in untreated serum showed significant binding with
only O-antigen and not CGL-reactive monoclonal antibody. No
reduction was observed in reactivity with anti-O-antigen monoclonal
antibody for 018:K1 as seen above, and binding to core was
insignificant. This may have occurred as a result of the inoculum
being prepared from a culture which itself had undergone three
subculture processes instead of the single subculture step usually
applied. Repeated subculture may therefore have selected particular
variants which differ from the initial population in the inoculum in
LPS antigenicity.
Comparison can, however, still be made between the organisms grown
in serum which was absorbed with either 018- or 086-containing
strains. The results were similar for both absorptions, with 018:K1
showing no binding and minimal binding to core and O-antigen
respectively, and 018:K~ showing moderate to high binding to only
O-antigen specific monoclonal antibody. Because of the low binding
of the anti-CGL monoclonal antibody in bacteria grown in SS, it
cannot be determined whether natural sheep antibodies to O-antigen
are enabling binding of anti-CGL. There does, however, appear to
exist some selective pressure on the capsulate strain grown in
absorbed serum for restriction of access of O-antigen specific
antibodies.
The labelling of bacteria with antibodies conjugated to FITC
followed by analysis of binding characteristics by flow cytometry
provides a highly sensitive technique for determination of binding
of monoclonal antibodies to lipopolysaccharide and could be applied
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to other bacterial cell surface components. There were, however,
several points at which anomalous results were obtained, and several
instances of test values below control values (bacteria reacted only
with anti-mouse-FITC labelled antibody) occurred. In the main, these
values were less than 5% below control values, but negative values
of up to 35% occurred on a few occasions. This indicates that this
assay requires refinement to determine optimal concentrations of
bacteria, monoclonal antibodies and secondary antibody as well as
incubation times and cytometry parameters.
Despite the above problems it has still been possible to determine
in conjunction with proteinase K digestion of bacteria and
polyacrylamide gel electrophoresis the following points:
i) expression of lipopolysaccharide epitopes on
the cell surface can be markedly altered by
variation of the growth environment,
ii) accessibility of anti-CGL is restricted to
certain growth conditions and care must therefore
be taken in assessment of binding and opsonic
ability of antibodies with respect to culture
conditions and phase of growth,
and iii) capsular material has an important bearing on
the ability of antibodies to bind to O-antigen and
CGL in organisms grown in untreated serum which
therefore implies that therapeutic preparations
should contain both bacteriolytic (anti-O-antigen
and capsule) and anti-toxic (anti-CGL) antibodies
to permit effective treatment of septicaemia.
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4:6. In vitro Anti-Endotoxic Activity of Human
Anti-Lipopolysaccharide Immunoglobulins.
The inhibitory activity of human immunoglobulins on the activation
of Limulus amoebocyte lysate (LAL) by purified 1ipopolysaccharides
was determined as an indication of the potential of antibodies to
neutralise the toxic activities of LPS.
a) Firstly the extent of activation of LAL was determined and the
activities of the LPSs assessed in descending order from most active
by weight was:
1. S. typhimurium R1102, Re
S . minnesota R595, Re
2 . E_^ coli 0 18
" " " 016
.. .. 06
3. P. aeruginosa Habs type 1
4 . S_^ typhimur ium R878 , Rc
5. " " " R1542, Ra
6. E. coli R2, Ra
7. " " " J5, Rc
These results are in general agreement with those of Cohen &
McConnell (1984), Guyomard & Darbord (1985) and Warren et al (1987)
in their assessment of the activity of LPSs in a LAL assay. The
present assay was carried out several times to determine the
activities of all 1 ipopolysaccharides, with LPS from E^_ coli 018
common to all repetitions. The activities of 018 LPS in each assay
was plotted on one graph (figure 3:42) and indicated that
test-to-test variation did occur, but that each activation curve was
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very similar in both shape and absorbance values at each LPS
concentration. This indicated that this assay was reproducible and
accurate.
b) Inhibiton was firstly attempted with human serum to determine
whether inhibitory activity would be demonstrable in the assay
system used (see MATERIALS AND METHODS). As shown in figure 3:43,
two normal human sera, with high (GL+) and low (GL-) anti-CGL
completely removed the LAL activity of E. coli 018 LPS. Because of
the differences in levels of anti-CGL (assigned values of 100% for
GL+ and 10% for GL-) the inhibitory activity when present undiluted
would appear to reside in factors other than or additional to
immunoglobulins of class G. It is possible that IgM may have
contributed to this activity, but as IgM levels were not determined
little can be inferred. Another factor which has been implicated as
a modulator of endotoxin activity in a LAL assay system is
high-density lipoprotein - HDLP (Warren e_t aiL 1987), although other
serum factors may also contribute (see Berger & Beger 1988 for short
review).
Irrespective of the factor responsible, it was clearly demonstrated
that LAL activity of purified LPS could be inhibited in this assay
system, therefore assessment of the capacity of purified IgGs was
carried out.
c) Initial results indicated that IgGs themselves possessed
extremely high LAL activity (figure 3:44a). A series of studies
indicated that, firstly, digestion of IgG with proteinase K followed
by PAGE and silver staining for LPS did not reveal the presence of
any pattern consistent with either rough or smooth type LPS, and
secondly, that the LAL activity of IgG was not inhibitable by
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polymyxin B even at concentrations which would neutralise an amount
of LPS of equivalent LAL activity. It was, however, not surprising
in retrospect that LPS was not detectable by silver staining as the
maximum equivalent concentration of LPS in the IgG of highest LAL
activity was approximately 167pg/ml (approximately 2000EU/ml, where
12EU is equivalent to 1 .Opg of LPS per ml), therefore from the
volume loaded onto PAG (50ul) only 8.35ng of LPS could be present.
The approximate amount loaded onto gels from normal poteinase K
digests is lOng (where a bacterial suspension with an A525 of
0.5-0.6 contains approximately 10^organisms/ml and an organism
contains femtogram - 10"'^g - amounts of LPS). The second line of
evidence does produce a strong indication that the activity of the
IgGs in the LAL assay is caused by factors other than contaminating
LPS. Possible candidates include a range of polysaccharide and
protein compounds (summarised by Baek et al 1985, Berger & Beger
1988, and Berger et al 1988) which are known to possess some LAL
activating capacity. It is possilble that some of these activators
may have eluted during column chromatography for the purification of
IgGs (see MATERIALS AND METHODS). This activity was greatly reduced
through dilution by a factor of 625.
d) Inhibition was carried out with IgG at a dilution pf 1 :500 as
dilution by 1:1000 was shown to possess only minimal inhibitory
activities (see figure 3:47). This dilution produced residual LAL
activity of IgGs, but inhibition was detectable in many instances.
IgG and LPS were incubated prior to addition of LAL to permit
maximal binding of anti-CGL (which may be present at only low levels
and which may possess only low avidity for CGL epitopes as suggested
by Appelmelk et. al 1986) .
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A high degree of variability was present between successive
measurements of inhibition despite identical conditions and in
contrast with the good reproducibility in measurement of LPS. This
may have arisen through differing solubilities of LPS in the
presence of IgG molecules, or as a result of the presence of
different cations in IgG and LPS preparations. Different species of
cations have been shown to alter the solubility of LPS (Baggerman et_
al 1988; Brade ert al 1987a; Galanos & Luderitz 1975; Galanos &
Luderitz 1976) and also to affect the activity of LAL enzymes
responsible for activation, and it is therefore possible that this
factor may contribute to the variability observed. Another
possibility that exists is in the pre-incubation step of IgG and LPS
which was carried out at room temperature. It is possible that
day-to-day variation may have altered the interaction between LPS
and IgG, therefore accounting for the variability.
One further possibility which should be investigated is the LAL
activity of outer membrane vesicles. These may be representative of
'extracellular toxic complexes' which have been detected Jar vivo
(Straus 1987; Straus £t_ £l_ 1985; Straus e_t a_l 1988) and which
contribute to the manifestations of Gram-negative bacterial
infection. In addition to LPS and phospholipid, these contain
proteins which may also contribute to toxicity (Bjornson ^t_ al 1988;
Johns e_t al 1988). This therefore represents one direction which
could be followed in determination of toxicity and of the
anti-endotoxic activity of immunoglobulin preparations, and may lead
to clarification of the role of immunoglobulins in neutralisation of
endotoxic activity.
It is thus suggested that a standard salt form of
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lipopolysaccharides of high solubility (prepared after
electrodialysis of LPS - see Galanos & Luderitz 1975) is used, and
that IgG preparations are extensively purified to remove
contaminants such as dextran or LPS to enable accurate determination
of anti-endotoxic activity of immunoglobulins.
Many inhibitions with IgG did, though, produce some inhibitory
activity. Inhibitory capacity did not absolutely reflect the
antibody profiles of the IgGs (see figure 3:4) particularly with
regard to E_^ coli 06 LPS which showed only minimal inhibition with
any IgG despite the presence of specific antibody. Additionally,
some LPS showed increased activity in the presence of certain IgGs -
possibly through the additive effect of the LAL activities of IgG
and LPS, although there is the possibility that binding of LPS by
IgG solubilised the LPS thereby exposing more lipid A sites which
could activate LAL enzymes.
d) Polymyxin was shown to possess strongly inhibitory activity
against all 4 LPS assessed, indicating that polymyxin binds to the
site responsible for LAL activation, that is the lipid A. This
polycationic antimicrobial agent possessed greater inhibitory
activity than any of the IgGs.
This series of experiments demonstrated that IgG prepared from human
serum may possess anti-endotoxic activity, but refinement of this
assay system is required to produce definitive indications of this
activity. If, however, this assay can be shown to produce consistent
inhibition it may find a strong relationship to the activity of
anti-endotoxin antibodies in vivo.
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4:7. Protective Activities of Immunoglobulins in vivo.
The serotypes of organism chosen to challenge animal models have
been diverse, but Escherichia coli and Pseudomonas aeruginosa have
been used most frequently. These two organisms represent the species
which contribute the highest proportion of fatalities from
Gram-negative septicaemia and are therefore of great relevance in
assessment of septicaemia in animals. The strains of E. coli used in
this study have all been relevant to septicaemia as determined by
Cross jrt al (1983) and Cheasty et al (1977), but many other studies
of the protective activity of various immunoglobulin preparations
have been carried out with serotypes of bacteria not commonly
associated with septicaemia. It is therefore hoped that a closer
reflection of human septicaemia is obtained by application of the
relevant organisms as in this assessment.
Many protection studies also involve administration of antibody many
hours prior to challenge with LPS or bacteria. This obviously does
not follow the situation in patients where signs and symptoms of
septicaemia are observed prior to initiation of therapy. It may thus
be more appropriate for therapy in models to be instigated after
challenge with bacteria or LPS, and this was indeed the preferred
timing of antibody administration in the current assessment.
Despite the above points of contention with the clinical situation,
it is beyond doubt that challenge of animals with LPS or bacteria
does give an indication of the action of these agents upon an
organism. Application of therapeutic agents (before, after, or
simultaneously with challenge) can allow assessment of their
potential to protect against the effects of Gram-negative bacterial
and 1ipopolysaccharide challenge, and the results obtained in this
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study are assessed below.
a) All experiments indicated that mice are particularly refractory
to the lethal effects of Gram-negative bacterial or
1ipopolysaccharide challenge. One means of compromise
(co-inoculation of bacteria with mucin and haemoglobin) produced a
large reduction in the lethal dose of bacteria, in particular the
capsulate E_^ coli 018 :K ] .
b) Clear differences were obtained in the lethal doses of smooth and
rough strains of P_^ aeruginosa and E_^ coli (tables 3:8 and 3:11
respectively), confirming the importance of the presence of
0-antigen in the virulence of Gram-negative bacteria.
c) The culture of P^ aeruginosa Habs type 1 in two different media
(nutrient broth and MALKA) indicated a small increase in lethality
of bacteria grown in the minimal medium. These differences may have
been reflected in alteration of LPS structure, but at the time this
was not assessed. This alteration in virulence supports the data
presented in section 3:5 showing that alteration of growth medium
causes changes in surface components of bacteria which in turn may
affect the virulence of the bacterium.
d) A normal human serum containing high levels of anti-CGL (HI-NS -
see table 3:11) was shown to possess limited protective action
against lethal challenge with P_^ aeruginosa Habs type 1 and several
O-serotypes of E_^ coli which are predominant in septicaemia.
e) Use of mucin and haemoglobin to lower the lethal dose of bacteria
failed to produce any noticeable protection with 4 normal sera (GL+,
GL-, MED 1, and MED2 - see table 3:14) against E. coli 018:K1 despite
a challenge dose of only 60 organisms (5 times minimum dose required
to result in death of all mice challenged). The results presented in
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table 3:16 did, however, show that some protective activity was
obtained in an adaptation of this model (where mice were challenged
with lower numbers of bacteria) with two IgG preparations containing
high levels of anti-CGL (igGs 5 and 24 - see figure 3:16 for
antibody profiles) and a monoclonal antibody specific for the
O-antigen of this organism (SZ184/2.5.5 - see MATERIALS AND
METHODS).
The very low lethal dose of bacteria in the mucin/haemoglobin model
of sepsis may partly be due to the virulence factors of the above
organisms, but it does not appear that this model provides an
appropriate means for the measurement of protection because of the
severe increase in virulence of bacteria in this model. Both factors
used to increase the virulence can be dealt with separately:
1. Haemoglobin provides a source of iron (see section 1:4) to
enable bacteria to multiply rapidly in an otherwise iron-depleted
environment. Iron is known to be an essential element in bacterial
metabolism and its presence may permit alteration of virulence
factors (including LPS, outer membrane proteins and capsule) and
thus the protective capacity of immunoglobulins (see, for example,
Brown & Williams 1985).
2. Mucin would appear to provide a highly protective environment
similar to that present in the slime excretions produced by some
bacteria during infection, notably P_^ aeruginosa (Pollack 1984)
among Gram-negative bacteria. Because of the presence of iron,
however, bacteria can multiply rapidly in the absence of any host
immune response. During growth in this environment, bacteria may be
producing the extracellular toxic complexes (ETC) as encountered in
K. aerogenes (Straus 1987) and P_^ cepacia (Straus e_t a^ 1988)
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infections, thereby resulting in death. A further possibility is
that bacteria are released en masse once the replication process has
enabled bacteria to occupy the entire volume of mucin, resulting in
a massive efflux of bacteria into the peritoneum and effectively
producing a large bacterial inoculum.
f) One further compromised model of bacterial challenge was applied.
Sub-lethal neutropenia was induced with cyclophosphamide in mice
(see MATERIALS AND METHODS), and mice were challenged with bacteria
and haematin (as a source of iron) followed by administration of
immunoglobulins. The overall results indicated that noticeable but
insignificant protection was demonstrated by three of the five
purified human IgG preparations (figure 3:17). These activities did
not, however, reflect the extent of cross-reactive IgG in the
preparations, although the presence of different subclasses of IgG
may have an important bearing on the outcome. This model was
representative of many patients who develop septicaemia through the
presence of neutropenia (see section 1:1:2). Despite induction of
neutropenia and the presence of excess iron, the lethal dose was
still very high (LD50 in the range of 10^-10^ organisms), but the
model has still provided a slight indication of the potential
protective capacity of IgG purified from human blood donors. Further
assessment of the extent of neutropenia (as carried out by
Vuopio-Varkila, 1988) and also the contribution of the iron in
haematin appears to be necessary to refine this model.
g) The toxicity of purified lipopolysaccharide in mice was shown to
be markedly reduced through co-inoculation with D-galactosamine and,
in agreement with the literature (Galanos e_t al^ 1979), a reduction
of approximately 10^-fold was obtained in lethal dose. The choice of
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solvent was also shown to have a bearing on the lethal activity of
LPS (section 3:7:4), thus stressing the importance of the salt form
of LPS on the toxic activity of LPS as first determined by Galanos
and colleagues (Galanos & Luderitz 1975; Galanos & Luderitz 1976).
Application of immunoglobulin to mice challenged with lethal doses
of LPS produced only small protective activity as shown in section
3:7:4, and results were highly variable from test to test.
Assessment of the protective activity of immunoglobulins was thus
more readily demonstrated in bacterial challenge models.
Careful consideration must therefore be taken in development of
animal models of septicaemia. Particular regard must be given to the
virulence factors possessed by organisms in relation to known
septicaemia strains, the culture conditions imposed for preparation
of challenge inocula, and in the mode of compromise induced in these
animals.
Further analysis of the immunoglobulin preparations may also be
necessary. It has been determined (Nys ert aJ 1988) that the
development of anti-LPS of different subclasses has an important
bearing upon the outcome of septicaemia in a patient, and therefore
subclass reactivity with CGL epitopes may have a bearing on the
potential therapeutic value of IgG preparations for the treatment of
septicaemia.
From the above presentation, it would thus appear that IgG prepared
from the serum of blood donors possessing high levels of anti-CGL
may provide a suitable means of prevention of fatalitites arising
from systemic Gram-negative bacterial infection in human patients
3 10
although the efficacy of these human immunoglobulin preparations
remains to be fully examined in animal models.
3 1 I
Summary of Conclusions.
In view of the results obtained during the course of this
investigation of some activities of anti-lipopolysaccharide
immunoglobulins, the following conclusions can be made:
The LPS-polymyxin ELISA for detection of anti-CGL immunoglobulins
represents an accurate and reproducible assay which identifies
antibodies of appropriate specificity for therapeutic application.
This arises as the antigenic presentation of LPS appears to resemble
other LPS-containing antigens. The clinical data presented here
indicated that the choice of antigens has been appropriate in
relation to the antibodies observed to be most closely related to
the presence or absence of endotoxin in shock patients. It would
thus appear that use of this assay may result in the selection of an
intravenous immunoglobulin preparation of high therapeutic
potential.
The antigenic relationships between various LPS molecules has been
extended, and implications in the choice of antigens for assays and
for production of antibodies has been noted.
Alteration of bacterial lipopolysaccharide for bacteria grown under
different media conditions has indicated that care must be taken in
extrapolating information obtained from in vitro determinations of
anti-LPS antibody activities. As a result of the differential
binding of antibodies to core and O-antigen for bacteria grown under
different nutrient conditions and because of the influence of
capsular material of this activity, bacterial strains and growth
conditions must be chosen carefully to mimic in vivo conditions.
Some anti-bacterial and anti-endotoxin activity was demonstrable in
a range of _in vitro and in vivo models with IgG purified from human
3 12
blood donors. It therefore appears that selection of donors with
high-titres of anti-CGL antibodies can provide a suitable source of
antibodies for passive immunisation of patients with systemic
Gram-negative bacterial infection and septic shock in conjunction
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net 0.0.(590) screening ELISA
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IgG-02
dilution = 1/ 100
ELISA ANTIGENS (LPS-polymyxin
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli 062 : C62 R a'
m n o i—• J5 : J5 R c'
E.coli (K12) : D31m4 R e
E.coli (K12) : ex D31m4 R lpA
P.aeruginosa :Habs-01 S 0
P.aeruginosa :PAc605 R b
K.aerogenes :MlOb R b
omplexes)
1 2
net 0.□. (590) screening ELISA
367
IgG-03
dilution = 1/ 100
ELISA ANTIGENS (LPS-polymyx in
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ 0 (Wt) S 0
E.coli 086 0 (Wt) S 0
E.coli 0111 0 (Wt) S 0
E.coli R1 HF 4704 R a
E.coli R2 EH 100 R a
E.coli R3 F 673 R a
E.coli R4 F 2513 R a
E.coli K12 mm294 R a
E.coli 062 062 R a'
E.coli J5 J5 R c'
E.coli (K12) D31m4 R e
E.coli (K12) ex Q31m4 R lp A
P.aeruginosa Habs-01 S 0
P. aerug inosa PAc605 R b
K.aerogenes MlOb R b
omplexes)
1 2
net O.D. (590) screening ELISA
368
I gG—0-4
dilution = 1/ 100
ELISA ANTIGENS (LPS-po1ymyxin complexes)












S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) s 0
E.coli 018 K- : 0 (Wt) s 0
E.coli 018 K+ : 0 (Wt) s 0
E.coli 086 : 0 (Wt) s 0
E.coli 0111 : 0 (Wt) s 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : 062 R a'
E.coli J5 : J5 R c '
E.coli (K12) :D31m4 R e
E.coli (K12) :ex D31m4 R lpA
P. aeruginosa :Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
1 2
net O.D. (590) screening ELISA
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IgG-05
dilution = 1/ 100
ELISA ANTIGENS (LPS-po1ymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S. typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S. typhimurium : 1102 R e
S.minnesata : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesata :exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E. col i 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli 062 : 062 R a'
E.coli J5 : J5 R c'
E.coli (K12) :D31m4 R e
E.coli (K12) : ex 031m4 R lpA
P.aeruginosa : Habs-Oi S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
0 1 2
net O.D. (590) screening ELISA
370
IgG-06
dilution » 1/ 100
ELISA ANTIGENS (LPS-po1ymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R IpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E. col i 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.cali A4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.cali (K12) : D31m4 R e
E.coli (K12) : ex D31m4 R lp A
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
1 2
net 0.0.(590) screening ELISA
371
IgG-07
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyx in complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S. typhimur ium : 878 R c
S.typhimurium : 1032 R d
S.typh imurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S .minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota :exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 0 (Wt) S 0
E.coli 0111 0 (Wt) S 0
E.coli R1 HF 4704 R a
E.coli R2 EH 100 R a
E.coli R3 F 673 R a
E.coli R4 F 2513 R a
E.coli K12 mm294 R a
E.coli 062 062 R a'
E.coli J5 J5 R c'
E.coli (K12) Q31m4 R e
E.coli (K12) ex D31m4 R lpA
P.aeruginosa Habs-01 S 0
P.aeruginosa PAc605 R b
K.aerogenes MlOb R b
1 E
net O.D. (590) screening ELISA
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IgG-08
dilution = 1/ 100
ELISA ANTIGENS (LPS-po1ymyxin
S. typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S. typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S. typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota :exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) s 0
E.coli 086 : 0 (Wt) s 0
E.coli 0111 : 0 (Wt) s 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 :F 2513 R a
E.coli K12 : mm294 R a
E.coli 062 : 062 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D31m4 R e
E.coli (K12) : ex D31m4 R lpA
P.aeruginosa :Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
omplexes)
1 2
net 0.0. (590) screening ELISA
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IgG-09
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes]
S.typhimurium : 0 (Wt) S 0
S. typhimurium : 1542 R a
S. typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R IpA
E. coli 06 : 0 (Wt) S 0
E. coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E. coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli A4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : 062 R a'
E.coli J5 : J5 R c"
E.coli (K12) : 031m4 R e
E.coli (K12) : ex 031m4 R Ip A
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
1 2
net O.D. (590) screening ELISA
374
IgG-10
d i lut ion =>
ELISA ANTIGENS (LPS-polymyxin
S. typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S. typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) s 0
E.coli 018 K+ : 0 (Wt) s 0
E.coli 086 : 0 (Wt) s 0
E.coli 0111 : 0 (Wt) s 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D3im4 R e
E.coli (K12) : ex D31m4 R lpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b








ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota :R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesata : R7 R d2P
S.minnesota : R595 R e
S.minnesata : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.cali R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.cali R3 :F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D31m4 R e
E.coli (K12) : ex D31m4 R lpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
1 2
net O.D. (590) screening ELISA
376
IgG-13
dilution - 1/ 100



























































































net O.D. (590) screening ELISA
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IgG-14
dilut ion 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S. typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S. typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S .minnesota :exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E. col i (K12) : 031m4 R e
E.coli (K12) : ex D31m4 R IpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
1 2




dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyx in complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E. col i 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E. coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E. coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E. coli J5 : J5 R c'
E.coli (K12) :03im4 R e
E. coli (K12) : ex 031m4 R lpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa :PAc605 R b
K.aerogenes : MlOb R b
1 2
net Q.D. (590) screening ELISA
379
IgG-16
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli Rl : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) :D31m4 R e
E.coli (K12) : ex D31m4 R lp A
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
1 2
net O.D. (590) screening ELISA
380
IgG-17
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S. typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S. typhimurium : 1032 R d
S.typhimurium : 1102 R e
S .minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.cali 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E. coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli 062 : 062 R a'
E.coli J5 : J5 R c'
E.coli (K12) : Q31m4 R e
E. coli (K12) : ex D31m4 R lpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b
K. aerogenes : MlOb R b
1 2
net 0.□. (590) screening ELISA
381
IgG-18
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D31m4 R e
E.coli (K12) : ex D31m4 R lp A
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b








ELISA ANTIGENS (LPS-palymyx in complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota :R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E. col i 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli 062 : 062 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D31m4 R e
E.coli (K12) : ex D31m4 R lpA
P.aeruginosa :Habs-01 S 0
P. aeruginosa :PAc605 R b
K. aerogenes : MlOb R b
1 2
net O.D. (590) screening ELISA
383
IgG-20
d i lut ion 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium 0 (Wt) S 0 $
S.typhimurium 1542 R a §
S.typhimurium 119 R b £
S. typhimurium 878 R C *
S. typhimurium 1032 R d
S.typhimurium 1102 R e \
S.minnesota 0 (Wt) S o &
S.minnesota R60 R a 1
S.minnesota R345 R b2 g
S .minnesota R5 R c 1
S.minnesota R7 R d2P |
S.minnesota R595 R e |
S.minnesota exR595 R lpA g
E.coli 06 0 (Wt) S 0 j
E.coli 016 0 (Wt) S 0 j
E.coli 018 K- 0 (Wt) S 0 j
E.coli 018 K+ 0 (Wt) S 0 I
E.coli 086 0 (Wt) S 0 [
E.coli 0111 0 (Wt) S 0 I
E.coli R1 HF 4704 R a i
E.coli R2 EH 100 R a i
E.coli R3 F 673 R a i
E.coli R4 F 2513 R a 1
E.coli K12 mm294 R a j
E.coli C62 C62 R a' 1
E.coli J5 J5 R c' |j
E.coli (K12) D31m4 R e |
E.coli (K12) ex D31m4 R lpA g
P.aeruginosa Habs-01 S 0 :|
P. aeruginosa PAc605 R b n
K. aerogenes MlOb R b .
i 2
net 0.0. (590) screening ELISA
384
IgG-21
dilution - 1/ 100
ELISA ANTIGENS (LPS-po1ymyx in
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : S78 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota :exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli 062 : 062 R a 1
E.coli J5 : J5 R c'
E.coli (K12) : D31m4 R e
E.coli (K12) : ex D31m4 R lpA
P.aeruginosa :Habs-01 S 0
P. aeruginosa :PAc605 R b
K.aerogenes : MlOb R b
complexes)
0 1 2




































: 0 (WtJ S 0
: 1542 R a
: 119 R b
: 878 R c
: 1032 R d
: 1102 R e
: 0 (Wt) S 0
: R60 R a
: R345 R b2
: R5 R c
: R7 R d2P
: R595 R e
exR595 R IpA
0 (Wt) S 0
0 (Wt) S 0
0 (Wt) S 0
0 (Wt) S 0
0 (Wt) S 0
0 (Wt) S 0
HF 4704 R a
EH 100 R a
F 673 R a




03 lm4 R e







net O.D. (590) screening ELISA
386
IgG-23
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium 0 (Wt) S 0
S.typhimurium 1542 R a
S.typhimurium 119 R b
S.typhimurium 878 R c
S.typhimurium 1032 R d
S.typhimurium 1102 R e
S.minnesota 0 (Wt) S 0
S .minnesota R60 R a
S.minnesota R345 R b2
S.minnesota R5 R c
S.minnesota R7 R d2P
S.minnesota R595 R e
S .minnesota exR595 R lpA
E.coli 06 0 (Wt) S 0
E.coli 016 0 (Wt) S 0
E.coli 016 K- 0 (Wt) S 0
E.coli 018 K+ 0 (Wt) S 0
E.coli 086 0 (Wt) S 0
E.coli 0111 0 (Wt) s 0
E.coli HI HF 4704 R a
E.coli R2 EH 100 R a
E.coli R3 F 673 R a
E.coli R4 F 2513 R a
E.coli K12 mm294 R a
E.coli C62 C62 R a'
E.coli J5 J5 R c'
E.coli (K12) D31m4 R e
E.coli (K12) ex D31m4 R lpA
P. aeruginosa Habs-01 S 0
P.aeruginosa PAc605 R b
K. aerogenes MlOb R b
1 2
net 0.0.(590) screening ELISA
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IgG-24
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium : 0 (Wt) S 0 ^
S.typhimurium : 1542 R a \
S.typhimurium : 119 R b *
S.typhimurium : 878 R
S.typhimurium : 1032 R d £
S.typhimurium : 1102 R e \
S.minnesota : 0 (Wt) S 0 \
S.minnesota : R60 R 3 1
S.minnesota : R345 R b2 §
S.minnesota : R5 R c 1
S.minnesota : R7 R d2P \
S.minnesota : R595 R e 1
S.minnesota : exR595 R lpA |
E.coli 06 : 0 (Wt) S 0 |
E.coli 016 : 0 (Wt) S 0 |
E.coli 018 K- : 0 (Wt) S 0 |
E.coli 018 K+ : 0 (Wt) S 0 |
E.coli 086 : 0 (Wt) S 0 (
E.coli 0111 : 0 (Wt) S 0 j
E.coli R1 : HF 4704 R a j
E.coli R2 : EH 100 R a §
E.coli R3 : F 673 R a j
E.coli R4 : F 2513 R a j
E.coli K12 :mm294 R a |
E.coli C62 : C62 R a' j
E.coli J5 : J5 R c' j
E.coli (K12) :D3im4 R e j
E.coli (K12) : ex D31m4 R lpA j
P.aeruginosa : Habs-01 S 0 |
P.aeruginosa : PAc605 R b |
K.aerogenes : MlOb R II
I I
i 2
net O.D. (590) screening ELISA
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IgG-25
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin
S.typhimurium :0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota :0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli Rl : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D3im4 R e
E.coli (K12) : ex 031m4 R lpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b








ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S. typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 0 (Wt) S 0
E.coli HI HF 4704 R a
E.coli R2 EH 100 R a
E.coli R3 F 673 R a
E.coli R4 F 2513 R a
E.coli K12 mm294 R a
E.coli C62 C62 R a'
E.coli J5 J5 R c'
E.coli (K12) D31m4 R e
E.coli (K12) ex D31m4 R lpA
P.aeruginosa Habs-01 S 0
P.aeruginosa PAC605 R b
K.aerogenes MlOb R b
1 2
net O.D. (590) screening ELISA
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IgG-27
dilution = 1/ 100
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IgG-28
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota : 0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesata : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) s 0
E.coli 0111 : 0 (Wt) s 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D3im4 R e
E.coli (K12) :ex D3im4 R lpA
P.aeruginosa : Habs-01 S 0
P. aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
I I
1 2
net O.D. (590) screening ELISA
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IgG-29
dilution - 1/ 100
ELISA ANTIGENS (LPS-po1ymyxin complexes)
S. typhimurium 0 (Wt) S 0
S. typhimurium 1542 R a
S. typhimurium 119 R b
S. typhimurium 878 R c
S. typhimurium 1032 R d
S. typhimurium 1102 R e
S.minnesota 0 (Wt) S 0
S.minnesota R60 R a
S.minnesata R345 R b2
S.minnesota R5 R c
S.minnesota R7 R d2P
S.minnesota R595 R e
S.minnesota exR595 R lpA
E.coli 06 0 (Wt) S 0
E.coli 016 0 (Wt) S 0
E.coli 018 K- 0 (Wt) S 0
E.coli 018 K+ 0 (Wt) S 0
E.coli 086 0 (Wt) S 0
E.coli 0111 0 (Wt) S 0
E.coli HI HF 4704 R a
E.coli R2 EH 100 R a
E.coli R3 F 673 R a
E.coli R4 F 2513 R a
E.coli K12 mm294 R a
E.coli C62 C62 R a'
E.coli J5 J5 R c'
E.coli (K12) D3im4 R e
E.coli (K12) ex D31m4 R lpA
P.aeruginosa Habs-01 S 0
P.aeruginosa PAc605 R b
K. aerogenes MlOb R b
1 2
net 0.0. (590) screening ELISA
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IgG-30
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium :119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesata :0 (Wt) S 0
S.minnesota : R60 R a
S.minnesata : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota :R595 R e
S.minnesota :exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli Rl : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 :F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D31m4 R e
E.coli (K12) : ex D31m4 R lpA
P.aeruginosa : Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
0 1 2
net O.D. (590) screening ELISA
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IgG-31
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota :0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota :exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 :F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 :mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) : Q31m4 R e
E.coli (K12) : ex 031m4 R lpA
P.aeruginosa :Habs-01 S 0
P.aeruginosa :PAc605 R b
K.aerogenes : MlOb R b
i |
1 2
net O.D. (590) screening ELISA
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IgG-32
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium : 0 (Wt) S 0
S.typhimurium : 1542 R a
S.typhimurium : 119 R b
S.typhimurium : 878 R c
S.typhimurium : 1032 R d
S.typhimurium : 1102 R e
S.minnesota :0 (Wt) S 0
S.minnesota : R60 R a
S.minnesota : R345 R b2
S.minnesota : R5 R c
S.minnesota : R7 R d2P
S.minnesota : R595 R e
S.minnesota : exR595 R lpA
E.coli 06 : 0 (Wt) S 0
E.coli 016 : 0 (Wt) S 0
E.coli 018 K- : 0 (Wt) S 0
E.coli 018 K+ : 0 (Wt) S 0
E.coli 086 : 0 (Wt) S 0
E.coli 0111 : 0 (Wt) S 0
E.coli R1 : HF 4704 R a
E.coli R2 : EH 100 R a
E.coli R3 : F 673 R a
E.coli R4 : F 2513 R a
E.coli K12 : mm294 R a
E.coli C62 : C62 R a'
E.coli J5 : J5 R c'
E.coli (K12) : D31m4 R e
E.coli (K12) : ex 031m4 R lpA
P.aeruginosa :Habs-01 S 0
P.aeruginosa : PAc605 R b
K.aerogenes : MlOb R b
1 2
net Q.D. (590) screening ELISA
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IgG-33
dilution - 1/ 100
ELISA ANTIGENS (LPS-polymyxin complexes)
S.typhimurium 0 (Wt) S 0 ^
S.typhimurium 1542 R a y/////A
S.typhimurium 119 R b |
S.typhimurium 878 R c ;
S. typhimurium 1032 R d |
S.typhimurium 1102 R e
S.minnesota 0 (Wt) S 0 I
S.minnesota R60 R a
S.minnesota R345 R b2
S.minnesota R5 R c
S.minnesota R7 R d2P |
S.minnesota R595 Re |
S.minnesota exR595 R lpA
E.coli 06 0 (Wt) S 0 |
E.coli 016 0 (Wt) SO |
E.coli 016 K- 0 (Wt) S 0 ^
E.coli 018 K+ o (wt) s o mi
E.coli 086 0 (Wt) S 0
E.coli 0111 0 (Wt) SO I
E.coli R1 HF 4704 R a §
E.coli R2 EH 100 R a
E.coli R3 F 673 R a
E.coli R4 F 2513 R a
E.coli K12 mm294 R a
E.coli C62 C62 R a1 |
E.coli J5 J5 Re*
E.coli (K12) □3im4 Re |
E.coli (K12) ex D31m4 R lpA
P.aeruginosa Habs-01 SO |
P.aeruginosa PAC605 R b |
K.aerogenes MlOb R b
0 1 2
net Q.D. (590) screening ELISA
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APPENDIX 2
Key to Appendix 2.
EU/ml:Endotoxin units/ml
Sm-Re: S_^ minnesota R595 LPS
S.min lipid A: S. minnesota lip
St-Ra: S. typhimurium R1542 LPS
St-Rc: S. typhimurium R878 LPS
St-Re: S.typhimurium R1102 LPS
Ec lipid A:E. coli K12 lipid A
Serum Endotoxin S IgG anti-LPS-cores















KEY: A=EU/ml: B=St-fla: C=St-Rc: 0=St-Re:














Serum Endotoxin £ IgG anti—LPS—cores















KEY: A=EU/ml: B=St-Ra: C=St-Rc: 0=St-Re:

































Serum Endotoxin £ IgG anti-LPS






KEY: A=EU/ml: B=S.min lipid A: C=Ec lipid A: D=Sm-fle: E-St-Re:










shock serum # MCM
0. (IgG) 3 EU/ml
18
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